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SUMMARY 
Cytomegalovirus (CMV) infection is a major complication after kidney 
transplantation. Despite antiviral therapy it contributes significantly to high 
morbidity. This study was aimed at (a) detecting· a CMV specific antigen pp6S 
in CMV -infected fibroblast cells and in leukocytes of kidney transplant 
recipients by flow cytometric assay (FCA) (b) determining the stimulation 
index (S.I.) of phytohaemagglutinin (PHA) and CMV-stimulated peripheral 
blood mononuclear cells (PBMC), (c) determining the levels of Thl- and Th-
2 related cytokines in the supernatant of stimulated PBMC from kidney 
transplant recipients with and without active CMV infection (d) determining 
immunophenotyping of cells found in the peripheral blood of CMV -infected 
and CMV -uninfected kidney transplant recipients by flow cytometry using 
antibodies specific to CD2+ (pan T), CD3+ (mature T), CD4+ (T helper), 
CD8+ (T suppressor), CD26+(T activated), CDI6+/CDS6+ (NK cell), 
CDI9+(pan B), CDIS+ (granulocytes). Thirty-five patients with, and 44 
without aCtive CMV infections, as diagnosed by a CMV antigenemia assay 
(AA), were inducted into this study. FCA distinguished clearly between the 
infected and uninfected fibroblast cells. Regarding kidney transplant 
recipients, the FCA was positive when the number of AA positive cells was 
five or more per SxI04. Moreover, the percentage .of antigenemia-positive 
cells by FCA correlated well with symptomatic CMV infections. After PHA 
and CMV stimulation ofPBMC from patients, S.1. was determined by 
radioactive thymidine uptake while the production of ThI-type cytokines 
[interleukin-2 (iL-2), interferon-y (IFN-y) and tumor n~crosis factor-a (TNF-
ex)] and Th2-type cytokines (IL-4, IL-IO) were measured by ELISA. PBMC 
of patients with active CMV infection showed significantly lower S.1. values 
than patients without an ongoing CMV infection (p<O.OOOI). Levels ofTh2-
type cytokines in CMV -infected and uninfected kidney recipients were similar; 
however, the levels of the ThI-tYPe cytokines were significantly lower in 
CMV -infected patients (p<O.OS). Low levels of ThI-type cytokines seem to 
correlate well with active CMV infection in kidney recipients. The percentage 
of CD3+ immunocompetent T lymphocytes and CD4+ T lymphocytes were 
consistently higher in kidney transplant recipients without an active CMV 
infection than in the group of recipients with an active CMV infection. These 
differences were statistically significant in the case of CD3+ (p<O.OS) and 
CD4+ (p<O.OOS). On the other hand the difference in percentage CD2+, CD8+, 
CDI6++CDS6+, CDI9+, CDIS+ cells were statistically insignificant. Therefore, 
these data suggest that active CMV infection in kidney transplant recipients is 
associated with a significant alteration in the lymphocyte proliferative 
responses, the levels of ThI-type cytokines (IFN-y, TNF-ex, IL-2), and the 
percentage of CD3+, CD4+ when compared to kidney transplant recipients 
without active CMV infection. 
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1. INTRODUCTION 
1.1 Herpesviruses. 
The herpe;; fumi1:y contains several of the most important human pathogens. 
Clinically, the herpesviruses exhIbit a spectrum of diseases. Some have a wide 
host-cell range, whereas others have a narrow host-cell range. The outstanding 
property of herpesviruses is their ability to establish lifelong persistent infections in 
their hosts and to undergo periodic reactivation. Their frequent reactivation in 
immunosuppressed patients causes serious health complications. Curiously, the 
reactivated infection may be clinically quite different from the disease caused by 
the primary infection. Herpesviruses posses a large number of genes, some of 
which have proved to play an important part in pathogenesis. 
Eight herpesviruses commonly infect humans: herpes simplex virus type 1 
(HSV -1) and herpes simplex virus type 2 (HSV -2), varicella-zoster virus (VZV), 
human cytomegalovirus (CMV), Epstein-Barr virus (EBV), and human herpesvirus 
types 6 and 7 (HHV6 and HHV7). There are nearly 100 viruses of the herpes 
group that infect many different animal species. The existence of a new human 
herpesvirus type 8 (HHV8) has been reported (Moore and Chang, 1995). 
1.1.1 Properties of herpesviruses. 
Important properties of herpes viruses are summarized in Table 1. 
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Table 1. Important properties of herpesviruses 
Virion: Spherical, 120-300 nm in diameter (icosahedral capsid, 100 nm). 
Genome: Double-stranded DNA, linear, MW 95-150 million, 120-240 kbp, 
reiterated sequences. 
Proteins: More than 35 proteins in virion. 
Envelope: Contains viral glycoproteins, Fc receptors. 
Replication:"Nucleus, bud from nuclear membrane. 
Outstanding characteristics: Establish latent infections; persist indefinitely 
in infected hosts, are frequently reactivated in immunosuppressed hosts. 
1.1.2 Structure and Compositions. 
Herpesviruses are large viruses. Different members of the group share 
architectural details and are. indistinguishable by electron microscopy. All 
herpesviruses have a core of double-stranded DNA, in the form of a torus 
(Nazerian, 1974), surrounded by a protein coat that exhibits icosahedral symmetry 
and has 162 capsomeres (Wildy and Watson, 1963). The nucleocapsid is 
surrounded by an envelope that is derived from the nuclear membrane of the 
infected cell and contains viral glycoprotein spikes approximately 8 nm in length 
(Wildyand Watson, 1963) (Fig. 1). 
The tegument, a term introduced by Roizman and Furlong (1974) to describe 
the structures between the capsid and envelope, has no distinctive features in thin 
sections but-may appear to be fibrous on negative staining (Furlong et al., 1972; 
Wildy and Watson, 1963). The tegument is :frequently distnbuted asymmetrically. 
The size ofherpesvirions has been reported to vary from 120 to nearly 300 
nm (Roizman and Furlong, 1974). The variation is in part due to variability in the 
,., thickness of tegument. Another major source of variability is the state of the 
envelope. The double-stranded DNA genome (MW 95-150xl06; 120-240 kbp) is 
linear and circularizes immediately upon release from capsids into the nuclei of 
infected cells. 
18 
Glycoprotein Spikes 
Figure 1. Diagram of herpesvirus and its nucleocapsid. 
Modified virsion from Atlas of virus diagram by Hans-W 
Ackermann and Laurent Berthiaume. 
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1.1.3 Classification. 
Herpes viruses share various biological properties. For example, synthesis of 
viral DNA and assembly of the capsids occurs in the nucleus of an infected cell, 
and host ·virus production is accompanied by the destruction of the cell. The DNA 
of the herpes viruses may also remain latently present in their host cells. In such 
latently infected cells, the viral genomes take the form of closed circular molecules. 
Classification of the numerous members of the herpesvirus family is complicated. 
A useful division into subfamilies is based on biological properties of the agents. 
The members of the family Herpesviridae have been classified by the Herpesvirus 
Study Group of the International Conunittee on the Taxonomy of Viruses (ICTV) 
into three subfamilies (i.e., the a/phaherpesvirnae, the betaherpesvirinae and the 
gammaherpesvirinae) on the basis of biological properties. A/phaherpesvirinae 
are classified on the basis of a variable host range, relatively short reproductive 
cycle, rapid spread in culture, efficient destruction of infected cells, and capacity to 
establish latent infections primarily but not exclusively in· sensory ganglia. This 
subfamily contains the genera Simp/exvirus (HSV-l, HSV-2) and Varicellovirus 
(VZV). The subfamily' betaherpesvirinae is characterised by a restricted host 
range. The reproductive cycle is long and the infection progresses slowly in 
culture. The infected cells frequently become enlarged (cytomegalia). The virus 
can be maintained in latent form in sensory ganglia, lymphoreticular cells, kidneys, 
and other tissues. This subfamily contains the genera CMV, and HHV6. In line 
with this, the.· nucleotide sequences of the HHV -6 genome is more closely related 
to that of CMV than to that of the other herpesviruses. This is also reflected at the 
protein level, where there are several closely related proteins, for example the 
glycoprotein B, the major capsid protein (MCP), and the DNA binding protein 
(P52). The target cells of gammaherpesvirinea like EBV are lymphoblastoid cells, 
and some cause lytic infections in.some"types of epithelioid and fibroblastic cells. 
Viruses in this group are specific for ToO or B-Iymphocytes. Latent virus is 
frequently demonstrated in lymphoid tissue. This subfamily contains the genera 
Lymphocryptovirus (EBV). 
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1.2 Human cytomegalovirus. 
5-10% of adult population throughout the world escape infection with CMV 
in Kuwait more than 90% are infected. The presence and type of clinical 
manifestations, and the sites and extent of virus excretion vary, but serological 
surveys conducted on all continents confirm the ubiquitous distribution of CMV 
(Weller, 1971). 
CMV characteristically produces cell enlargement with intranuclear 
inclusions. These cellular changes seen in tissues of patients with fatal infection led 
to the early designation of the term "cytomegalic inclusion disease" (CID), even 
before the causative agent was isolated (Hanshaw, 1968). Humans are believed to 
be the only reservoir for CMV, so CMV is highly species-specific and can be 
propagated in vitro in cells of human origin (human fibroblastic tissue). CMV, 
including the commonly studied laboratory strain AD169, was first isolated in 
human fibroblast cell culture independently in three laboratories (Rowe et al., 
1956; Smith, 1956; Weller et al., 1957). Strains of AD169 are widely used in many 
laboratories, adapted to grow well in laboratory conditions. Clinical isolates of 
CMV exhibit different' levels of virulence and tissue tropism. This might be 
attributed to the fact that fresh clinical isolates carry at least i 9 genes that are not 
found in laborarory strains (Cha et al., 1996). CMV replicate in human fibroblast 
cell 'cultures very slowly resulting in a small amount of cell-free virus. Infection 
usually spreads from cell to cell. Consequently, it may take sometimes several 
weeks for the development of observable cytopathic effect. Though many 
genetically different CMV strains circulate in the human population, these strains 
show a high degree of antigen similarity. 
The CMV genome is the largest of all known human herpes viruses. It 
contains more than 235 kbp encoding for at least 200 proteins (Chee et al., 1990). 
The genome has a high GC content (57.2%) and is divided into a unique long (UL) 
and a unique short (US) region, each of which is flanked by an internal (I~, IRs) 
and terminal (T~, TRs) base pair repeat sequences (Fig. 2). 
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lRL IRL IRs TRg 
UL Us 
II~----------~III I 
Figure 2. Structural organization of the human CMV 
genome. UL and Us represent the long and short unique 
sequences, respectively. Terminal (TR) and internal repeat 
(IR) sequences are indicated by black boxes 
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Three types of virus particles are produced in the CMV -infected cell. Firstly, the 
characteristic infectious virion. Secondly, particles that resemble the original virion 
in morphology but lack DNA, the noninfectious enveloped particles (NIEPs). 
Thirdly, the so-called dense bodies which lack both nucleocapsid and viral DNA. 
Dense bodies which are largely composed of the tegument protein pp65 usually 
accumulate in the cytoplasm of infected cells and surronded by an envelope 
containing glycoproteins (Irmiere and Gibson, 1983; Klages et al., 1989; Landini et 
al., 1987). In vitro, virions, NIEPs, and dense bodies all have the same capacity to 
penetrate the host cell. Immediately after the viral protein fuses with the cell 
membrane the capsid surrounded by the matrix enters the cytoplasm (Topilko and 
Michelson, 1994). 
Similarly to other herpesviruses, CMV replication is tightly regulated by a 
muhistep process. During a productive infection, cellular transcription factors 
probably interact with a long regulatory viral DNA sequence and initiate the 
transcription of a small number of immediate early (IE) genes which are believed 
to be the key regulators controling viral replication. At -least some of the IE 
proteins represent nonstructural regulatory proteins which induce the expression of 
early (E) genes. Early' (E) proteins are required for viral DNA replication. 
Following viral DNA replication, late (L) proteins are synthesized, many of which 
are incorporated into the virion or aid the process of progeny assembly. 
, The capsid of CMV consists of a small number of proteins. Immature 
capsids, the so called B-capsids, which are particles that still need to be packed 
with DNA and envelo~, are largely composed of the following proteins: the 
MCP, the assembly protein (AP), the minor capsid protein (mCP), and the smallest 
capsid protein (SCP). It is postulated that the assembly protein plays a role in 
DNA packaging. Immature capsids can be enveloped to produce NIEPs or be 
filled with DNA and subsequently enveloped to become virions. 
Several proteins can be found in the tegument. However, the most abundant 
tegument proteins are the basic phoshoprotein pp150, a product ofUL32, and the 
lower matrix protein pp65, a product ofUL83. The function of both proteins is.not 
clear yet, but comparison with known functions of similar proteins in other herpes 
23 
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viruses suggests that they are involved in viral gene regulation and in modification 
ofthe host cell metabolism (Mocarski, 1993). 
The lower matrix protein pp65 is the most abundantly produced tegument 
component of CMV in infected fibroblasts. In dense bodies pp65 accumulates to 
generate up to 95% of the protein mass. Nevertheless, pp65 is hardly present in 
virions (Hensel et 01., 1995; Irmiere and GIbson, 1983). During active CMV 
infection, accumulation of pp65 can be detected in peripheral blood leukocytes 
(Grefte et 01., 1992a,b). This technique, known as the CMV-antigenemia assay 
(AA), can be used as a valuable diagnostic tool to demonstrate and quantify CMV 
, infection. Two studies tried to define the importance of the gene encoding the 
pp65 in the virus cycle. In one study, in which a pp65 deletion mutant virus was 
used, it appeared to be a non-essential protein for viral replication in vitro 
(Schmolke et 01.: 1995b). However, in another study, which used a stably 
expressed antisense RNA to the UL83 gene which encodes for pp65 , viral 
replication was severely inhibited (Dal Monte et 01., 1996). More work is required 
to resolve these apparent differences. 
Of the three major viral phosphoproteins pp65, pp150, and pp71 , pp71 is the 
minor component. Pp71 " is also known as the upper matrix protein and is the 
product of the UL82 gene, immediately adjacent to the pp65 gene. Both proteins, 
pp71 and pp65, are translocated to the nucleus of the cell during the first minutes 
afterVi1'us uptake by a cell (Liu and Stinski, 1992; Schmolke et 01., 1995a). Two 
other CMV tegument phosphoproteins have been identified, but their function has 
not been elucidated yet: pp28, which is the highly immunogenic product of the 
UL99 gene, and pp67, a product from a spliced transcript that includes a portion 
of the UL65 gene. 
To date, three distinct families of glycoprotein complexes have been 
described to be present in the CMV envelope; gCI, gCII, and gCIII. The gCI 
complex, better known as the gB, homologue of HSV (CMV gB) is the most 
studied CMV induced glycoprotein. gCI, encoded by the UL55 gene, plays a key 
role in infection. Neutralizing antibodies to gB have no effect on the attachment of 
virions to cells but prevent the virion to penetrate cells. gB also promotes 
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transmission of infection from cell to cell, and fusion of infected cells (Navarro et 
al., 1993). The gCII complex consists of at least two immunologically and 
biochemically distinct glycoproteins which are disulfide linked to each other (Karl 
et al., 1990). One group of gCII glycoproteins may be encoded by a gene in the 
US6 gene· family. This gene family is not essential for viral replication in culture 
(Kollert-Jons et al., 1991). The gene encoding the second glycoprotein has been 
identified as ULI00 (Karl et al., 1994). ULIOO encodes for a 45-kD envelope 
protein. The exact role of this product is not known. The gCII complex is the 
major heparin binding component of the virion envelope, which is responsible for 
the initial interaction of the virus with the cell surfilce (Compton et al., 1993). 
One component of the gCIII complex is the glycoprotein gH, the product of 
,gene UL75. The product of UL115, the CMV gL glycoprotein, fqrms a stable 
complex with gH'and filcilitates the transport of gH to the cell surfilce (Kaye ey al., 
1992). Anti-gH antibodies can prevent cell to cell transmission of the virus 
(Rasmussen et al., 1991). These three glycoprotein complexes though are not 
essential for viral replication but they seem to play a very. important role in the 
transmission, penetration and fusion of the virus with infected cells. 
1.2.1 Infected cells and cells involved in latency. 
. CMV can establish both acute and chronic infections. After clearance of the 
infectious virus, the viral genome persists for life in the infected host, giving a 
possibility to reactivation of viral replication. During an active infection resuhing in 
active viral production the salivary glands are an important place for growth and 
dissemination of CMV. During disseminated CMV infection viral antigens have 
been found in various organs. In lung tissue, epithelial cells and fibroblasts were 
the predominantly infected cells, while in gastrointestinal tissue mostly fibroblasts, 
endothelial, epithelial, and smooth. muscle cells were infected. All these cell types 
might have the capacity to harbour CMV during latency and may be the source of 
recurrent infection. 
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While great progress has been made in the understanding of the mechanisms 
of CMV replication control and pathogenesis, our understanding of the 
-
mechanisms of establishment and maintenance of CMV latency and reactivation 
has remained incomplete and there is still controversy regarding the site of latency. 
Since CMV is transmitted with blood and organs from CMV -seropositive 
individuals, much in vitro research has focused on latency in blood cells. The 
general assumption concerning latency is that in latently infected cells viral DNA 
can be detected but no viral protein. As concerns CMV and cells of the immune 
system, in vivo, CMV interacts with endothelial cells monocytes, macrophages, 
, polymorphonuclear, leukocytes (PMNL) and bone marrow progenitor cells 
(Michelson, 1997). In 1991, Taylor Wiedeman et al., for the first time detected the 
latent CMV genome in peripheral blood CDI4+ monocytes of healthy seropositive 
carriers but not in the T cell population of these subjects nor in the 
polymorphonuclear cells (Taylor-Weideman et al., 1993). Monocytes positive for 
CMV DNA did not produce any viral RNA, but after in vitro stimulation and 
differentiation the monocytes-derived macrophages expressed immediate-early 
RNA transcripts. However, no transcripts encoding for other viral proteins could 
be detected, indicating ·that this does not lead to virus production (Taylor-
Weideman et al., 1994). Later studies showed, however, that monocytic cell 
precursors at specific developmental stages could be efficiently and productively 
infected in vitro with clinical isolates of CMV suggesting that in vivo monocytes 
may acquire CMV during their development in bone marrow (Movassagh et al., 
1996). Later viral DNA was found in CDI3+ and CD34+ progenitor cells of 
monocyteslgranulocytes in the blood and bone marrow which may be the site of 
latency rather than peripheralmonocytes (Gema et al., 1992; Kondo et aI., 1996; 
Mendelson et al., 1996; Torok-Storb et al., 1992). 
As early as 1984, Myerson et al. (1984) proposed that endothelial cells were 
the common denominator for viral dissemination; CMV antigens and nucleic acids 
(DNA and mRNA) have been detected in endothelial cells of numerous organs. 
Endothelial cells of blood veSsel have been also discussed as a possible site of 
latency (Grefte et al., 1994; Hackstein et al., 1996). 
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In both normal and immunosuppressed individuals, numerous investigators 
have reported the detection of CMV in peripheral blood monocytes and PMNL 
using a variety oftecbniques including polymerase chain reaction (PCR); (Gerna 
et al., 1992; von Laer et al., 1995), in situ hybridization (Dankner et al., 1990; 
Hendrix et al., 1997; Link et aI., 1993; Turtinen et al., 1987), in situ PCR 
(Yonemitsu et al., 1996), virus isolation (Carney and Hirsch, 1981; Jordan, 1983) 
and detection of CMV antigens (Orefte et al., 1992a,b; The et al., 1990). CMV 
antigen-positive rtlacrophages have been observed in the lung and spleen of normal 
seropositive subjects (Toorkeyand Carrigan, 1989) and in the placenta of mothers 
, prenatally infected .with CMV (Sinzger et al., 1996). CMV mRNA transcripts can 
be detected in vivo in bone marrow aspirates of some, but not all, healthy 
seropositive donors (Kondo et al., 1996; Torok-Storb et al., 1992). 
1.2.2 Epidemiology. 
Natural transmission of CMV occurs by direct or indirect person-to-person 
contact. CMV is very labile to heat and dryness, hence close or even intimate 
contact is believed to· 00 required for its horizontal spread (Lang and Kummer, 
1975). Sources of virus include oropharyngeal secretions, 'urine~ cervical and 
vaginal excretions, semen, breast milk, tears, feces, and blood (Lang and Kummer, 
1975; Stagno et al., 1980). Human CMV infection is endemic and is present 
throughout the year rather than being seasonal (Gold and Nankervis, 1982). 
1.2.3 Pathogenesis and pathology. 
1.2.3.1 Normal Hosts. 
The virus has a 4 to 8 week incubation period in normal older children and 
adults after viral exposure. In most caseS~ CMV infection in normal hosts leads to 
a clinically mild infection. Uncommonly, CMV infection in normal hosts results in 
the development of a mononucleosis syndrome clinically indistinguishable from the 
mononucleosis syndrome associated with EBV infection and may account for 
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approximately 8% of cases of infectious mononucleosis syndromes (Horwitz et al., 
1979; Klemola et al., 1970). Persistent fever, myalgia, and nonspecific 
-
constitutional symptoms are common, as is cervical adenopathy. Infrequent 
complications of CMV mononucleosis include pneumonia, hepatitis, CNS 
involvement, aspetic meningitis, and a variety of immunologic abnormalities 
suggestive of autoantibody production (Klemola et al., 1967, 1970; Phillips et al., 
1977). Laboratory findings include atypical lymphocytosis, and elevated hepatic 
transaminases (Klemola et al., 1967, 1970; Phillips et al., 1977). 
, 1.2.3.2 Congenial and perinatal infections. 
CMV infections in the foetus and the newborn may be severe. About 1 % of 
live births annually in the USA have congenital CMV infections (Demmler, 1991; 
Yow et al., 1988). About 10% of these suffer cytomegalic inclusion disease and a 
high percentage of babies with this disease exhibit developmental defects and 
mental retardation (Fowler et al., 1992; Stagno et al., 1986); Human CMV can be 
transmitted i~ utero with both primary and reactivated maternal infections (Stango 
et al., 1986 and 1980; . Yow et al., 1988). Generalized cytomegalic inclusion 
disease (CID) results most often from primary maternal infections. Early in the 
course of infection, CMV is disseminated widely in various organs of the body. 
The Virus may infect the placenta during infection and in some cases penetrate the 
placenta to infect the foetus. 
1.2.3.3 ImmunocompromisedHosts. 
In man, CMV is an important pathogen in the immunologically immature and 
in the immunocompromised host (Meyers et al., 1986). Serious disease is seen 
after intrauterine infection, in transplant patients and in individuals suffering from 
acquired immunodeficiency syndrome (AIDS) (Rubin, 1990). Manifestations are 
protean in that they can vary from asymptomatic excretion to manifestations in 
organs or organ systems such as in CMV -mononucleosis, CMV -retinitis, 
28 
interstitial pneumonia and disease of the gastrointestinal tract, and to general 
infection associated with multiple symptoms, as seen during congenital CID. 
1.3 Role of CMV infection in the process of organ allograft rejection. 
It was suggested that CMV infections might trigger rejection of transplant 
organs (Lautenschlager et al., 1992). CMV infections are major infectious 
cQmplications after organ transplantation, and a variety of clinical manifestations 
such as fever, leukopenia, thrombocytopenia, encephalitis, retinitis, pneumonia, 
, hepatitis and glo~rulopathy have been described as being associated with CMV 
infection (Rubin, 1990). In general, CMV is considered to be a significant risk 
factor in transplantation. An association between either acute or chronic rejection 
and CMV infection.has been reported in several clinical series of renal (Poteil-
Noble et al., 1993), liver (O'Grandy et al., 1988) and heart (Grattan et ai., 1989) 
transplantations. 
It should be emphasized that with the use of improved immunosuppressive 
protocols and effective anti-rejection therapies, the results of organ transplantation 
have progressively improved, yet the problems of CMV infection morgan 
transplant patients have not been resolved. 
1.3.t' CMV in renal transplantation. 
CMV infection is closely linked to acute rejection. Rejection favours CMV 
infection due to the increased immunosuppressive treatment that usually 
accompanies signs of transplant rejection. Acute rejection is observed from the 
second week and chiefly during the first 2 months after transplantation. The 
perception of swollen kidneys is infrequent, as is fever. In practical tenns and in 
most cases, infection is associated with changes in renal functions: reduced 
diuresis, increased creatininaemia, reduced natriuresis. In renal transplantation 
CMV has been suggested to cause graft glomerulopathy associated with viremia 
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(Richardson et aI., 1981) and to trigger the immune mechanisms of acute rejection 
in kidney transplant patients (Pouteil-Noble et al., 1993). 
-
CMV infectivity has been studied in various cellular components of the 
kidney. Human glomerular, mesangial, tubular and endothelial cells were isolated 
and infected with human CMV strain AD 169 (Ustinov et al., 1991). All types of 
human renal cellular components could be easily infected with CMV (Ustinovet 
al., 1991) as had been shown with in vitro studies (Heieren et al., 1988a,b; Ho et 
al., 1984) which demonstrated that several types of tissue cells such as mesangial 
cells and endothelial cells, can be readily infected by CMV. 
CMV infectio~ contributes not only to the onset of acute rejection but also to 
chronic rejection episodes. Chronic rejection of renal allografts is characterized by 
a progressive worsening of the renal function, typically beginning in the first 3 to 6 
months following transplantation, but sometimes much later. In chronic rejection 
the following clinical picture may appear: high blood pressure, a proteinuria, a 
gradual increase in creatininaeinia evidencing a progressive reduction of 
glomerular filtration rate. To ascertain whether CMV infection has any clinical 
impact on the appearance of acute or chronic rejection in renal transplantation, 290 
consecutive kidney allegi-aft recipients transplanted during 2 years were analyzed 
(Lautenschlager et ai., 1992). The follow up time was 3 years. Of these, 42 
developed a virologically confirmed (culture and/or pp65 AA (section 1.4)) 
infection with active CMV infection (80%) appearing during the first 3 months 
(80±22days). However, in the CMV infected group, 45% of the patients 
underwent signs of acute rejection during the first year, but only one graft was 
rejected. In the CMV -infected patients with chronic rejection 4/42 grafts were 
rejected. The differences were not considered significant. However, in another 
analysis of a large clinical material in Helsinki Center, consisting of 1,177 adult 
renal transplant patients with an 8 year follow up, CMV infection (culture and/or 
pp65 AA (section 1.4)) had a significant effect on long-term grafts survival and the 
development of chronic rejection (Isoniemi et al., 1997). 
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1.3.2 CMV in heart transplantation. 
Though-clinical studies have shown that acute rejections are more frequent in 
transplant patients with CMV infection than in those without (Grattan et al., 
1989), the "most important is the role of CMV in chronic rejection also called 
cardiac allograft vasculopathy. CMV infection is most closely associated with 
cardiac allograft vasculopathy which is characterized by arteriosclerotic changes 
(Everett et al., 1992). In a series of clinical studies, including 80 heart transplant 
patients, CMV was shown to be linked with histopathological changes of the 
, vascular wall in human endomyocardial biopsies (Koskinen et al., 1993a). CMV 
was associated with accelerated arterial thickening of the small intramyocardial 
arteries and subendothelial inflammation of the vascular wall (Koskinen et al., 
1993b). 
1.3.3 CMV in liver transplantation. 
The liver is a preferred site for CMV replication, and liver grafts have been 
found to be the most conimonly affected organ in primary CMV infections (Stratta 
et al., 1989). In addition to a variety of other CMV':'associated clinical 
manifestations, CMV hepatitis is a common finding in liver transplant patients 
(paya et al., 1989). Thus, the graft itselfis often affected both directly by the virus 
and also by the immune response against the virus, and this may cause diagnostic 
problems. The most c<)mmon differential diagnostic question in liver 
transplantation is whether loss of the organ is due to rejection or to viral infection 
(Lautenschlager et al., 1990)~ Liver allografts were monitored by:frequent fine-
needle aspiration biopsies and transplant aspiration cytology to demonstrate the 
inflammation associated either with acute rejection or viral infection. Acute 
rejections appeared shortly (7±3 days) der transplantation with a high peak of 
inflammation and intense lymphoid activation in the graft, which subsided within a 
few days with antirejection therapy. CMV infection, demonstrated by the pp65 AA 
(section 1.4), developed later (33±11 days) after transplantation with mild 
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lymphoid activation recorded not only in the graft but also in the peripheral blood 
of the patient. The inflammation subsided slowly during antiviral therapy with 
-
ganciclovir. CMV infection seemed not to be linked to early acute rejection 
episodes. The importance of concomitant CMV infection and late acute rejections 
has been reported by others (Cakalogu et ai., 1995). 
Some years ago, an association between CMV infection and chronic liver 
allograft rejection was reported (O'Grady et ai., 1988). Furthermore, persistent 
CMV DNA was "found in the hepatocytes of liver graft with chronic rejection 
(Arnold et ai., 1992). Recently, in situ DNA hybridization demonstrated that the 
, CMV genome per~ists not only in hepatocytes but also in the bile ducts and 
vascular endothelial cells (Lautenschlager et ai., 1997a). As persistent CMV DNA 
was found just in those structures that are targets for chronic rejection, these 
findings support the suggestion of involvement of CMV in the process. CMV may 
cause direct damage to the cells, or may activate immune responses against 
infected cells, or the mild immune' response against the viru$ may activate various 
cytokines, which leads to increased expression of human -lymphocyte antigens 
(HLA) thus triggering the mechanisms ofalloresponse. 
1.3.4 CMV in bone marrow transplantation • 
. CMV infection is one of the major threats to the recipient of an allogeneic 
stem cell graft (Boeckh et aI., 1996; Meyers et aI., 1986;). The incidence of CMV 
infection increases with intensity and duration of immunosuppression and 
approaches 70% in allogeneic bone marrow transplant (BMT) recipients who are 
either CMV·seropositive and/or receiving a transplant from a CMV-seropositive 
donor (Meyers et ai., 1986). CMV disease is still associated with significant 
morbidity in these high-risk patients and, in spite of combined treatment with 
ganciclovir and high-dose immunoglobUlin, also with a high fatality rate in 
recipients of an allogeneic stem cell transplant (Ljungman et aI., 1992, 1994). 
CMV -associated disease consisting of fever, malaise, atypical lymphocytosis, 
leukopenia, myalgia and arthralgia is frequently observed in recipients ofBMT and 
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often precede CMV enteritis or CMV·induced interstitial pneumonitis. The most 
threatening CMV -associated complication following bone marrow transplantation 
is CMV-induced interstitial pneumonia, which develops 7-10 weeks after 
transplantation. The mortality of CMV -induced interstitial pneumonia after bone 
marrow transplantation exceeds 70% (Meyers et al., 1986). Strategies have been 
evaluated to prevent CMV disease with chemotherapy (ganciclovir and/or 
foscarnet), either administered prophylactically or early (preemptive therapy). 
Preemptive antiviral therapy based on sensitive screening tests (Boeckh et 01., 
1996). as well as antiviral chemotherapy (Goodrich et 01., 1993) have been shown 
, to significantly redu~e CMV disease in high risk patients. 
1.3.5 CMV in experimental models of transplantation. 
Animal models have been used to investigate the role of CMV infection in 
renal transplantation. In experimental models of mouse and rat for CMV infection 
in allograft recipients it has been demonstrated that latent -CMV is transferable 
through kidney allografts (Bruning et ai., 1989; Hamilton and Seaworth, 1985). It 
has been suggested that the infection is brought to the graft by inflammatory cells 
and that the virus, carried by a small number of cells in ·the graft, may be 
reactivated by allogenic stimulation and immunosuppression. (Bruning et 01., 
1989). 
Experimental studies have been mainly focused on the effect of CMV on the 
ongoing process of chronic .rejection of the kidney allograft in a rat animal model 
that resembles the clinical situation as closely as possible (Lautenschlager et 01., 
1997b). This included triple drug immunosuppression by steroids, azathioprine and 
cyclosporin similar to that used with patients in most transplant centres. The use of 
cyclosporin alone is considered unadvisable because it causes long-term changes in 
the graft, which cannot always be. distiIiguished from those of chronic rejection 
(Mihatsch et 01., 1995). A rat model of chronic renal allograft rejection was 
developed (Soots et 01., 1997) in which, by using a certain rat strain combination 
and mild triple drug therapy, the grafts showed chronic allograft damage within 
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40-60 days, fidfi1ling the histological criteria of chronic rejection according to the 
Banffcriteria (Solez et ai., 1993). The chronic changes of the graft were evaluated 
-
by the chronic allograft damage index, which is derived from 6 histopathological 
changes characteristic for chronic renal allograft rejection. These are interstitial 
inflammation and fibrosis, glomerular sclerosis and mesangial matrix increase, 
vascular intimal thickening and tubular necrosis (Isoniemi et ai., 1994). The model 
of rat CMV (RCMV) infection (Bruggeman et ai., 1983) was then applied to this 
experimental model of renal transplantation. RCMV infection increased the 
inflaDlIJlRtion monitored by frequent fine-needle aspiration biopsy cytology (von 
, Willebrand and L~tenschlager, 1996), increased the macrophage response, 
generated fibrosis and narrowed the arteries and arterioles significantly earlier in 
infected transplant rats than these occurred in uninfected transplant rats. 
Histologically, chfonic rejection was diagnosed as early as 20 days after 
transplantation in CMV-infected grafts (Lautenschlager et ai., 1997b). One 
characteristic finding associated With CMV infection, and not seen in uninfected 
grafts, was the early (5-7 days after transplantation) medical-necrosis of the large 
arteries (arteria renalis). This study also demonstrated the gradual development of 
RCMV infection in the- gfaft, the virus first seen in the tubular cells and thereafter 
in the arteries, until at day 20 the graft was rejected (Lautensch18ger et ai., 1997b). 
RCMV infection (von Willebrand and Lautenschlager, 1996) was also tested 
in the experimental transplantation of rat aorta allografts. Wrthout 
immunosuppression these slowly developed arteriosclerotic alterations such as 
persistent perivascular inflammation, smooth muscle cell proliferation, and intimal 
thickening, which are similar to that of the heart transplant model (Mennander et 
ai., 1991). In this model it was demonstrated that RCMV accelerated the chronic 
rejection of vascular allografts, induced a prominent inf1ammatory response in the 
rat aorta allograft,' doubled the proliferation of smooth muscle cells and induced 
intimal thickening (Lemstr6m et ai.,- 1993). 
When the rats received basic triple drug immunosuppression treatment the 
enhancement of the inflammation was reduced, as well as the arteriosclerotic 
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changes (Lemstr6m et al., 1994). This experiment also demonstrated the important 
role of the immune response in the phenomena associated with CMV. 
To study the effect ofCMV in a standardized experimental model of hepatic 
transplantation, RCMV infection was used to study acute rejection of liver 
allografts in the rat (Martelius et al., 1997b). When the animals were infected with 
RCMV, the portal inflammation associated with acute rejection was significantly 
increased and also more severe bile duct damage was recorded in the graft 
(Martelius et al., t997a). 
, 1.4 Laboratory dia,IDosis of CMV infeetioa. 
The best means of diagnosing CMV infection is virus isolation. The virus can 
be recovered most readily from throat wasmngs and urine. Other body fluids, as 
well as biopsy materials, sometimes yield CMV. In culture, 1-2 weeks are usually 
needed for the appearance of cytological changes, and these consist of small foci of 
swollen, translucent cells with large intranuclear inclusions (Griffiths, 1984). 
Immunofluorescence is frequently used to demonstrate CMV antigen direCtly from 
clinical samples and often there is an advantage in combining virus isolation and 
immunofluorescence. In particular, immunofluorescence examiriation of inoculated 
culture will markedly decrease the usual time required for .demonstration of 
cytoPathic effects. 
Several serological methods (complement fixation test, radioimmunoassay, 
immunofluorescence and EUSA techniques) may be used to detect CMV-specific 
IgM or IgG antibody responses. Neutralization tests for antibody detection are less 
reliable because the preparations of CMV employed must be free of infected cells, 
which is difficult because standard virus suspensions contain mainly cell-associated 
virus . 
The increase in the number of patients with AIDS or organ transplants has 
resulted in an increase in opportunities to consider the diagnosis of CMV infection, 
and the possibility of effective therapy if infection is diagnosed sufficiently early 
has heightened the need for accurate and rapid laboratory methods for diagnosis of 
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viral infection. In addition, the well-established epidemiology of CMV transmission 
from blood transfusions (Alder, 1983) and donor organs (Chou, 1986) has created 
-
a continuing need for serologic methods suitable for screening donors and 
recipients in efforts to avoid adverse clinical outcomes in immunodeficient 
recipients. " 
Rapid and accurate diagnosis of active CMV infection in transplant recipients 
and in patients with autoimmune diseases is of great importance in avoiding over-
treatment with in1munosuppressive drugs and in guiding antiviral therapy. For 
these reasons rapid. and sensitive methods of detecting the virus have been 
, developed. Apart fr<Jm virus isolation and serological methods, the diagnosis of an 
active CMV infection can be achieved by utilizing the presence of CMV structural 
antigens in peripheral blood leukocytes (van der Bij 1988b). In peripheral blood 
-
leukocytes of heart transplant patients with CMV infection a CMV-specific antigen 
was detected by monocloJlal antibodies to CMV IE antigen. This antigen has been 
identified as a 65 kD viral matriX phosphoprotein (pp65) .(van der Bij 1988b). 
Monoclonal antibodies react with the pp65 antigen expressed mainly in blood 
leukocytes (van der Bij 1988a,b). This method seems to have been a breakthrough 
in the rapid diagnosis of systemic CMV infections in immunocompromised 
patients. The method, known as the CMV AA is extremely Useful for detecting 
active CMV infection in transplant patients. The assay consists of the following 
four steps, 1) isolation of blood leukocytes; 2) preparation of microscopic slides; 
3) immunoperoxidase staining with the use of murine monoclonal antibodies to 
CMV immediate early antigen (pp65); 4) evaluation and semiquantitative scoring 
(van der Bij et al., 1988a, b). On average, the test provides diagnostic infoImation 
about 1 week earlier than other methods. The major drawback of the AA is the 
need for immediate processing of blood samples to achieve optimal sensitivity and 
the consideration of certain technical aspects to avoid pitfalls (Boeckh et al., 
1992). 
Among the different techniques used to confirm. an active CMV infection, the 
detection of the CMV pp65 !las the advantage of quantifYing the viral load 
according to the number of antigen containing cells, which correlates well with 
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manifestations of CMV disease (Gerna et 01., 1992). However, the quantification 
of antigen-positive cells by the AA. is subjective and demands very careful and 
-
time-consuming microscopic examination (Gerna et 01., 1992). Wrth the advent of 
effective antiviral chemotherapy for human CMV infection, more rapid and 
sensitive techniques are required to identifY CMV infection during the acute stage 
of the illness and also to monitor antiviral therapy (Boeckh et 01., 1996). DNA 
amplification by the polymerase chain reaction (peR) has proved to be a reliable 
method to detect' CMV genome in clinical materials (Einsele et oz., 1991a,b). 
These assays have helped guide new antiviral strategies and improve patient 
, management (Einse~ et 01., 1991a,b). More recently quantitative PCR assays have 
become available (Gerna et 01., 1995). 
Serological testing is also used to confirm exposure to CMV but this requires 
both acute and convalescent sera, demonstrating a fourfold rise in titre. This 
technique is less reliable since immunosuppressed patients may not have a change 
in antibody titre even in the presence of an active CMV infection (Drew et al., 
1985). 
The use of flow cytometry in the detection of CMV infections has grown to 
significant proportions (Eimendorf et 01., 1988; Jiwa et al., 1994; McSbarry, 1994; 
Ploem-Zaaijaer et al., 1994). 
1.5 Immunity to CMV. 
It has been established from exp~nts with murine CMV (MCMV) that 
under certain. experimental conditions natural defense mechanisms such as genetic 
resistance and natural killer· cells (NK cells) can considerably contribute to 
resistance against lethal infection with a high dose ofvirus (Bukowski et 01., 1984; 
Scalzo et 01., 1992). The absence of a specific immune response despite the 
presence of NK cells, eventually results in a fatal outcome (Welsh et 01., 1991). 
Therefore, attention has concentrated in recent years on situations in which the 
critical parameter is not the init~ dose of infectious virus, but the capacity to limit 
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virus growth and spread in an antigen-specific manner. This has focused on 
antibodies and on the role ofT lymphocytes in the control ofCMV infection. 
1.S.1 Humoral immunity. 
The humoral immunity system affords protective immunity by the generation 
of neutralizing antibodies, which can interact either with free virus particles, or 
with viral glycoproteins expressed on the surfitce of infected cells. Antibodies 
directed against the envelope glycoprotiens ftequently neutralize the virus in vitro 
(Middeldrop et al." 1986; Navarro et aI., 1993). For CMV, the majority of 
neutralizhlg antibodies descnbed to date are specific for the CMV glycoproteins 
gB (UL55) (Utz et al., 1989) or gH (UL 75) (Hamilton et al., 1991), which are 
expressed both on the viral envelope, and the infected cell surtace. In addition to 
neutralizhlg free virus particles, some antibodies have been shown to prevent cell-
to-cell spread of the virus (Navarro et al., 1993). Antibody might also playa role 
in killing CMV-infected cells, by either antibody plus complement-mediated cell 
lysis (Middeldorp et al., 1986), or antibody-dependent cellular cytotoxicity 
(Kirmani et al., 1981), both of which have been demonstrated to occur in vitro. 
A potential evasion mechanism to evade humoral immunity is the induction 
of a receptor for the Fc portion of IgG by CMV (MacCormac and Grundy, 1996; 
Sakuma et al., 1977). The Fc receptor has been demonstrated on the surfitce of 
infected endothelial cells and fibroblasts (MacCormac and Grundy, 1996). It is not 
known wheth~f the CMV Fe receptor is also present on the viral envelope, where 
it could function to prevent the binding of neutralizhlg antibodies. 
I.S.2 Cell-mediated immunity • 
" 
While infections by CMV are often unnoticed in immunocompetent hosts, 
where it causes only mild or subclinical disease, in immunocompromised patients it 
may cause severe clinical sympJoms (Meyer& et al., 1986). Following a primary 
infection the virus remains in a latent ~te and is subsequently reactivated in 
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immunosuppressed patients undergoing transplantation or in conditions such as 
Cancer or AIDS (Rubin, 1990). However, the mechanisms of tissue injury caused 
-
by CMV infection in renal transplant recipients are not well understood. Host 
immune responses to CMV infection involve different compartments of the 
immune system. Studies in immunosuppressed humans and animals have revealed 
that CD4+ and CDS+ T cells are of crucial importance in the maintenance of 
immunity to CMV as well as for the eradication of an ongoing infection 
(Borysiewicz et al., 1988; Jonjic et al., 1989 and 1990). In human and animal 
experiments, the adoptive transfer of syngeneic, polyclonal CD8+ T cells to 
, immunosuppressed jndividuals has been shown to provide protection from CMV 
disease (Quinnan et al., 1982; Reusser et al., 1991). Cytotoxic CD8+ T cells have 
been described as being important effectors of the anti-CMV response and are 
mostly directed against matrix proteins such as pp65 (Doherty et al., 1992; 
Reusser et aI., 1991, Riddell and Greenberg, 1994, Wills et aI., 1996). Adoptive 
immunotherapy with CMV-specific CD8+ T cell clones from allogeneic donors has 
been shown to prevent the development of CMV disease (Reddehase et al., 1985, 
1987). In addition, allogeneic transfer of CMV -specific CD8+ cell clones has been 
found to reconstitute cellUIar immunity against CMV in vivo (Riddell et al., 1992). 
It has also been shown that infusion of increasing doses of T-cell clones results in 
an increased CMV-specific cytotoxic T lymphocyte response in -recipients (Walter 
et al., 1995). 
1.5.3. CMV persistence: esCape from cell-mediated immunosurveiJlanee.-
At the effector level, the immune system must either deal with free virus 
particles, rendering them non-infectious, or virus-infected cells, which must be 
.,. killed before the virus has replicated. N~,utropbils and macrophages can take up 
and destroy many free infectious agents, however CMV can survive in both of 
these cell types, and this part of the innate immune system is thus not effective in 
dealing with CMV. The potentially protective effector mechanisms of defense 
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against CMV and the mechanisms CMV can use to evade them are discussed 
below. 
1.5.3.1 Human CMV inhibits the expression of MHC class I molecules. 
Based on the observation that 1) MHC class I is reduced on the surface of 
CMV infected cells, 2) there is a· perinuclear retention of MHC class I, 3) the 
association of ~2..lnicroglobu1in (~2m, 12kD) with class I heavy chain (He) is not 
affected by CMV infectio~ and 4) that there are large decreases in steady-state 
levels of class I HC without a reduction in class I HC mRNA have fueled 
investigations into the mechanisms mediating these phenomena (Barnes and 
Grundy, 1992; Be~rsma et al., 1993; Yamashita et al., 1993). Metabolic labeling 
analyses show that the reduction in free He is the result of accelerated degradation 
and this phenotype correlates with CMV IE or E gene products (Beersma et al., 
1993; Yamashita et al., 1993). 
The principle structure of CMV -genome is the unique 'nucleotide sequence, 
the long UL and the short US. To identifY genes responsible for the class 
I degradation, Jones ei al., (1995) screened a panel of CM-y deletion mutants, 
each unable to express one of 18 nonessential open reading frames. The products 
of tW9 genes, US2 and US 11, were shown to independently dectease MHC class I 
expression by mediating the cytosolic degradation of HC by the proteosome. US2 
and US 11 have a high degree of homology with another CMV glycoprote~ US3 
(Ahn et al., 1996) and it haS been speculated that the US3 protein functions in an 
analogous fashion. However, the US3 protein does not enhance degradation of 
MHC class I molecules, rather it retains ~2m-associated HC in the endoplasmic 
reticulum (ER) (Ahn et aI., 1996; Jones et al., 1996; Tenney and Colberg-Poley, 
.• 1991). In addition to inhibiting MHC class I expression, the CMV early US6 
glycoprotein disrupted the transport of proteasome-generated peptides into the ER 
(Ahn et al., 1997; Hengel et aI., 1997). Peptide translocation was restored in a 
recombinant CMV lacking US6 (Ahn et al., 1997). 
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Based on the analyses of the functions of the US2, US3, US6 and USll gene 
a model ofCMV inlnDition ofMHC class I expression has been developed. During 
immediate early times postinfection the US3 gene product retains P2m-associated 
HC in the ER. At early times postin:fection US2 and US11 proteins target 
predominantly free HC for proteolytic degradation and US6 disrupt the transport 
of polyosome generated peptides to ER. Furthermore, there is cooperation 
between, the US3, US2 and USll gene products at early-late times postinfection 
since the US2 and us 11 proteins shuttle US3-retained class I HC to the cytosol 
for degradation (Wiertz et al., 1996a,b). 
1.5.3.2 CMV escapes CDS+ cytotoxic T lymphocyte lysis. 
Cell-mediated immunity is critical to the control of CMV infection and in 
individuals with depleted lymphocyte number and function (e.g. AIDS patients and 
transplant recipients), (Doherty et '01., 1992; Li et al., 1994). CD8+ T lymphocytes 
playa critical role in the antiviral effector arm of the adaptive immune system, i.e. 
CMV-specific, MHC class I restricted CD8+ cytotoxic T lymphocytes.(CTL) lyse 
CMV-infected cells (Borysiewicz et al., 1988; Doherty et al., 1992; Reusser et al., 
1991; Riddell et al., 1992). The importance ofCMV-specific CTL is established by 
their ability to limit the severity of CMV infection in immunocompromised hosts 
. . 
(Quinnan et al., 1982; Riddell et a1., 1992, 1994). 
CD8+ CTLs target peptides derived from CMV proteins presented in the 
context of the.' MHC class I HC molecule (Kootstra et al., 1997). Peptides are 
generated in a proteasome complex, a multicatalytic protease that mediates the 
adenosine triphosphate (ATP)-dependent degradation of ubiquitin-conjugated 
protein (Heemels and Ploegh, 1995). Cytosolic proteins are degraded by the 
proteasome and peptides are translocated into ER to be loaded onto MHC class I 
heterodimers by the transporters' associated with antigen processing (TAP) 
(Heemels and Ploegh, 1995). After their synthesis in the ER, MHC class I 
molecules are loaded with peptides of 8-11 amino acids, forming a stable 
trimolecular complex (Kootstra et al., 1997}. 
41 
,'1 
Inhibition of MIlC c1ass I molecule expression'is a common theme in viral 
immunoevasive mechanisms. Both, DNA viruses (adenovirus, herpesvirus, 
papovavirus, and poxvirus) and RNA viruses (coronavirus, rhabdovirus, 
paramyxovirus, and retrovirus) inhibit MIlC c1ass I expression (reviewed in 
Rinaldo, 1994). The widespread use of this mechanism by divergent viruses 
supports the proposal that decreasing MHC c1ass I expression provides a selective 
survival advantage to the microorganism, allowing the evasion of MHC class I 
restricted CD8+ CTL immunosurveilIance. 
, 1.5.3.3 CMV evad~ NK cell lysis. 
NK. cells can recognize and kill virus-infected cells, and CMV -infected cells 
have been shown to be killed by NK cells in vitro (Borysiewicz et al., 1986; Starr 
and Garrabrant, 1981). The killing of CMV-infected target cells in vitro by NK. 
cells differs from that of other target cells, in that a prolonged assay period of 
approximately 18 hours (rather than the usua14 hours) is needed before killing can 
be demonstrated (Starr and Garrabrant, 1981). It is thought that some 'form of 
activation of the NK. cellS is necessary before lysis can occur and there is some 
evidence for a protective role of NK. cells againSt CMV disease in transplant 
recipients in vivo (Quinnan et al., 1982). 
NK. cells lyse target cells which express little or no MHC c1ass I molecules, 
i.e. 'missing self' (Scalz et ai., 1992; Weinberg et al., 1996). NK. cells, induced 
immediately i.611owing CMV infection lyse CMV-infected cells during ,acute 
infection (Bancroft et al., 1981; Scalzo et al., 1992; Weinberg et aI., 1996) and are 
an essential component of the acute response to viral infection (Bancroft et ai., 
, 1981; Bukowski et ai., 1984). 
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The identification of an CMV encoded glycoprotein (from gene UL18) 
homologous to MHC class I was a breakthrough discovery in understanding how 
CMV-infected cells escape NK. cell lysis (Beck and Barrel, 1988). The UL18 
protein binds endogenous 132m and carries it to the surface of the infected cell 
(Browne et'a/1990; Grundy et al., 1987a). Where the UL18/p2mheterodimers are 
loaded with peptides, the profile of which is similar to cytoplasmic proteins 
typically found in the context of MHC class I heterodimers (Fahnestock et al., 
1995). 
Given that MHe class I negative CMV -infected cells are targets ofNK cells 
it was hypothesized~that the UL 18/P2m1peptide complex protected CMV -infected 
cells from NK cell lysis (Fahnestock et al., 1995). Experiments have been 
performed to dir~ly assess the role of UL18 in inhibiting NK. cell lysis have 
shown that MHC class I negative B cell line transfected with UL 18 confers 
resistance to lysis by NK cells (Reyburn et al., 1997). 
CMV and MCMV encode MHC class I homologues which protect infected 
cells from NK. cell lysis. The effect of the ULI8 protein in vivo was c~terized 
by utilizing deletion mu~ants of MCMV. m144 is the MCMV MHC class I 
homology (Farrell et al., 1997). Replication of these mut~s during acute 
infections is severely restricted by NK cells in visceral org~ of BALB/c mice 2-6 
days postinfection, with titres 400-fold lower than wild type viIus (Farrell et al., 
1997). 
The data suggest that ml44-induced inhibition of NK cell lysis is critical to 
maintenance of MCMV in viSceral organs during the acute phase of infection when 
innate immunity constitutes the major antiviral effector mechanism (Farrell et al., 
I 997}. CMV infection confers resistance to NK-cell-mediated cytolysis in vitro 
. and in vivo (Farrell et al., 1997; Reyburn et al., 1997). In addition to the UL18 
"' and ml44 genes, it has been proposed ~t the MCMV gp34IMHC class I HC 
complex also inhibits NK. cell lysis (KIeijnen et al., 1997). 
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1.5.3.4 CMV escapes CD4+ T Iympboeyte immunosarveiUanee. 
CD4+ T helper cell subsets play important roles in both humoral and cell-
mediated immunity. Murine CD4+ T cells participate in the clearance ofCMV from 
salivary glatids (Lucin et al., 1992), while human CD4+ T cells have been reported 
to playa role in the defence against intracellular pathogens (pieters, 1997). 
However, the participation of CD4+ T cells in responses to CMV infection, 
through the secretion of cytokines such as interferon-'Y (IFN-y) and tumor necrosis 
fuctor-a (1NF-a) and mechanisms such as cytotoxicity and helping B and CD8+ 
cells are still not weD established (Fish et 01., 1996). 
CD4+ T cells recognize antigens presented in the context of MHC class II 
molecules (Pieters,.- 1997). Professional antigen-presenting cells such as dendritic 
cells, macrophages, B cells, and thymic epithelial cells constitutively express MHC 
class II molecules (Glimcher and Kara, 1992; Boss, 1997). MHC class II molecules 
are highly polymorphic heterodimers consisting of a and p-c~ (pieters, 1997). 
For inducible antigen-presenting cells, such as activated T cells, endothelial cells, 
and epithelial cells, IFN-y· is the most potent inducer of MHC class II molecules 
(Boss, 1997; Glimcher and Kara, 1992). 
CD4+ T lymphocytes are a requisite component of anti-CMV immunity 
(Joqjic et al., 1989). The primary role of CD4+ T cells in CMV infection is an 
afferent one, augmenting CDS+ T lymphOcyte and B lymphocyte responses to 
CMV infection. A more d.ire.ct role of CD4 + T cells in mediating viral clearance 
may be due to' MHC class II restricted cytolysis or direct antiviral effects of the T 
helper (Th) I-type cytokines released by CMV-activated CD4+ T cells (Davignon 
et al., 1996; Lucin et al., 1992; Muller et 01., 1992; Rinaldo, 1994). CMV 
infection inhibits MHC class II expression in arterial and venous endothe~ cells in 
vitro and in vivo (Knight et al., 1997; Sedmak et al., 1994). Infected endothelial 
cells treated with IFN-y lack class II antigens on their surfuce and in their 
cytoplasm (Sedmak et al., 1994). 
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Also, there is accumulating evidence that CMV disrupts MHC class II 
expression in monocytes, which constitutively express MHe class II molecules. 
CMV -infected monocytes lack cytoplasmic and surface expression of MHC class 
II molecules but the mechanism of this is presently unknown (Fish et al., 1996). 
CMV-infected cells escape CD4+ T cell immunosurveillance, which appear to be a 
conserved immunoevasive strategy that provides a survival advantage to the 
pathogen (Slater et al., 1991). 
1.5.3.5 Mechani.m of immunosuppression by CMV. 
Escape from munosurveillance by T lymphocytes and lysis by NK cell are 
critical immunoevasive strategies for intracellular microorganisms. CMV has 
evolved diverse mechanisms for evading host cellular immunity: 1) Lysis by CD8+ 
CTL is inhibited by multiple glycoproteins within the unique short component of 
the CMV genome that inhibits MIlC class I expression, 2) By surfilce expression 
of the protein UL18 and m144; 3) CD4+ T cell immunosurve~ is inhibited by 
disrupting IFN-y inducible and constitutive MHe class II expression. The 
establishment of a latent· or persistent infection requires subversion of host 
immunity. The finding that divergent viruses have coevolved analogous means of 
escaping cellular immunity emphasizes that there are key immune functions which 
must be disabled in achieving a persistent infection or reactivation of a latent virus. 
When looking at the mechanisms of immune suppression which occur during 
acute infection_ by CMV, it .. is relevant to consider that what the virus does to 
modulate the·· immune system is a reflection of its way to survive. Like all 
herpesviruses, CMV becomes a permanent resident of its host following primary 
infection. This implies that the virus must not only escape immune responses aimed 
at its elimination, but that it must also have devised ways to control its own level 
'" of replication, and hence its expressi<:>n, to 'evade detection by the immune system. 
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1.5.3.6 Possible mechaDisms iDvolved iD CMV iDfectioD aDd graft/traDsplaDt 
rejectioD. 
Several mechanisms have been suggested to explain the relationship between 
CMV infection and graft rejection. The two main possibilities are either that the 
virus acts as an adjuvant and triggers the rejection cascade in the allograft or that 
the rejection activates the latent virus. Whether one of the mechanisms, or even 
both of them, are Involved has not yet been established. A great number of in vivo 
and in vitro studies support the hypothesis that CMV may trigger rejection. In 
, particuJar, increased, expression of MHC class I and II antigens on lymphocytes 
which have been noted during allograft rejection but also in association with CMV 
infection (Grundy et ai., 1988a; van Dorp et ai., 1989; van Es et ai., 1984; von 
Willebrand 1986). 
In the early studies, the upregulation of MHC class I and II antigens, 
mediated by IFN-y, was thought to be the key to understand·the mechanisms (van 
Es et ai., 1984; von Willebrand 1986). Large amounts of IFN-y are produced by 
activated lymphocytes during viral infections, but also during rejection episodes 
(Hall et ai., 1984). Class II induction has been demonstrated to be crucial for 
allograft rejection (Hall et ai., 1984), and an increase of foreign class II was simply 
thought to increase the immunogenicity of allograft and trigger rejection. It seems 
that CMV alone cannot induce class II expression of cultured human endothelial 
cells in vitro (Ustinov et aI., 1991; van Drop et aI., 1989), and inflatnmatory cells 
are needed to. be present to' induce this process (Waldman et ai., 1993). These 
inflammatory cells are always present in the allograft, especially if there is an 
ongoing aIloresponse. Thus, the viral infection in the graft induces or increases the 
. expression of MHC antige.ns on the cell surfilce and triggers the antiallograft 
". response or enhances the already ongo~ rejection. The met that rejection often 
precedes the clinical evidence of CMV infection could be explained by the long 
incubation time of several weeks, as the virus usually is of donor origin and is 
received with the graft at the moment oftranspJantation (Grundy et ai., 1988b).1t 
co.uld be suggested ~t the very early phase of the infection, or even the latent 
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virus, may already induce MHC antigen expression, both class I and II, before the 
clinical symptoms and laboratory diagnosis of the infection. On the other hand, 
CMV has also been demonstrated to suppress MHC antigen expression in infected 
cells (Scholz et al., 1992; Sedmak eJ al., 1994; Yamasbita et al., 1993). 
Another suggested mechanism is that allograft rejection causes the infection 
by activating the latent virus is also posssible. In experimental models of mouse 
and rat CMV infection in allograft ,recipients it has been demonstrated that . latent 
CMV is transferable through kidney allograft (Hamilton and Seaworth 1985). It is 
suggested that the infection is brought to the graft by the inflammatory cells and 
, that the virus carrie4 by a small number of cells in the graft may be reactivated by 
allogenic stimulation and inununosuppression (Bruning et al., 1989). The 
alloreactive lymphocytes then produce IFN-yand cause the increase of MHC 
antigens, also class I, antigens (Grundy et aI., 1988a). The class I molecules is 
especially important in the immune response against the virus to mediate cytotoxic 
lymphocytes or natural killer cells (Quinann et al., 1984). The class I molecule, or 
the 132m chain of it, bas also been suggested to be the receptor for CMV (Grundy 
et al., 1987b), and CMV ~ been demonstrated to bind to 132m molecules (Grundy 
et al., 1987a). The incfease of the possible receptors on the ~ll surfuces in the 
graft could filcilitate the viral binding and promote the infection. In man, the 
itnpo~ance of inflammatory cells in CMV infection bas been confirmed by a study 
demonstrating that the principal CMV -infected cells in the kidneys of renal 
transplant patients with primary CMV infections are infiltrating inflammatory cells 
(Gnann et al., 1988). 
Further information on the mechanisms by which CMV infection may 
contnbute to graft rejection bas been published. DNA sequence analyses have 
demonstrated that CMV encodes a molecule similar to the MHC class I antigen 
.' (Beck and Barrel 1988). This molecule Iu\s been suggested to bind 132m and could 
be involved with virus-cell attachment. On the other hand, this molecule might 
interfere with the induction of cell-mediated MHC-restricted inununity and 
cytolytic T cell response against the infected cells (section 1.5.2.3). In addition, 
sequence homology lq1d immunologic cross·reactivity of CMV with the HLA-DR 
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p-chain have been demonstrated (Fujinami et al., 1988). The viral IE-antigen-
induced antibodies have been found to recognize the DR antigens. This 
phenomenon could explain some mechanisms of autoimmunity associated with 
viral infections. The cross-.reactivity would also fit in the allograft rejection 
mechanisms: 
Thus, at the early phase of immune activation either due to aJIoresponse or to 
immune ,response against the virus, both of these factors can exacerbate the 
immune response." On te other hand, the inflammatory cells infiltrating the graft 
during the aJIoresponse may bring the latent virus to the graft, and the virus is 
activated by the cytoldnes produced during the early phase of aJIoresponse. 
1.6 CMV and cytokines. 
1.6.1 Cytokines. 
Cytoldnes are peptide or glycopeptide mediators of relatively low molecular 
mass (rarely more than 8-25 kD) and often consisting ofjusi a single chain. The 
cytokine family includes a large (and still growing) number of proteinaceous 
intracellular signa)jng molecules that mediate a variety of actions with and without 
the immune system. Because no brief definition can encompass all features of the 
members of this very diverse family, cytokines are best defined' by a list of their 
characteristic properties (Table 2). Cytoldnc.:s are produced by a variety of different 
cells and very often several unrelated cell types can produce the same cytokine. 
The nomenclatUre of cytokines reflects its evolution from many distinct sources 
(Vilcek and Le, 1994). 
Thl and Th2 cells are the major, functional subsets of T helper cells 
. (Mosmann and Coffinan, 1989; Romagnani, 1992); Thl cells induce several 
", cytotoxic and intlammatory reactions by ili,e production ofIL-2, IL-12, IFN-r and 
TNF, and are responsible for cell-mediated inflammatory reactions, delayed-type 
hypersensitivity and tissue injury in infectious and autoimmune diseases. In 
contrast, activation ofTh2 subsets ofT cells results in the production ofIL-4, IL-
s,IL-6, IL-9, IL-lO ~d IL-13, which stimulates predominantly humoral immune 
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responses mediated by antibodies. Thl and Th2 subsets are of major importance in 
determining the class of immunoprotective function in infectious diseases. Thus, a 
-
bias either towards Thl-dominance or Th2-dominance can make a difference 
between effective elimination of the virus and exacerbation of the disease 
(Mosmann and Sad, 1996). Research on mv infection (Clerici and Shearer., 
1993), murine AIDS (GazzinelJi et al., 1992), vaccinia virus (Actor et al., 1994), 
herpes simplex virus (Jayaraman et.al., 1993) and influenza virus (Graham et al., 
1994) has shown that generally Th2 responses exacerbate the infection, while Thl 
responses are protective. 
1.6.2 Modulation of cytoldne levels by CMV • 
. ' 
It is hard to assess the effect of CMV infection on cytokine production in 
Vivo. Observations made on in vitro studies may appear clearer, but when 
extrapolated to in vivo animal models, the results are sometimes surprising and 
even contradictory (Haagmans et al., 1994; Pavic et al., 1993; Price et al., 1996; 
Shanley el al., 1994; Yerkovich el al., 1997). Two aspects ofCMV and cytokines 
will be considered here; CMV modulation of cytokine levels in vivo and in vitro 
and the effect of cytokines on CMV expression and replication. 
CMV can induce increased cytokine production by both the infected cell and 
by cellS such as leukocytes which interact with the infected cell. Table 3 shows the 
range of cytokines induced by infection of fibroblasts, many of which could 
contribute to i,fumunopathology. For example, interferon (lFN)-P released from 
infected cells (Rodriguez et al., 1987) can upregulate the expression of class I 
faA on uninfected cells (Gruitdy et al., 1988a). Another cytokine affected by 
CMV infection is interleukin (11)-6 (Almeida et al., 1994; St-Jeor et al., 1993). 
Infected fibroblasts show induction of IL-6 expression and supernatants from 
CMV -infected cells induce IL-6 expression within 30 minutes of contact with 
endothelial cells (Almeida et al., 1994). 
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Table 1. 
Characteristic features of cytokines. 
1. Most cytokines are simple polypeptides or glycoproteins with 
molecular weight =8-25 kD (but many cytokines form homodimers or 
homotrimers). One cytokine (IL-12) is a heterodimer. 
2. Constitutive production. of cytokines is usually low or absent; 
production is regulated by various inducing stimuli. 
3. Cytokine production is transient and the action radius is usually short 
(typical action is autocrine or paracrine, not endocrine). However, 
some cytokines are found in the circulation during systemic infections. 
4. Cytokines produce their actions by binding to specific high affinity cell 
surface receptors. 
5. Most cytokine actions can be attributed to an altered pattern of gene 
expression in the target cells. Phenotypically, cytokine actions lead to 
an increase (or decrease) in the rate of cell proliferation, change in cell 
differentiation state, and/or a change in the expression of some 
differentiated fuiJ.ctions. 
6. Although the range of actions displayed by individual"cytokines can be 
broad and diverse, at least some actions of each cytokine are targeted 
at hematopoietic cells. 
7. Cytokines often act by increasing (or decreasing) or by trasmodulating 
receptors for other"cytokines. 
8. Structurally dissimilar cytokines may have a similar spectrum of actions 
(redundancy). 
9. A single cytokine often has multiple target cells and multiple actions 
(pleiotropism). 
10. Because cells and tissues·in the' body are rarely, if ever, exposed to a 
single cytokine at a time, many cytokine actions retlect the result of 
synergistic or antagonistic interactions among several cytokines. 
so 
Magnan et al. (1994) reported down-regulation of bone marrow stromal cell 
IL-6 production 72 h after CMV infection, even when cells were stimulated with 
lipopolysaccharide. However, Taichman et al. (1997) found no significant 
modification of IL-6 levels following infection of mixed bone marrow stromal and 
progenitor cells. 
Table 3. 
Cytokine induction by CMV. 
Cytolcines induced by CMV infection in cultured fibroblast cells 
IFN-P 
IL-6 
TGF-p 
Cytolcines induced by CMV infection/challenge of 
monocyteslmonocytic cell lines 
TNF-a 
IL-l 
IFN-a 
IL-6 is a cytokine which exerts ~ultiple biological activities, including 
regulating immune responses, haematopoiesis. Among these, induction of T cell 
proliferation and cytotoxic T 'Cell differentiation are just two of the many effects of 
IL-6 which may enhance pathological immune responses. In addition, IL-6 can 
a.tIect cells in many different ways. When IL-6 binds to its receptors on B cells, the 
. cells are stimulated to differentiate and secrete antibody (Hirano et al., 1990). IL-6 
". like IFN-P, is an endogenous pyrogen (~kowiak, 1998), and the viral induction 
of both of these cytokines could cOntribute to the high fever observed during 
episodes ofCMV infection in transplant recipients (Lui et al., 1992). 
The production of transforming growth mctor-p (TGF-P) is enhanced by 
CMV infe.ction of fi1>robJasts (Michelson- et al., 1994). CMV replication is 
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stimulated by treatment of fibroblast with recombinant TGF-J3 (Michelson et al., 
1994). A nlllIl:ber of other cytokines have been reported to be produced by CMV 
infection or CMV challenge of monocytes or monocytic cell lines. Enhanced 
production of tumor necrosis factor (TNF)-a (Smith et al., 1992; Turtinen et al., 
1989), IL-l'(Crump etal., 1992; Iwamoto et ai., 1990), and IFN-a (Noraz et al., 
1997) have been described, all of which are endogenous pyrogens (Mackowiak, 
1998) as, well as pro-inflammatory cYtokines. 
1.6.3 Induction of cytokines by CMV in transplant recipients. 
As concerns CMV and cytokines, two aspects will be reviewed. CMV 
modulation of cytoldnes in vivo and in vitro and the effect of cytokines on CMV 
expression and replication in transplant recipients. 
1.6.3.1 Interleukins (lLs). 
Interleukins are a larje group of cytokines (lL-l to IL-18) produced mainly 
by T cells, though some are also produced by mononuclear phagocytes, or by 
tissue cells. They have a variety of functions, but most of them are involved in 
directing other cells to divide and differentiate. Each interleukin acts on a specific, 
limited group of cells which express the correct receptors for that interleukin. 
IL-l is produced by macrophages and a variety of other cell types 
(Oppenheim et 'al., 1986). The biological activities of the IL-l molecules Wried 
and important for immune reactivity. IL-l can induce cells to synthesize more of 
itself and other cytokines, such as TNF, and IL-6. In fact, IL-l, IL-6 and TNF are 
all pro inflammatory cytokines with overlapping biological properties. Another 
.~ critical function ofIL-l is the activation ofT cells (Hemnann et al., 1988). As a 
consequence of this activation, IL-i, IL-4 and granulocyte-macrophage colony 
stimulating factor (GM-CSF) are produced (Herrmann et al., 1988). 
Following CMV infection -in liver transplant patients, IL-l serum levels 
slowly decrease, whe}'eas they remain elevated in patients undergoing acute 
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rejection or bacterial infections (TUg et al., 1991). In bone marrow transplant 
patients, IL-l receptor antagonists ·serum levels are significantly increased in 
CMV-infected, CMV-reactivating patients, graft-versus-host disease or fever of 
unknown origin when compared with bone marrow transplant patients without 
complication (Schwaighofer et al., 1997). Brain-derived macrophages and 
microglial celIs do not produce IL-l upon CMV infection (Pulliam et al., 1995), 
suggestin,g cell type specificity in IL-l induction by CMV. In contrast, infection of 
human endothelial" celIs in culture leads to suppression of IL-l (by 82%) when 
assayed 5 hours postinfection (Woodro1fe et al., 1993). 
IL-6 is another. potent pleiotropic cytokine which is produced by a variety of 
lymphoid and nonlymphoid celIs (Hirano et al., 1990) (section 1.6.3). In lungs of 
CMV -infected lung transplant patients, there was a significant increase of IL-6 in 
sera and BAL fluid, compared to uninfected patients, patients without 
complications, and those undergoing acute rejection (Magnan et al., 1994). A 
significant increase in IL-6 transcription in BAL fluid celIs was also detected by in 
situ hybridization, suggesting that IL-6 was produced in siiu in CMV -infected 
lungs (Humbert et al., 1993). The production of IL-6 by alveolar macrophages 
from lung transplant patients reflected in' vivo measurements suggesting in situ 
production (Humbert et al., 1993). 
1.6.3.2 Interferons (IFNs). 
Although. The interferons were first identified in 1957 as antiviral proteins, 
they are now also recognised as immunoregulatory proteins capable of altering a 
variety of cellular processes, such as cell growth, di1ferentation, gene transcription, 
and translation (Baron et al., 1991; Hooks and Detrick, 1992). There are three 
general types oflFNs: IFN-a,-f3, and -"( (Baron et al., 1991). The cell making the 
IFN and the substance triggering its production are important filctors in 
determining the type of IFN produced. IFN-a is produced by leukocytes in 
response to a variety of IFN -inducers, such as viruses, bacterial products, 
polynucleotides, tumo~ celIs, and allogeneic celIs. The cell types responsible for 
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synthesizing IFN-a. include B cells, T cells, macrophages, NK, and large granular 
cells. If any o~these inducers should interact with fibroblasts, epithelial cells, or to 
a lesser extent, leukocytes, IFN-f3 is produced. As an integral part of the immune 
response, T cells (either CD4+ or CD8+) are capable of manufacturing IFN-y. The 
interaction of sensitized T cells with antigens or specific antigen-antibody 
complexes results in the production ofIFN-y. The NK cell has also been shown to 
produce·· IFN-y. Moreover, thecytokine IL-2, which is produced by T 
lymphocytes, can also stimulate T cells to produce IFN-y. 
The IFNs can positively or negatively regulate cellular actions. These IFNs 
may then function in-a number of ways: they may inhibit virus replication, suppress 
cell proliferation and oncogene expression, and alter cell differentation. The 
antiviral actions of -the IFNs are not based on their direct interaction with virions. 
IFNs can modify immune reactivity by acting at the level of B cells, T cells, NK 
cells, macrophages, basophils, or bone marrow stem cells (Baron et al., 1991; 
Hooks and Detrick 1992). 
CMV not only induces interferon (Rodrigues et al., 1987) but is sensitive to 
its action in vitro (Rasmussen et al., 1984), although its role in vivo is unknown. 
No mechanisms are currently known by which the virus 'could evade this 
potentially protective host anti-viral response. 
Levels of IFN-a. were not notably increased in sera of CMV-infected liver 
transplant recipients (Arnold et al., 1993). Feldman et al., (1994) studied the 
frequency of lEN-a. -producing cells following in vitro challenge of peripheral 
blood mononuClear cells with DNA and RNA viruses. Enveloped viruses such as 
CMV elicited an IFN-a. response. 
IFN-f3 is the main form oflFN induced by CMV infection of endothelial cells 
(Sedmak et al., 1995). UV -irradiated CMV -infected cell supernatants partially 
block MHC class II expression in uninfeeted cells. This block can be partially 
alleviated by the addition of anti-IFN-f3 antibodies, suggesting that CMV -induced 
IFN-f3 plays some role in CMV_ .. induced inhibition of MHC class II expression 
(Sedmak et al., 1995). Low-multiplicity _infection of fibroblasts with CMV 
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apparently induces IFN -13 production, which can protect surrounding cells from 
infection (Hanwrecht and Steinmassl, -1994). 
IFN-y does not appear to be elevated in BAL fluid of bone marrow 
transplant patients with CMV pneumonia (Slavin et al., 1993). Human CMV IE-
specific CD4+ T cell clones, when stimulated specifically in vitro, secrete IFN-y in 
quantities sufficient to inhtbit CMV replication in neighboring cells (Davignon et 
al., 1996). Co-culture of activated lymphocytes from peripheral blood of bone 
marrow transplant recipients, with autologous CMV -infected fibroblast greatly 
augmented the production oflFN-y (Duncombe et al., 1990). The production of 
this cytokine has also been descnbed following culture of CD4+ T cells with 
infected endothelial cells (Waldman and Knight, 1996). 
Treatment of.· human fibroblasts with IFN-a or IFN-f3 hardly affects IE 
protein synthesis but blocks early and late antigen expression, as well as 
extracellular virus production up to 99% (Torigoe et al., 1993). In this respect, 
there is one case report of successful treatment with IFN-f3. of a renal allograft 
patient who had CMV-associated hepatitis and duodenal ulcer (Yagisawa et al., 
1995). 
1.6.3.3 Tumor necrosis facton (TNFs). 
lNFs are cytokines with inflammatory and antitumor activity which are 
presently identified as TNF~ and TNF-f3. TNF-a and TNF-f3 are siruc~ 
related, binds to the same cellular receptors and produce similar biological changes 
in a variety of cells. While· TNF-a is produced by neutrophils, activated 
lymphocytes, macrophages, NK cells, and some nonlymphoid cells, such as 
astrocytes, endothelial cells~ smooth muscle cells, and some transformed cells, 
TNF-f3 appears to be solely produced by T ·cells. 
CMV infection is associated with a significant elevation of TNF-a in 
bronchoalveolar (BAL) fluid in lungs of lung transplant recipients, compared to 
what is seen in the lungs of patients undergoing only acute rejection (Rondeau et 
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aI., 1991; Smith et aI., 1992). TNF is not increased in sera ofIatter patients but 
TNF receptors are elevated in the lungs of pulmonary transplant patients (Humbert 
et al., 1994). 
CMV IE protein-specific human CD4+ T cell clones stimulated with antigen 
produce TNF-~ in amounts which play a role in inhibiting CMV replication in 
neighbouring astrocytoma cells (Davignon et aI., 1996). Docke et al., (1994); and 
Fietze e( al., (1994) proposed that enhanced TNF levels observed during various 
diseases might be '~ factor for enhancing CMV replication in vivo. They tried to 
establish a correJation between CMV antigenemia and enhanced TNF levels in 
plasma and found that blood mononuclear cells of almost all patients with septic 
disease were positive for CMV antigen and that corresponding plasma contained 
enhanced levels ofTNF. 
'The interaction' between lymphocytes and CMV -infected cells such as 
fibrobJasts can augment cytokine production from lymphocytes. This has been 
shown for 'in vitro activated' lymphocytes from peripheral blood of bone marrow 
transplant recipients, where co-culture with autologousCMV -infected, but not 
uninfected, bone marrow fibrobJast greatly augmented the production of the pro-
inflammatory cytokine TNF-a (Duncombe et al., 1990). The production of this 
cytokine has also been described following culture of CD4+ T cells with infected 
endoili,elial cells (Waldman and Knight, 1996). CMV -induced TNF production can 
enhance CMV expression. TNF, via interaction with either of its receptors (p75 
and p55) upregulates CMV repli~tion. (Laegreid et al., 1994; Medvedev et al., 
1996). The resUlts imply that stimuJation of either of the TNF receptors 'can 
generate intracellular signals leading to induction of factors that can stimuJate 
transcription from CMV genome (Medvedev et al., 1996) . 
. ,. 1.6.3.4 Transforming growth factor ~. 
TGF-~ is a multifunctional cytokine that often demonstrates opposing 
effects, on the development, physiology, and immunologic responses of a variety 
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of cells. This cytokine is known to influence cellular differentiation, bone 
formation, haematopoiesis, cell cycle progression and cell migration. 
TGF-p belongs to a fiunily of proteins that can potently down-regulate 
lymphocyte functions (Kehrl et al., 1991; Sporn and Roberts, 1992). Through this 
mechanism, it plays an important role in modoying inflammatory and 
immunological responses (Wahl et al., 1989). Only one study has addressed TGF-
.~ levels in vivo in the supernatants of alveolar macrophages from lung transplant 
patients with CMV infection. This showed that cellular TGF-p content increased 
but not TG~-p secretion (Magnan et al., 1996). 
In vitro studies show that CMV infection of fibroblast induces transcription 
and secretion of TGF-p (Michelson et al., 1994). Following infection of bone 
marrow stromal cells stimulated with lipopolysaccharide, two patterns of TGF-J3 
production were seen: either decreased production irrespective of 
lipopolysaccharide stimulation or no effect of CMV (Lagneaux et al., 1996; 
Taichman et al., 1997). 
1.6.4 Concluding remarks. 
CMV maintains an intriguing and complex relationship with its host. It 
establishes latency in cells involved .in immune responses, particularly bone marrow 
progenitors and monocytes. Replication of CMV in macrophages has been shown 
to depend on the differentiation of these cells (Ibanez et al., 1991;· Lathey and 
Spector, 1991). Thus when CMV is threatened by an immune response, it is 
precisely this response that activates CMV replication. Subsequently, its 
replication has negative effects on these and surrounding cells, thereby rendering 
the immune response incapable of eliminating the virus completely. CMV also 
seems to take advantage of soluble mediators of immune responses, either by 
sequestering them, or by using their stimulatory effects on certain pathways to 
replicate more efficiently~ Thus, CMV has established a symbiotic relationship with 
its host, thereby assuring its perpetuation. 
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1.7 MAJOR OBJECTIVES AND AIMS. 
In view of the importance of CMV infection in kidney transplant recipients 
this study has two major objectives. The first objective is to establish flow 
cytometric assay for the detection of the CMV related pp65 antigen in PMNL of 
kidney transplant recipients since flow cytometry is generally highly sensitive, 
quantitative, rapid and objective. The second objective is to investigate the cell-
mediated imnlune response in CMV -infected kidney transplant recipients by 
detecting the level of various cytokines and by analyzing different leukocyte subsets 
. for any alteration in numbers. 
The first objective involves the establishment of a flow cytometric assay for 
the early detection of CMV -specific antigens in PMNL by using monoclonal 
antibodies. Then, a comparison between CMV -antigenemia and flow cytometric 
assays for the detection of CMV -specific antigen (pp65) will be made. 
The second objective involves investigating peripheral blood mononuclear 
cells (PBMC) from CMV -infected and CMV -uninfected "kidney transplant patients 
for cellular responses to the mitogen (PHA) and CMV antigens. On the other hand, 
levels of Thl-type cytokines (IL-2, lNF-a, IFN-'Y) and Th2-type cytokines (lL-4, 
IL-IO) will be measured in the supernatant after coculturing PBMC of CMV-
infected and CMV -uninfected kidney transplant patients with PHA· and CMV 
antigen. Also, flow cytometric analysis will be made for different lymphocyte subsets 
from CMV -infected and CMV -uninfected kidney transplant patients for the 
detection of alterations, if any in numbers of T lymphocytes, T cell subsets, B cells, 
granulocytes and NK cells. 
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2. MATERIALS, METHODS AND STUDY POPULATION. 
2.1. Blood samples. 
Pretransplant blood samples were collected from recipients before the 
administration of immunosuppressive drugs. Post-transplant samples were collected 
every two weeks for a period of 6 months. Blood samples were also collected during 
deterioration of renal function and at any suspected CMV -related infections in two 
EDTA containing tubes and transferred to the laboratory within 2-3 hours. One tube 
-
was processed for antigen detection and the second tube was processed for mitogen 
and CMV -induced stimulation ofPBMC. 
2.2. Study population. 
2.2.1 General characteristics. 
Table 4 shows, some demographic parameters of the study population. 
Seventy-nine kidney. transplant patients (31 female, 48 male) who received kidney 
transplants between 1996 and 1998 were inducted into this sru9y. 
Table 4 
Demographic parameten of the study population. 
Mean Age Sex Ethnic origin 
(range) M F Kuwaiti Non-Kuwaiti 
(%) (%) (%) (%) 
37 48 31 73 6 
(18-60) . (61%) (39010) (92%) (8%) 
* IgG test was done before., transplantation. 
As can be seen from table 4, the age range is from 18 to 60 years, with an 
average of 37 years. Seventy-three kidney transplant patients were Kuwaiti and 6 
- I 
. were Non-Kuwaiti (2 Egyptians, 2 Indians, 1 Syrian, 1 Iranian). All patients received 
an iriununosuppressive regimen of cyclosporin A, azathioprine and_steroids. Post 
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transplantation patients received a fixed amount of cyclosporin as specified by Table 
5. Cyclosporin TRAF levels were checked in whole blood every 12 hours. 
TableS 
Cyclosporin level recommended for kidney transplant patients. 
Time after Blood cyclosporin 
transplantation level nglml 
0-3 weeks 250-300 
-
1-3 months 200-250 
4-6 months 150-200 
oe 
6-12 months 100-150 
2.2.2 Specific data. 
2.2.2.1 CMV seropositivity. 
CMV -IgG was detennined on pretransplant blood sample by indirect 
immunofluorescent test (Gull Laboratories, USA). Only one patient was IgG 
l'legative. 
2.2.2.2 U aderlying disease. 
The underling disease complications that lead to kidney loss are categorised 
as folliows: glomerulonephritis (n=31), chronic tubulointerstitial disease (n=13), 
diabetes mellitus (n=10), adult polycystic kidney disease (n=9), hypertension (n=6), 
obstructive uropathy (n=5) and other causes (n=5). 
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2.2.2.3 HLA matching. 
HLA matching was done on three molecules; HLA-A, HLA-B, and HLA-
DR. 1.2 recipients had a complete match, 8 with one allele mismatch, 27 with two 
allele mismatch, 10 with three allele mismatch, 12 with 4 alleles mismatch, and 10 
with 5 alleles mismatch. HLA matching of the recipients is shown in Table 6. 
Table 6 
ADele differences between donors and recipients 
Complete Differences in alleles 
match 1 2 3 4 5 
No of 
recipients 12· 8 27 10 12 10 
2.2.2.4 Source of donor kidney. 
Due to the shortage of live related or unrelated donor kidney, almost half of 
the patients received cadaver kidneys. The other half of the recipients received live 
related or un-related kidneys (Table 7). 
Table 7 
Source of donor kidney. 
Donor Total 
Live related Live unrelated Cadaver 
20 (25%) 26(32%) 33 (42%) 79 
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2.2.3 D!agnostic criteria. 
In principle diagnosis of CMV infection/disease conformed to the guidelines 
suggested by Ljungman and Plotkin (1995). Clinically, a CMV infection was 
suspected when recipients suffered one of the following symptoms: unexpected 
feyer, arthralgia, leukopenia, thrombocytopenia, pneumonitis, hepatitis, retinitis and 
gastrointestinal u1ceration. Patients who had at least one of the CMV -associated 
symptoms and being antigenemia -positives were considered to have a CMV 
disease. 
2.3 Cell lines. 
The MRC-5 diploid cell line-derived from fetal lung tissue was obtained from 
the American Type Culture Collection (ATCC) and maintained in the growth 
medium described below. 
2.4 Human cytomegalovirus (CMV). 
The AD 169 straip of human cytomegalovirus was obtained from ATCC. 
2.5 Growth and maintenance media. 
Minimal essential medium (MEM) and RPMI-I640 medium were purchased 
from GibcoLife Sciences, UK. In order to prevent microbial contamination the 
following antibiotics (GibcoLife Sciences, UK) were added to the media: fungizone 
at a concentration of 50 unitslml of ~edium, penicillin at a final concentration of 100 
unitslml, and streptomycin sulfate at a concentration of 100 J1g/ml of medium. 
Growth and maintenance media were supplemented with 10% fetal bovine serum 
respectively (pBS; Flow Laboratories, UK) for the growth medium or 2% FBS for 
. the maintenance ptedium. 
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2.6 Trypsin versene solution (TIV). 
Trypsin-versene (TN) solution consisted of 0.25% trypsin (GibcoLife 
Sciences, UK) in phosphate buffer saline (PBS) containing 0.02% ethylene diamine 
tetraacetic acid (EDT A; GibcoLife Sciences, UK). PBS, magnesium and calcium 
free phosphate buffered saline in tablet form were purchased from Flow 
Laboratorie~ UK. Ten tablets were dissolved in one liter of distilled water and 
autoclaved. The solution was then stored at 40 C. 
2.7 CeU culture preparation. 
Cell monolayers grown in Roux flasks (25 cm2 or 75 cm2 flasks, Nunclon, 
Denmark) were split and propagated according to Hsiung (1982). The medium was 
discarded from the flask and the cell layer was washed two to three times with PBS. 
Prewarmed TN was added to the flask (1 ml to 25 crrt flask and 2 ml to 75 cm2 
flask). After one minute, the excess TN was decanted and the flask was incubated at 
37°C for another' 5~10 minutes, if needed until the cells detached. An adequate 
amount of prewarmed MEM growth medium was added to the flask and the cells 
were suspended by pipetting to break any clumps which might be present within the 
Cell suspension. Flasks of25 cm2 and 75 cm2 were then seeded with 10 ml and 15 ml 
of cell suspension, respectively. They were then incubated at 37°C until further use. 
For 96-w,ell plates, 0.1 to 0.2 ml of cell suspension was added to each well (10,000 
cells/well). 
2.8 Virus titration. 
Virus titration was performed as descnDed by Grist et al., (1974). An 
aliquote of stock virus suspension was thawed at 37°C, and ten-fold serial dilutions 
were made in MEM (e.g. from 10.1 to 1(}3 dilutio~. Virus titrations were carried 
. out in 96-well t~sue culture plates (flat-bottomed 96-well, Falcon products, USA). 
When a confluent monolay~r developed in the wells, medium was removed and the 
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cell layers were washed three times with PBS. Each virus dilution was inoculated 
(0.1 mIlwell) in duplicate wells. After a 30 minute incubation for virus adsorption, 
0.1 ml of maintenance medium was added to each well. Control cells were 
maintained in 0.2 ml of maintenance medium. Plates were then incubated at 37°C 
and the degree ofCPE was recorded daily microscopically. The titre of the virus was 
then calculated by the 50% tissue culture infectious dose end point (TCIDso) method 
of'Reed -Muench (1938). 
2.9 Propagation of virus in cell culture. 
The human CMV strain AD169 was propagated in MRC-5 cell monolayers 
grown in 25 C~2 or 75 cnt flasks at one time and the same batch of CMV -infected 
MRC-5 was used throughout the study. The medium was discarded from the flask 
and the monolayer was washed two or three times in prewarmed PBS. The cell layer 
was incubated with 0.3 ml of stock virus. The multiplicity of infection was 0.1 
viruslcell. After a 30 minute incubation at room temperature maintenance medium 
was added. Flasks' were then incubated at 37°C and observed daily for the 
appearance of cytopathic effect (CPE). When the CPE progressed to 100010, medium 
was collected and any detached cells were removed by centrifugation for 10 minutes 
at 1500 rpm. Undetached cells were removed by trypsinization (section 2.4). After 
centrifugation the pellets were collecte~· suspended in MEM medium and stored at -
70°C in. -aliqoutes of 106 cells/ml. The count was adjusted by using a 
haemocytometer (Neubauer, W.Germany). 
2.10 CMV Antigenemia assay (AA). 
2.10.1 Specimen Collection and Preparation. 
Approximately 5 ml of venous EDT A-treated venous blood was collected 
from each patient on using_aseptic venipuncture technique. Samples collected were 
. processed for the AA within 2-3 hours. 
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2.10.2 Isolation of leukocytes from peripheral blood and immunoperoxidase 
staining. 
.. Polymorphonuclear leukocytes (PMNL) were isolated by the dextran 
sedimentation·method as previously described (Grefte et ai., 1992a,b). Following 
incubation and centrifugation, the cell pellet was suspended in PBS and erythrocytes 
lySed with 0.8 mM ammonium chloride. The remaining cells were centrifuged, 
washed in PBS, counted by a coulter counter (Coulter Electronics, USA) and 
spotted onto CMV-we microscopic slides (INCSTAR Corporation, USA) (50,000 
-
cells per spot). Each microscopic slide contained one positive control well consisting 
of fibroblasts infected with CMV strain AD169, one negative control well consisting 
. of uninfecte<t fibroblasts. They were then dried and fixed in acetone, stained with 
CMV -vue Kit (INCST AR Corporation, USA) according to the manuf3cturerls 
recommendation. PBML were incubated with a mixture of two different monoclonal 
antibodies (clones C 1 0 and C 11) directed against the CMV lower matrix, early 
structural protein. PMNL containing the CMV -specific pp65 antigen were counted 
under a light microscope. 
A dark brown to red-brown nuclear or perinuclear staining within PMNL 
was taken as a positive result. Samples from each patient. were tested in duplicate 
and scanned at 200x-400x magnification for the presence of CMV -infected cells. A 
sample displaying 5 or more pp65 . antigen-containing cells out of 50,000 was 
considered as being positive. A lack of specific staining of PMNL upon examination 
of the duplicate wells was taken as a negative result. Any cytoplasmic colouration in 
the absence of nuclear or perinuclear staining was considered negative. 
2.11 Stimulation ofPBMC with PHA. 
2.11.1 Purification ofPBMC. 
Peripheral blood mononuclear cells (PBMC) of AA-negative and AA-
- I 
positive kidney transplant recipients were obtained by Ficoll-Hypaque (pharmacia 
Biotech, Sweden) density gradient centrifugation of 5 m1 of peripheral blood. Blood 
6S 
was carefully Jayered over Ficoll-Hypaque solution in a test tube, in a ratio of2:1 (5 
ml blood, 2.5 ml Ficoll-Hypaque solution). Care was taken to avoid mixing of blood 
with the gradient. The sample was centrifuged at 1800 rpm at room temperature for 
15 minutes. The interface, which contained the PBMC, was careful1y removed with a 
Pasteur pipette and washed 3 times in a test tube using RPMI-1640 medium 
containing 10% FBS. Washing was done by centrifugation at 1200 rpm for 10 
minutes after which the supernatant was discarded. The pellet containing the PBMC 
was suspended and counted by using a Coulter counter. 
-
2.11.2 PBA-induced proliferation of PBMC. 
PBMC . suspended in RPMI-I640 medium and adjusted to 1 ()6 ce1Is/ml 
aliquoted into 96 well tissue culture pJates at a density of lOs cells in 100 f.11 per well, 
and 100 f.11 phytohemagglutinin (PHA) (Sigma Chemicals, USA) of a 5 f.1g1ml 
solution was added for a period of24 and 96 hours at 37°C. The concentration of5 
f.1g1ml was chosen on the basis of optimal proliferation in our Jaboratory. For each 
sample a negative control was included by incubating PBMC for the same period in 
the absence of PHA. The supernatants from three wells were harvested after 24 
hours and six wells after 96 hours, while cells in an another three wells were pulsed 
with 1 f.1Ci per well eH] thymidine (Amersham, U.K.) at 96 hours of incubation for 
assessment ofPHA-induced proliferation. Thymidine-pulsed wells were harvested 18 
hours Jat~r onto glass filter fibers (1205-401, Filtermat A, Wal1ac, Turlcu, Finland) 
and the radioactivity was counted by a BetapJate 1205 ScintilJation counter 
(Pharmacia, Finland). The stimuJation index was calcuJated as a ratio of thymidine 
uptake between PHA~stimuJated PBMC and non-stimuJated PBMC. Background 
thymidine uptake in the absence of PHA was in the range of 80 cpm to 500 cpm. 
StimuJation indices of 50 or mOre were considered positive. The cut-off of 50 was 
based on experience in our Clinical Immunology Laboratory that an S.I. less than 50 
generally indicates low proliferation due to poor immune status of the subjects. 
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2.11.3 CMV -induced proliferation of PBMC. 
PBMC of AA-positive and AA-negative kidney transplant recipients and 
CMV::-infected fibroblast were suspended in RPMI-I640 medium and adjusted to 1()6 
cells/ml aliquoted into 96 well tissue culture plates at a density of lOS cells in 100 J.11 
per well with 100 J.11 of a lOs freeze-thawed CMV -infected fibroblast per well and 
incubated for a period of 24 and 96 hours. The concentration of lOS CMV-infected 
fibroblast per well was chosen on the basis of optimal proliferation. For each sample 
a negative control was included by incubating PBMC for the same period of time 
with uninfected fibroblasts. The supernatants from three wells were harvested after 
24 hours and six wells after 96 hours, while cells in an another three wells were 
pulsed with -1 J.1Ci per well eH] thymidine (Amersham, U.K.) at 96 hours of 
incubation for assessment of CMV -induced proliferation. Thymidine-pulsed wells 
Were harvested 18 hours later onto glass filter fibers (1205-401, Filtermat A, Wa1lac, 
Turku, Finland) and the radioactivity was counted bya-Betaplate 1205 Scintillation 
counter (Pharmacia). The stimulation index was calculated as a ratio of thymidine 
uptake between· CMv -stimulated ·PBMC and uninfected fibroblast-stimulated 
PBMC. Background thymidine uptake of PBMC stimulated with uninfected 
fibroblast control was in the range of 100 to 1000 cpm. Stimulation indices of less 
than 3 were considered to be proliferation negative (Boland et al., 1990; van Zanten 
et al., 1995). 
2.12 Assay for cytokines. 
Thl-type cytokines (lL-2, 1NF-a and IFN-y) and Th2-type cytokines (lL-4 
and IL-I0) were measured by ELISA using kits obtained from Immunotech SA 
(France). The recommendations of the manumcturer were followed. 
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2.12.1 Assay principle. 
Supernatants were assayed by sandwich ELISA with two immunological 
steps._The standard and sample were assayed at the same time for each run. Briefly, 
the first step of the procedure leads to the capture of the relevant cytokines (present 
in the sample) by monoclonal anti-cytokine anttoodies bound to the wells of 
microtiter plates. In the second step, biotinylated monoclonal antibody was added 
together with streptavidin-enzyme (peroxidase or alkaline phosphatase) conjugate. 
The biotinylated antibody binds to the antibody-antigen complex, and in turn, binds 
the conjugate. After incubation, the wells were washed and the binding of 
streptavidin-enzyme via biotin was detected by the addition of a chromogenic 
. substrate. The. intensity of the colour produced was proportional to the 
concentration of the cytokine present in the sample. 
2.12.2 Assay procedure. 
Cytokines . were estimated in the supernatants of PBMC of AA-negative 
kidney recipients and AA-positive recipients stimulated with PHA and CMV-
infected fibroblasts for 24 hours (for IL-2) and 96 hours (for TNF-a, IFN-y, IL-4 
and IL-I0). The lyophilized cytokine standard was recostituted as recommended. 
Serial dilutions of the cytokine standafd were prepared prior to each assay. Two well 
on the plate was left empty for subtrate blank. 50 ~l per well of standard or sample 
.. 
were added in duplicate and incubated for 2 hours at room temperature (IS-25°C) 
with shaking (350 rpm). The first immunological step was followed by washing the 
wells, including those of substrate blank, using an automatic washer (Labsystems, 
Finland). After w~ the plate for three times, 50 ~l of biotinylated antibody and 
.. 
1 00 ~l of streptavidin- conjugate were added to all wells, except to that for standard 
blank and incubated for 30 minutes at room temperature (lS-25°C) with shaking 
(350 rpm). The second inpnunological step was fQllowed by washing the wells, 
- including that 6f substrate blank, as before. Then 1 00 ~l of chromogenic substrate 
was added to all wells, including that for substrate blank. After that the plate was 
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incubated for 30 minutes at room temperature (18-25°C) in the dark with shaking 
, 
(350 rpm) . Finally, 50 ,.d of stop solution was added to all wells, including the 
subtrate blank and the plate was read at 450 nm against substrate blank. The colored 
product was measured using a Multiscan MS microplate reader (Labysystems, 
Finland). The sensitivity of each of the assays was as follows: 5 pglml for IL-2, 10 
pg/ml for 1NF- <l, 3 pglml for IFN- ,,(,5 pglml for IL-4 and 5 pglml for IL-lO. 
2.12.3 Evaluation. 
The concentration of cytokines in a sample was determined by interpolation 
from a standard curve that was constructed for every test run using reference 
. recombinant cytokines. The standard curves were drawn on linear graph paper, 
plotting the concentrations of the cytokine standard on the horizontal axis and the 
corresponding average absorbance on the vertical axis ... The "spline" mode was used 
for a computerized evaluation of the results. The absorbance of the unknown was 
plotted on the vertical axis and was read off the corresponding concentrations of the 
samples cytokines .ori the horizontal axis. 
2.13 Flow cytometry. 
2.13.1 Fixation ofCMV-infected cell cultures for flow cytometry. 
~ described before (section 2.7), MRC-5 cells were inoculated- with stock 
virus and after 30 minutes absorption period fresh medium was added, and the 
incubation started. This w~ considered 0 time. 
Detached cells were collected by centrifugation at 1500 rpm for 10 minutes. 
Attached cells were removed with a 0.25% TN solution, centrifuged at 1500 rpm 
for 10 minutes, added to detached cells, suspended in PBS, counted with a 
haemocytometer (Neubauer, W.Germany), adjusted to 1.0 -1.5 X 106 cellslml and 
fixed in cold 90% methanol (l part PBS + 9 parts MEOH) with continuous shaking 
and stored at -20°C until processed for flow cyto~tric analysis (E1mendorf et al., 
1988; Mcsharry, 1994). 
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2.13.2 Collection oCgranulocytes Cor flow cytometric analysis. 
The dextran sedimentation method described before (section 2.8.2) was used 
to isolate PMNL from the blood samples. Then PMNL were counted (Coulter 
counter, USA) and adjusted to 2xl06 cells/ml with cold PBS, fixed with cold 90010 
methanol and stored at -20°C until they were stained for flow cytometric analysis. 
2.13.3 Staining of PMNLs and MRC-5 for Flow cytometric analysis. 
Fixed and permeaIized cells (MRC-5 or PMNL) were stained by the 
procedure of)mpert-Marcille et al., (1997) using mouse monoclonal antibodies 
. (Clonab, Biotest, Dreieich, Gennany), specific to the CMV lower matrix, early 
structural (Pp65) antigen. After removing the fixative by centrifugation at 1000 g for 
5 minutes, cells were washed in PBS containing 20% human AB serum (PBSI AB). 
Cells were resuspended in 200 J.l.1 of mouse monoclonal antibody (Dako, Denmark) 
to CMV pp65 antig~ diluted 1:5 in PBS!AB. Optimal staining was achieved at 1:5 
dilution of mouse monoclonal antibody to CMV pp65 antigen. For each test sample, 
a control was included. Thus, control cells were suspended in 200 J.l.1 of isotypica1ly-
~ched monoclonal antibody (IgG2b) (Cahaglfebu, Marnes la Coquette, France). 
Both tubes were then incubated at 37°C for 60 minutes with shaking. The cells were 
washed ~ce with PBS/AB by centrifugation and then both tubes sample and 
control were incubated with 200 J.l.1 of 1 :20 diluted FITC-conjugated goat anti-
mouse immunoglobulin (Clonab, Biotest, Dreieich, Germany) at 37°C for 60 minutes 
with shaking. Optimal staining was achieved at 1 :20 dilution of FITC-conjugated 
goat anti-mouse immunoglobulin. This was followed by two rinses in PBS! AB and 
the cells were suspended in 200 J.l.l of PBS lAB and analyzed by an EPICS-Profile II 
(Coulter Electronics, USA) flow cytometer. 
Controls used: mock-infected MRC-5 fibroblast cells, PMNL from patients 
. without active CMV infections served as negative controls. MRC-5 cells infected 
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with the AD169 reference strain (at a multiplicity of infection between 0.1 viruslcell) 
served as positive controL 
2.14 IlIlmunoOuoreseence ceU surface staining with monoclonal antibodies. 
2.14.1 Staining procedure for surface markers. 
The assay was performed within 5 hours of venipuncture. Blood samples 
were kept around 25°C until processing. The following monoclonal antibodies 
(Cyto-StatlCoulter Clone, Coulter electronics, USA) were used: 
1. Double labeled monoclonal antibodies: 
. i) Clone T4-RD1 rrS-FITC: recognizes CD4+ (T cell inducer) and CDS+ (T cell 
suppressor/cytotoxic) lymphocytes. 
ii) Clone TII-RDIIB4-FITC: recognizes CD2+ (pan T cell) and CDI9+ (pan B 
cell) lymphocytes. 
iii) Clone CD3 FITC/CDI6/CD56 RDl: recignizes CD3+ (mature T cells), CDI6+ 
(NK. cells, minority ofT cell, granulocytes and some macrophages) and CD56+ (NK 
cells and minority ofT cell). 
2. Single-labeled monoclonal antibodies 
i) Clone CD1S-FIrC: recognizes CD1S+ (granulocytes) in whole blood by flow 
Cytometry.-
ii) Clone Tal-FITC: recognizes CD26+ (activated T lymphocytes, B lymphocytes 
and macrophages) in whole blood by flow cytometry. 
Appropriate isotype controls were used for the monoclonal antibody optimal 
staining was achieved with white blood cell counts in the range of 3-10 x 1 ()6 
cellslml. White blood cell counts exceeding 10 x 1 ()6 cells/ml required dilution, while 
counts below 3 x 1 ()6 cell/mI required centrifugation and resuspension in autologous 
- . , 
. plasma, to achieve counts in the range of3-10 x 106 cells/mI. 
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For each sample, eight siliconized 12 x 75 mm tubes were used. Five 
contained specific monoclonal antibodies and the remaining three served as isotype 
controls. Ten J.11 of monoclonal antibodies and isotype control monoclonal antibodies 
were added to the labeled tubes. Then 100 J.11 of the venous blood sample was added 
to each test tube and vortexed gently. Samples were processed after an incubation 
period of10-12 minutes at room temperature (l8-25°C). 
2.14.2 Preparation of Leukocytes. 
Leukocytes were prepared using Coulter Immunoprep Leukocyte System 
which is a rapid, gentle, no-wash erythrocyte-lysing system that maintains the 
-
. integrity of leukocyte morphology and cell surface. After the staining procedure, test 
tubes were placed into Coulter Q-prep Immunology workstation. The reagents 
delivered to the blood sample mcluded: 
i} Red blood cell lysing agent (Formic acid) 600 J.1VSample 
ii} Stabilizing agent (sodium carbonate, sodium chloride and sodium sulphate) 
265 J.1Vsample 
iii} Cell membrane fixative (paraforma1dehyde) 100 J.1Vsample 
}lrepared samples were kept at room temperature and anaiyzed by flow cytometry 
within two hours. 
2.14.3 Flow cytometrie analysis. 
Samples were analyzed by an EPICS-Profile II flow cytometer. Fluorescence 
intensity of the cells w~ measured with a 488-nm air-cooled Argon laser in the flow 
cytometer. The instrument was ca1i!>rated daily by using various quality control 
reagents. Data acquisition was triggered by cell size (forward versus 90 light 
scatter). The green fluorescence was fihered through a 530 band pass absorption 
filter and red fluorescence was fihered through a 575 band pass absorption fiher . 
. Debris and dead _cells were excluded from the analysis by the conventional scatter 
gating method. At least 50,000 PMNL or 10,000 MRC-5 fibroblasts were gated by 
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light scatter (PMNL gates were assessed for accuracy when appropriate by using 
CD 15 sfaining. All data were expressed in log fluorescence histogram form. The 
threshold of positivity for the green or red fluorescence intensity was arbitrarily set 
based on the negative control sample. 
2.15 Statistical analysis. 
For calculating the cell count by heamocytometer the following formula was 
used: Cell count (per mI) = number of cells counted/number of lmm2 squares 
counted x l/dil~tion factor x 104 cell/mI. 
For calculating the positive predictive value (posPV) and the negative 
. predictive valUe (NegPV) the following formulas were used: PosPV = (number of 
patients with positive test results and CMV -related disease/total patients with 
positive test results) xlOO. NegPV = (number of patients with negative test result 
and without CMV -related symptoms/total patients with negative test results) xlOO. 
Cytokine data were analyzed by standard non-parametric· t-tests. The p 
values were derived' from standard Mann-Whitney tests using the SPSS statistics 
software package (SPSS Inc, New York, USA). 
13 
3.1 Flow cytometric assay. 
3.1.1 Introduction. 
3. RESULTS 
It is J>f great importance to diagnose active CMV infuction as early as 
possible using a rapid,sensitive and accurate diagnostic procedure to avoid over-
treatment with immunosuppressive drugs and to guide antiviral therapy. During 
active CMV iDfection, PMNL appear in the circulation in low frequencies that 
express the CMV pp65 protein antigen. Because flow cytometry is an advanced 
. technology, which can be used to analyze a large number ofspecifica1ly labeled cells 
in a quantitative manner, it seemed appropriate to use flow cytometry for rapid and 
accurate detection of CMV -specific antigens in leukocytes of clinical samples of 
CMV -infected patients. This early detection of CMV :-infected cells would then 
provide a reliable methology for the diagnosis ofCMV infection especially in kidney 
transplant patients. In view of this, my first objective was to establish a flow 
Cytometric assay for the early detection of CMV -specific antigens in PMNL. 
3 .. 1.2 Establishment of a model cell culture system for standardizing Dow 
cytometric detection of CMV -specific antigens. 
Prior to the detection of CMV -specific antigens in PMNL in clinical samples 
from kidney transplant recipients it was essential to be able not only to detect .CMV-
specific pp65 antigen in CMV-infected MRC-5 cells but also to distinguish between 
CMV -infected and uninfected MRC-5 cells by flow cytometric assay (FCA). For the 
purpose of standardization, MRC-5 "diploid cell line was inoculated with AD169 
strain of CMV (multiplicity of infection = 0.1 virus/cell) and incubated for seven 
days (section 2.6). CMV-infected and uninfucted MRC-5 cells were fixed (section 
2.11.1) and stained with inonoclonal antibody to I CMV pp6S antigen (section 
2.11.3). Optimal-staining was achieved at 1:5 dilution of monoclonal antibody to 
CMV pp65 antigen. Mock-infected MRC-5 cells were used as negative control to 
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exclude nonspecific fluorescence. FCA was carried out in duplicate and repeated 
three times to ensure validity ofthe data When infected MRC-5 diploid cell line was 
tested for the presence of pp65 antigen by flow cytometry it was possible to detect 
the presence of antigen presenting cells as early as one day post infection. Figure 3 
show the results of the FCA for the detection of CMV -specific pp65 antigen in 
CMV -infected MRC-5 cells from day one to day seven post infection. The 
percentage of cells expressing the pp65 antigen increased proportionally with time 
after infection. On day one post infection more than 51 % of the cells expressed the 
antigen. That was followed by a gradual increase until it reached more than 90% on 
day seven (Fig. 3). It was important to know whether FCA seperates between CMV-
infected and uninfected MRC-5 cells. How FCA differentiates between infected and 
non-infected cells can be demonstrated the best by histograms. As it is presented in 
Fig. 4 the fluorescence histogram of FCA gives a complete seperation between 
CMV -infected and uninfected MRC-5 cells. 
The results ofFCA obtained with CMV-inf~ted and uninfected MRC-5 cells 
were encouraging to study the usefulness of flow cytometry for the detection of 
CMV -specific pp65 antigen in PMNL of kidney transplant recipients. 
3.1.3 Detection of CMV-specific pp65 antigen in 'PMNL by antigenemia and 
flow cytometry assays. 
Following the standardization ofFCA using CMV-infected MRC-5 cells, the 
assay-was tested on PBMLs of kidney transplant recipients with and without active 
CMV infection. Since the CMV antigenemia assay has been used in our laboratory 
for the early diagnosis of CMV infection in kidney transplant recipients~ it provided 
an opportunity to compare the validity ofFCA with that of the antigenemia assay. 
For this purpose, PMNL were separated from blood samples using the dextran 
sedimentation method (section "2.8.2). Isolated PMNL from each clinical sample 
were tested by both assays as described for the FCA in section 2.11.1 and 2.11.3 and 
for the antigenemia assay (AA) in section 2.8.8. 
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Fig. 3. Detection of pp65 antigen in CMV -infected MRC-5 cells. 
CMV -infected MRC-5 ~ells were harvested at daily intervals from day 
one to day seven post infection and screened using flow cytometry to 
detect the proportion of cells containing the pp65 antigen. Closed circles 
represent the mean percentage (±SEM) of the specific fluorescence. 
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Fig. 4. Fluorescence histograms of CMV-infected (A) and uninfeded 
MRC-5 cells (B) stained with anti-pp65 monoclonal antibodies and 
screened by flow cytometer. Histogram (A) represents results of cells stained 
. on day 5 post infection. The data for (A) and (B) were collected with the same 
instrument settings. LFL 1, log of FITC fluorescence intensity for line 1. Line 1 
respresents the area which was arbitrary set based on the negative control 
sample which represents the proportion, 82%, of pp65 containing MRC-5 
cells. 
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For the sake of comparison, PMNL from 79 kidney transplant recipients 
were tested for the presence of CMV specific pp65 antigen by both AA and FCA. 
Samples tested included 35 AA-positive and 44 AA-negative kidney transplant 
recipients. As it is seen in Fig. 5 the AA can be evaluated microscopically to 
identifY AA-negative and AA-positive cells. Fig. 6 shows the distribution of AA-
positive samples by months after transplantation in relation to clinical presentation. 
As can be seen from the figure, fever was a common clinical complication among 
AA-positive kidney transplant recipients throughout the period of 6 months post 
transplantation. On the other hand, AA-positive kidney transplant recipients 
suffered from fever and leukopenia during the first four months post 
transplantation whereas systemic infections were seen only during the first and 
second month post transplantation. Since the level of immunosuppressive therapy 
(cyclosporin level) decreases with time after transplantation, it could contribute to 
the variations of clinical manifestations in AA-positive kidney transplant recipients. 
The following results were obtained by the AA: 12 patients had 5-20 AA positive 
cells/5x104, 11 patients 21-50, 5 patients 51-100, 4 patients 101-200 and 3 more 
than 200. Studing these samples by FCA showed (Table 8) that the FCA was 
negative in all of the AA negative patients (n=44). As an example Fig. 7 shows the 
fluorescence histograms of PMNL from a kidney transplant recipient who had 200 
CMV AA-positive cells. Samples with 5-20 AA positive cells per 5xl04 showed an 
0.6% positivity by FCA. The mean percentage of positivity increases 
proportionally with the number of AA positive cells reaching 9.4% when the 
number of AA positive cells was greater than 200. By comparing the percentage of 
AA-positive cells with the percentage of FCA (Table 8), we can conclude that 
FCA has a higher sensitivity than that of the AA. This, however, could be due to 
nonspecific fluorescence which may play a part in the seemingly higher sensitivity 
of the FCA. To elucidate the role of nonspecific staining more samples need to be 
examined. Fig. 8 shows a comparison between AA and FCA. The regression 
square (Rsq)= 0.927 calculated from the results indicates that there 
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(A) (B) 
Fig. 5. The result of (A) AA-negative case (B) AA-positive case of 
kidney transplant recipients. A positive result viewed as dark brown to 
red-brown nuclear or perinuclear staining within PMNL, while a negative 
result demonstrates no specific staining of PMNL upon examination of 
the duplicate wells under a light microscope at 200x-400x magnification. 
Hematoxylin was used as a counterstain. This is a selected field , normally 
positive cells are very rare. 
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Figure 6. Distribution of AA-positive samples in months 
after transplantation with the clinical presentation. White 
bars represent patients with prolonged fever, gray bars 
represent patients with fever and leukopenia, black bars 
represent patients with systemic infection. 
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Fig. 7. Fluorescence histograms of CMV-infected case from kidney 
transplant recipients (the Number of AA-positive PMNL >200 cells 
per 50,000) stained with (A) isotypically-matched control (B) anti 
CMV-monoclonal antibodies (IgGl). The data for (A) and (B) were 
collected with the same instrument settings. LFLl, log of FITC 
fluorescence intensity. The horizontal line represent the gate arbitrary set 
to estimate the number of positively stained cells (it excludes 98% of 
cells stained with the control antibody) which represent the proportion, 
7.8%,ofpp65-containing,PMNL. 
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Table 8 
Number of antigen-positive PMNL as determined by AA and FCA. 
No of Mean No CMV -related FCA FCAMean 
Patients ofAA Clinical Symptoms fluorescence FI valueb 
tested positive %(±SD) 
cellsa (%) 
44 2 (0.004) no symptoms, AA 0.01 (±O.Ol) 0.4 
negative 
12 12 (0.024) fever 0.6 (±O.02) 0.8 
11 34 (0.07) fever 1.8 (±O.02) 3.6 
5 74(0.15) fever, leukopenia, 2.6 (±O.04) 5.8 
4 173 (3.5) fever, leukopenia, 4.2 (±O.09) 8.7 
3 370 (7.4) fever, leukopenia, 9.4 (±O.05) 11.8 
hepatitis and elevated 
liver enzymes 
a: AA is considered positive when 5 or more pp65 positive cells per 50,000 
are detected. 
b: Mean FI values were obtained by gating on the population of interest 
and calculating the mean fluorescence intensity. 
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Fig. 8. Correlation between the fluorescence of CMV-infected 
PMNL screened by flow cytometry to detect the proportion of 
cells containing the pp65 antigen and the number of AA-
positive PMNL containing the pp65 antigen in 35 kidney 
transplant recipients with active CMV infection. 
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is a strong correlation between AA and FCA (p<O.OOOl). It is important to 
know how FCA results correlates with the CMV -related clinical manifestations. 
FCA had a negative predictive value of 97.5% while its positive predictive value 
was 82.4%. Taking the similar criteria applied in the case of AA in account these 
. values are close to that of FCA (86% and 76% respectively). Overall the results 
suggest that FCA is as good as the AA for spotting ofCMV-infected cells. 
Since the determination of the number ofCMV-infected cells by the AA is a 
rather· cumbersome and sUbjective methodology, FCA may offer an alternative 
being a much faster and objective method to detect CMV antigen positive cells by 
screening a larger number of cells with considerable accuracy. Therefore the FCA 
may have the potential to diagnose an ongoing CMV infection and to monitor the 
effect of antiviral therapy in kidney transplant recipients. Moreover, FCA reveals 
prognostic information about CMV infection at an equally sensitive level but in a 
more rapid manner than the antigenemia assay. 
3.2 Proliferation of PBMC. 
3.2.1 Introduction. 
Due to the importance of the cell-mediated immunity in the control of CMV 
infection (section 1.5.2) the next objective was to study some aspects of the 
cellular immune responses of kidney transplant recipients with and without active 
CMV infection. In this respect PBMC responses to mitogen (PHA) and CMV 
antigen (CMV-infected MRC-5 cells) were investigated. PBMC were obtained 
from the 79 kidney transplant recipients by Ficoll-Hypaque density gradient 
centrifugation (section 2.9.1) and their stimulation indices (S.I.) to PHA and 
CMV-antigen were determined (section 2.9.2 and 2.9.3). The proliferation of 
PBMC to PHA and CMV antigens was carried out for each patient in triplicate 
along with a negative control to ensure validity of the data. 
During active CMV infection cytokines may play an important role in 
determining the outcome of infection (sectio~ 1.6.3). Due to the strong influence 
of Thl- and Th2-type responses on the outcome of CMV infections, Thl- and 
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Th2- type cytokine profiles of kidney transplant recipients with and without active 
CMV infection were investigated. The levels of Thl-type cytokines (IL-2, TNF-a, 
IFN-y) and Th2-type cytokines (lL-4, IL-IO) were measured in the supernatant of 
PBMC stimulated either with PHA or with CMV antigen by ELISA (section 2.10). 
The determination of the levels of Thl- and Th2- type cytokines gave an 
opportunity to calculate the ratio ofThl- and Th2-type cytokines. It was presumed 
that the ratio of Thl- and Th2-type cytokines would give a better parmeter for 
characterising the association between CMV infection and cytokine production 
than measuring their levels alone. 
3.2.2 PHA-stimulated cell mediated immune responses. 
PHA induced-proliferation of PBMC from 35 AA-positive and 44 AA-
negative kidney transplant recipients were assessed by thymidine uptake (section 
2.9.2). Fig. 9 shows the stimulation indices ofPBMC from AA-positive and AA-
negative kidney transplant recipients after stimulation with PHA. Stimulation index 
of greater than 50 was considered to be a positive proliferative response. The 
stimulation indices were found at a significantly lower level in infected individuals 
as compared to uninfected individuals. The calculated p value showed a high level 
of difference between CMV-infected and non-infected patients. The results are 
demonstrated in Fig. 9. When the proliferative response of PBMC was related to 
the number of AA-positive cells, it was found that the stimulation indices in the 
AA-positive kidney recipients was inversely related to the degree of antigen 
positivity (Rsq=0.75, Fig. 10); in other words, patients who had a higher number 
of CMV -antigen positive cells showed lower stimulation indices than did patients 
Who had lower number of CMV -antigen positive cells. The S.I. was as low as 2 
When the number of CMV -pp65 positive cells was 500 while it was as high as 60 
When the number of CMV -pp65 positive cells was around 10. The results are 
shown in Fig. 10. 
Fig. 11 shows the correlation between the mean value of PHA S.1. for AA-
positive ~idney transplant recipients and the clinical events. As can be seen from 
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Fig. 11 the S.1. was lower in patients with severe, systemic CMV -related disease 
when compared to those with less severe clinical manifestations (fever, fever and 
leukopenia). 
Table 9 
Mitogen-induced PBMe proliferation* in AA-positive 
and AA-negative kidney transplant recipients. 
Proliferation Pro liferation 
positive negative 
AA-
positive 2 33 
AA-
negative 43 1 
Total 45 34 
* PBMC proliferation was considered as positive when the S.1. was ~50. 
Total 
35 
44 
79 
As can be seen from Table 9, of the 35 AA-positive patients 33 (94%) were 
proliferation-negative. On the other hand, of the 44 AA-negative patients only 1 (2%) 
Was unresponsive to PHA. In the next phase of the study, PHA stimulation indices of 
PBMC from AA-positive kidney recipients were examined according to their CMV 
status; firstly when they were free of CMV infection (negative in the AA), secondly 
When they had an active CMV infection (presenting with symptoms and being positive 
in the AA), and thirdly when they recovered from the infection. 
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Figure 9. Stimulation indices (S.I.) of 35 AA-positive and 44 AA-
negative kidney transplant recipients after stimulation of PBMC 
with PHA for 96 hours. Horizontal lines represent medians. 
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Fig. 10. Correlation between PBMC proliferation 
(stimulation index) in response to mitogenic stimulation 
and the number of AA-positive PMNL in kidney 
transplant recipients with active CMV infection. 
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Figure 11. Correlation between the mean value of PHA 
stimulation indices for AA-positive kidney transplant 
recipients and the clinical events. White bars represent 
patients with fever, gray bars represent patients with fever and 
leukopenia, black bars represent patients systemic infections. 
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Data are presented in Fig. 12 As it is shown the indices were at a lower level 
during active CMV infection (B, median 8.1.= 24, p<0.0005) when compared with 
the indices obtained before the active CMV infection (A, median 8.1.=80, 
P<0.0005). The indices though marginally increased remained relatively low after 
the AA became negative again (C, median 8.1.=28, p<0.05). A comparison 
between the stimulation indices of AA-negative, symptom-free recipients (Fig. 
12D) and that of the AA-positive patients before active CMV infection (Fig. 12A) 
showed a significant difference in the 8.1. (p<0.0005). This implies that the 
reduced immunoresponsivness may be one of the factors that triggers the 
activation of CMV. PHA stimulation indices for a selected number of AA-positive 
and symptomatic patients (n=5) who became AA-positive on the second month 
after transplantation (Fig. 13A) were in the negative range «50). On the other 
hand, stimulation indices determined monthly for a period of 6 months for selected 
number of AA-negative, asymptomatic patients (n=5), though fluctuated, always 
remained in the positive range (>50) (Fig. 13B). The result of PHA stimulation 
clearly shows that active CMV infection influences certain cellular responses 
measured by stimulation indices. Results suggest that active CMV infection has a 
diminishing effect on the cellular response. Though stimulation indices are related 
to cellular response, this approach cannot give information about the subsets of 
cells involved in the interaction with active CMV infection. Therefore the study 
has been extended to analyse the levels of cytokines produced by different subsets 
of cells involved in the process of the immune response. 
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Fig. 12. Stimulation indices of PHA-stimulated PBMC from kidney 
transplant recipients when patients were AA-negative (A) when 
these patients became AA-positive, (B) and when the patients 
became AA-negative again (C). (D) stimulation indices of AA-
negative patients. Horizontal lines represent medians. 
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Figure 13. Response to PDA stimulus of successive 
samples obtained from (A) AA-positive and 
symptomatic patients (B) AA-negative and 
asymptomatic patients (selected data). 
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3.3 Thl-type cytokines. 
When levels of Thl-type cytokines (lL-2, TNF-a and IFN-y) were measured in the 
culture supernatant of PHA stimulated PBMC it was found that the mean levels of 
IL-2, TNF-a and IFN-y were consistently higher in the 44 kidney recipients 
without an active CMV infection than in the group of the 35 kidney recipients with 
an active CMV infection. These differences were statistically significant in the case 
of IL-2 (p<O.05) at 24 hours, IFN-y (p<O.0005) and TNF-a (p<O.005) at 96 
hours. P values were calculated by the Mann-Whitney test. The results of this 
analysis showed that ThI-type cytokines levels are lower in kidney recipients with 
active CMV infection than in those without active CMV infection. Data are shown 
in Fig. 14. 
3.4 Th2-type cytokines. 
Levels of Th2-type cytokines (lL-4 and IL-lO) were also determined in 35 
AA-positive and 44 AA-negative kidney transplant recipients. Fig. 15 shows the 
levels of Th2-type cytokines produced by PHA-induced PBMC in AA-negative 
and AA-positive kidney transplant recipients. There were no statistically significant 
differences in the levels of IL-4 and IL-IO between AA-positive and AA-negative 
groups. These results suggest that Th2-type cytokine secretion is not affected 
significantly by active CMV infection. In order to get a better picture on the 
production of cytokines of kidney transplant recipients with and without active 
CMV infection the ratio ofThllTh2 cytokines was investigated. 
3.5 ThlITh2 cytokines ratios produced by PHA-stimulated PBMC. 
The ratio of Thl to Th2-type cytokines in a given sample is considered to be 
of greater significance than the levels of cytokines alone. It seems to give a better 
understanding of the ~sociation between CMV infection and cytokine production. 
Therefore, the ratios of different Thl to Th2-type cytokines produced by PHA-
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Fig. 14. Levels of Thl-type cytokines produced by PHA-induced PBMC 
after 24 hours of culture for IL-2 and 96 hours of culture for IFN-y and 
TNF-a as measured by ELISA. Dark bars represent mean levels (±SEM) 
of the cytokines in AA-negative individuals; white bars represent mean levels in 
AA-positive subjects. 
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Fig. 15. Levels of Th2-type cytokines produced in the supernatant of PHA-
induced PBMC after 96 hours of culture as measured by ELISA. Dark bars 
represent mean levels (±SEM) ofthe cytokines in AA-negative individuals; white 
bars represent mean levels in AA-positive subjects. 
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stimulated PBMC were calculated. The mean values of Thl-type cytokines were 
compared to that of Th2-type cytokines produced by PBMC of kidney transplant 
recipients with and without active CMV infections. The difference between the 
two groups in some of the Thl :Th2 ratios was found to be striking. Table 10 
depicts the ratios ofThl to Th2-type cytokines. 
Table 10 
Thl: Th2 cytokines ratios of PHA-stimulated PBMC from AA-positive and 
AA-negative kidney transplant recipients. 
Thl:Th2 Ratio AA-negative AA-positive 
patients patients 
After 96 hours of 
culture 
. TNF-a:IL-4 18.6 8.4 
TNF -a:IL-I 0 2.6 1.3 
IFN-y:IL-4 1.3 0.2 
IFN-y:IL-IO 0.18 0.04 
As can be seen from Table 10, the TNF-a:IL-4 ratio at 96 hours were lower 
in the AA-positive group as compared to the AA-negative group, indicating a lower 
rhl-bias in the AA-positive group. In the cases ofTNF-a:IL-lO, IFN-y: IL-4 and 
IFN-y:IL-IO the differences in ratios are not as striking, even though the ratios are 
consistently lower in inf~cted individuals. Thus, the results support the view that 
there is a general trend of a lower production of Thl-type cytokines by the AA-
positive group than by the AA-negative group. Studing the responses of PHA-
stimulated PBMC of kidney transplant recipients provided data about a decreased 
cellular immune response of CMV infected individuals. Exploring this problem 
96 
further, responses of PBMC to CMV antigen (CMV-infected MRC-5 cells) were 
investigated. 
3.6 CMV infected fibroblast-stimulated cell mediated immune responses. 
The previous section described the responses of PBMC stimulated with a 
mitogen which provides a non-specific stimulus. This section describes the 
stimulation of PBMC with an antigenic stimulus, i.e. CMV antigens. This line of 
experimentation is expected to provide information on the specific response of 
PBMC to CMV antigens. PBMC from kidney transplant recipients were stimulated 
with CMV-infected MRC-5 cells (section 2.9.2) and the induced-proliferation was 
assessed by measuring the thymidine uptake (section 2.9.3). S.1. of >3 was 
considered to be a positive response. 
Table 11 
PBMC proliferation in response to CMV antigens in 
AA-positive and AA-negative kidney transplant recipients. 
Proliferation Proliferation Total 
positive (%) negative (%) 
AA-positive 4(11%) 31(89%) 35 
AA-negative 40(91%) 4(9%) 44 
Total 44 35 79 
As can be seen from Table 11, of the 35 AA-positive patients 31 (88% ) 
Were proliferation-negative; while only 4 (9%) of the 44 AA-negative patients 
Were unresponsive to CMV antigens., PBMC of CMV -infected transplantees 
responded poorly to stimulation by CMV antigens as compared to CMV -negative 
transplantees. Fig. 16 depicts the stimulation indices of PBMC obtained from 35 
AA-positive and 44 AA-negative kidney transplant recipients after stimulation with 
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CMV. The PBMC of AA-positive kidney transplant recipients showed significantly 
lowered stimulation indices in response to stimulation with CMV-infected 
fibroblasts than did AA-negative kidney transplant recipients. Median levels of 
stimulation indices were significantly lower in AA-positive kidney transplant 
recipients (2.0) as compared to AA-negative kidney transplant recipients (10.5) 
~th a p value of <0.0001. In the group of AA-positive recipients the number of 
CMV-pp65 positive cells varied between 10-500; the S.I. reached as low as 1 
when the number of CMV -pp65 positive cells was 500 and as high as 11.5 when 
the number of CMV -pp65 positive cells was around 10. 
Fig. 17 shows the stimulation indices of PBMC from AA-positive before (A), 
during (B) and after (C) recovery from active CMV infection (being free of antigen 
positive cells and symptoms). As can be seen from Fig. 17, the stimulation indices 
Were decreased during active CMV infection (median S.I=2, p<0.005) as 
compared with the indices of the same group of kidney transplant recipients before 
active CMV infection (median S.I.= 5.7, p<0.005). On the other hand, the indices 
of the same group of kidney transplant recipients after active CMV infection (C) 
increased marginally (median S.I.= 2.S, p= O.OS). When comparing the stimulation 
indices of AA-negative and symptom-free recipients (Fig. 17D) with that of the 
AA-positive patients before active CMV infection occurred (Fig. 17 A) a significant 
difference in the S.1. (p<0.002) could be seen. This implies that reduced 
immunoresponsivness may be one of the factors that triggers the activation of 
CMV. Stimulation indices by CMV antigen for a selected number of AA-negative, 
asymptomatic patients (n=5) were followed monthly for a period of 6 months. 
Though there were some changes in the levels of the S.I., it remained in the 
positive range (>3) during the study period(Fig. 1 SA). On the other hand, when 
lymphocytes of a selected AA-positive and symptomatic patients (n=5) who 
became AA-positive on the second month after transplantation were stimulated by 
the CMV antigen the S.1. values remained in the negative range «3) (Fig. ISB). 
As it is shown, S.1. values for these patients started to increase when the CMV 
infection was over. Therefore, these results suggest that an active CMV infection 
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Fig. 16. Stimulation indices of PBMC from 35 AA-positive and 
44 AA-negative kidney transplant recipients in response to 
stimulation with CMV-antigens (CMV-infected MRC-5) for 96 
hours. Horizontal lines represent medians. 
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Fig. 17. Stimulation indices of CMV-stimulatedPBMC of kidney 
transplant recipients when patients were AA-negative (A) when these 
patients became AA-positive, (B) and when the patients became AA-
negative again (C). (D) stimulation indices of AA-negative patients. 
Horizontal lines represent medians. 
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Figure 18 . . Stimlation indices from (A) five AA-negative kidney 
transplant recipients, (B) from five AA-positive kidney transplant 
recipients stimulated with CMV -infected MRC-5 over a period of six 
months. 
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may have a suppressive effect on the proliferative response of PBMC by CMV 
antigen. 
3.7 Thl-type cytokines. 
Fig. 19 shows, the mean levels of Thl-type cytokines produced by CMV-
stimulated PBMC of 35 AA-positive and 44-AA-negative kidney transplant 
recipients. The mean levels of IL-2, TNF-a. and IFN-y were consistently higher in 
kidney recipients without active CMV infection than in the group of recipients with 
active CMV infection. These differences were statistically significant in the case of 
IL-2 at 24 hours of incubation (p<0.0005) and IFN-y and TNF-a. at 96 hours of 
incubation (p<0.05). It is evident that kidney recipients with active CMV infection 
produce lower levels of Thl-type cytokines than do kidney recipients without an 
active CMV infection. Therefore, these data suggest that active CMV infection is 
associated with a decrease in the production of Thl-type cytokines produced after 
stimulation with CMV antigens. 
3.8 Th2-type cytokines. 
The levels of IL-4 and IL-I0 were measured in the culture supernatant of 
CMV -induced PBMC after 96 hours. Fig. 20 shows the results of the 35 AA-
Positive and 44 AA-negative kidney transplant recipients. The results showed no 
significant differences (p>0.05) in the mean levels of IL-4 and IL-IO between the 
AA-positive and-AA-negative groups after stimulation with CMV antigens. It 
appears that Th2-type cytokines production are not influenced significantly by 
active CMV infection in kidney transplant recipients. 
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Fig. 19. Mean levels of Th1-type cytokines produced after stimulation 
of PBMC with CMV-infected MRC-5 cells. Levels of IL-2 were 
measured at 24 hours and levels of IFN-y, TNF-a at 96 hours. Dark 
bars represent mean level (±SEM) of the cytokines in AA-negative 
individuals; white bars represent mean levels in AA-positive kidney 
transplant recipients. 
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Figure 20. Mean levels of Th2-type cytokines . produced after 
stimulation of PBMC with CMV-infected MRC-5 cells. Levels of 
IL-4 and IL-IO were measured at 96 hours. Dark bars represent mean 
levels (±SEM) of the cytokines in AA-negative kidney transplant 
recipients; white bars represent mean levels in AA-positive kidney 
transplant recipients. 
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3.9 ThlITh2 cytokines ratios produced by CMV-stimulated PBMC. 
The ratios of different Thl to Th2-type cytokines produced by CMV-
stimulated PBMC were calculated. The mean values of Thl-type cytokines were 
compared to that of Th2-type cytokines produced by PBMC of kidney transplant 
recipients with and without active CMV infections. Table 12 depicts the ratios of 
Thl to Th2-type cytokines. 
Table 12 
Thl: Th2 cytokines ratios of CMV -stimulated PBMC of AA-positive and AA-
negative kidney transplant recipients. 
Thl:Th2 Ratio AA-negative AA-positive 
patients patients 
After 96 hours of 
culture 
TNF-a:IL-4 2 1 
TNF-a:IL-I0 0.08 0.04 
IFN-y:IL-4 1.1 0.8 
IFN-y:IL-I0 0.04 0.03 
As can be seen from Table 12, the TNF-a:IL-4 and TNF-a:IL-lO ratio at 96 
hours were lower in the AA-positive group as compared to the AA-negative 
group, indicating a lower Thl-bias in the AA-positive group. In the cases ofIFN-
y: IL-4 and IFN-y:IL-lO the differences in ratios are not as striking, even though 
the ratios are consistently lower in AA-positive kidney transplant recipients. Thus, 
data show that there is· a general trend of a lower production of Thl-type 
cytokines by the AA-positive group than by the AA-negative group. 
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3.10 Immunophenotyping analysis of cells in the peripheral blood of AA-
positive and AA-negative kidney transplant recipients. 
It is known that CMV infection causes changes in the counts of lymphocyte 
subsets in peripheral blood (Beik et al., 1998; Belles-Isles et al., 1998). It is of 
great importance to enumerate percentage of different phenotype subsets during 
active CMV infection for diagnostic and prognostic purposes. Whole blood from 
AA-positive and negative kidney transplant recipients were analyzed by flow 
cytometry to detect changes, if any, in the number of different cellular subsets. 
Each patient sample was stained by antibodies specific to CD2+ (pan T), CD3+ 
(mature T), CD4+ (T helper), CD8+ (T suppressor), CD26+ (T activated), CDI6+/ 
CD56+ (NK cell), CDI9+ (pan B) and CDI5+ (granulocytes) (section 2.12.1). For 
each monoclonal antibody an appropriate isotypically matched control was used in 
each run. 
Fig. 21 shows the results of the mean percentage of cells for different 
lymphocyte phenotype subsets in peripheral blood of kidney transplant recipients 
with and without active CMV infection. The percentage of CD3+ 
immunocompetent T lymphocytes and CD4+ T lymphocytes were consistently 
higher in kidney recipients without an active CMV infection (AA-negative) than in 
the group of recipients with an active CMV infection (AA-positive). These 
differences were statistically significant in the case of CD3+ (p<O.05) and CD4+ 
(p<O.005). On the other hand between AA-positive and AA-nagative cases, in the 
percentage of cells expressing CD2+, CD8+, CD 16+ + CD56+, CD 19+, CD 15+ there 
was no statistically significant diffference (p>O.05). Fig. 22 and 23 show the 
percentages of cells expressing CD4+ and CD3+ respectively in kidney transplant 
recipients before the detection of active CMV infection (A), during active CMV 
infection (B) and after the recovery from the CMV infection (C). It was found that 
there was a significant decrease in the percentage of both CD4+ and CD3+ positive 
cells in kidney recipients during active CMV infection (CD4+ median = 22, 
p<O.005; CD3+ median = 41 p<O.05) when compared to the percentage of the 
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same group of kidney recipients before active CMV infection (CD4+ median = 36, 
p<O.005; CD3+ median = 59, p<O.05). After the loss of antigenemia the 
percentage ofCD4+ and CD3+ cells in these patients were increased (p<O.05). It is 
evident that kidney recipients show a significant alteration in the number of CD4+ 
and CD3+ T cells according to their CMV antigenemia status. Therefore, these 
data suggest that CMV infection is associated with a decrease in the number of 
CD3+, CD4+ T cells. 
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Figure 21. Immunophenotyping of cells in the peripheral blood of 
kidney transplant recipients with active CMV infection (35 patients) 
and without active CMV infection (44 patients) as detected by the 
AA. Dark bars represent mean percentage (±SEM) of the cellular antigens 
in AA-positive individuals; white bars represent mean percentages in AA-
negative kidney transplant recipients. 
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Figure 22, Percentages of CD4+ cells as detected by flow cytometry in 
kidney transplant recipients before active cytomegalovirus infection (A) 
during active CMV infection, (B) and after active CMV infection (C) as 
determined by the antigenemia assay. Horizontal lines represent medians, 
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Figure 23, Percentages of CD3+ cells as detected by flow cytometry in 
kidney transplant recipients before active cytomegalovirus infection (A) 
during active CMV infection, (B) and after active CMV infection (C) as 
determined by antigenemia assay. Horizontal lines represent medians. 
110 
4. DISCUSSION 
CMV is a ubiquitous virus in the human population, and primary infections 
are mostly without clinical symptoms in healthy individuals. After primary 
infections the virus is never completely eliminated from the host but remains 
sequestered in a cell population from which it can reactivate. During latency there 
is a constant interaction between the virus and the immune system: the latent virus 
evades immune destruction most probably by inducing substances which block 
immune recognition and down-regulate immune responses. This is signified by the 
fact that in the event of local reactivation of CMV, viral proteins are promptly 
recognized and further multiplication of the virus is controlled by the immune 
response. Thus, in healthy individuals localized viral expression stimulates 
adequate immune response to prevent further spread of the virus. However, in 
immunocompromised individuals the balance between viral activity and immune 
responses shifts in favour of the virus and consequently severe CMV infections 
may occur. CMV continues to be an important post-transplant pathogen in organ 
transplant recipients and is responsible for a substantial fraction of the morbidity 
and mortality that follows organ transplantation (Hibberd and Snydman, 1995). 
Because of the growing number of allograft transplantations, this agent constitutes 
a major pathogen in hospitalized patients. It has been reported that between 60% 
and 100% of renal transplant recipients develop CMV infection (as measured by 
virus excretion) (Pollard, 1988). 
Various antiviral agents have been used in attempts to treat established CMV 
disease (Alford, 1984). The preparations have included leukocyte interferon, 
interferon-stimulators (measles virus), transfer factor and nucleoside drugs, 
[iododeoxyuridine, fluorodeoxyuridine, cytosine arabinoside, adenine arabinoside 
(vidarabine), and acyclovir] (Alford, 1984). None of these regimens proved to be 
clinically useful. Recently, a derivative of acyclovir, 9-(1,3-dihydroxy-2-
propoxymethyl) guanine (gancyclovir) and a previously known inhibitor of viral 
DNA polymerases, phosphonoformic acid (foscarnet), have been shown to have 
potent activity against CMV in vitro. The mechanism of action of gancyclovir is 
III 
thought to reside in its nucleic acid chain-terminating activity, while foscarnet 
appears to inhibit the activity of the viral DNA polymerase directly (Snoeck et ai., 
1993). In post-transplant patients, initiation of therapy as early as possible during 
~tive CMV infection is important in the management of CMV infection. 
Therefore, early diagnosis and treatment of active CMV infection plays as 
important role in the control and management of this virus (Noble and Faulds, 
1998). 
Traditionally, CMV infection has been demonstrated by virus isolation and 
identification in cell culture or by the finding of inclusion bodies in biopsy 
specimens (Griffiths, 1984). Serologic testing has been used to confirm exposure 
to CMV but requires acute and convalescent sera demonstrating a fourfold rise in 
titer and is less reliable since immunosuppressed patients may not have a change in 
antibody titer in the presence of active CMV infection (Drew et ai., 1985). 
Although the combination of viral replication in tissue culture, a rising antibody 
titer, and inclusion bodies on histopathology is a sensitive and accurate indicator of 
virus infection, as long as 8 weeks may be required for virus indentification and 
Confirmation of diagnosis (Griffiths, 1984). With the advent of effective antiviral 
chemotherapy for human CMV infections, more rapid and sensitive techniques are 
required to identify CMV infections during the acute stage of the illness (Boeckh 
et ai., 1996; Ljungman et ai., 1992; Snoeck et ai., 1993). The availability of 
antigenemia assay (AA), a method that detects the presence of CMV-specific 
antigen by monoclonal antibodies expressed mainly during active infection has 
been used to identify CMV infection directly in clinical specimens (Boeckh et ai., 
1996, Griffiths et ai., 1984, van der Bij 1988a,b). AA can also be used as a 
quantitative marker of virus load that permits a detailed view of the interaction 
between CMV and the host. The advantage of this AA is that an identification of 
virus infection can be made in a number of hours only during active viral 
replication, it has an advantage over the highly sensitive PCR method that detects 
the viral genome regardless the activity of the virus. This technique, however, can 
be labor intensive and may not be useful for screening the large number of samples 
received in a clinical virology laboratory. 
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Flow cytometry is a technique which can be used to analyze a large number 
of specifically labeled cells and quantify their fluorescence. This technology may 
allow more rapid and sensitive detection of CMV -specific antigen and may be 
ijseful for the identification and quantification of CMV -infected cells in clinical 
samples. However, prior to utilization for diagnostic purposes, it must be 
standardized and compared to established methods. The parameters of FCA can be 
tested on human diploid fibroblast cells infected with CMV to establish the validity 
of such an approach. The results showed that FCA performed well in the detection 
of MRC-5 cells infected with CMV since it was possible to detect the presence of 
antigen presenting cells as early as one day post infection (section 3.1.2). When 
cells were stained with FITC-labeled monoclonal antibodies specific for the CMV-
early matrix protein (pp65), the antigen-containing cells were detected by the FCA. 
Analysis of the sensitivity of FCA was investigated by testing for the presence of 
CMV pp65 antigen in PMNL of kidney transplant recipients. In these samples the 
FCA detected the pp65 antigen even when the number of AA positive cells was 
between 5-20 indicating that the FCA was at least as sensitive as the AA (section 
3.1.3). 
These results showed that the FCA detects the CMV pp65 antigen in PMNL 
of kidney recipients with active CMV infection. An advantage of the FCA is that 
large numbers of cells and samples can be screened in a short time with accuracy 
and efficiency. FCA has a potential to be used for the diagnosis of an ongoing 
CMV infections, to monitor the effect of antiviral therapy in kidney transplant 
patients and to analyze the mechanism of CMV infection. Since the FCA is based 
on the detection of an antigen, which appears in the leukocytes only during active 
viral replication, it also has an advantage over the highly sensitive PCR method 
that detects the viral genome regardless the activity of the virus. Further studies 
should be carried out to study the possibility of using the technique of 
immunofluorescent staining and flow cytometry on direct clinical samples and it 
maybe able to provide results in less time without the need to purify PMNL from 
peripheral blood samples. This method may also be useful for the detection of 
other pathogens, where specific monoclonal antibodies are available. 
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Due to the monocytotropic character of CMV, it exhibits an intimate 
relationship with the host immune system, and is therefore of great interest to 
study this relationship and to understand the nature of immune responses against 
CMV infection in transplant patients. The host immune response to CMV involves 
specific as well as nonspecific immune surveillance mechanisms, which 
undoubtedly play roles in clearing virus infection. This is a complex process in 
general and particularly complex in immunocompromised patients because CMV 
itself induces immunosuppression and can interact with cells of the immune system 
(Koszinowski et a1., 1990). One of the most marked effect of CMV -infected 
monocytes is their immunosuppressive effects on lymphocyte proliferative 
responses. During acute CMV infection lymphocytes from mononucleosis patients 
do not respond to stimulation with the mitogen concanavalin A (con A) (Carney 
and Hirsch, 1981). When monocytes from seronegative donors are infected in vitro 
with CMV and added to autologous lymphocytes, there is no lymphoproliferation 
follOwing con A stimulation (Carney and Hirsch, 1981). Similarly, in vitro 
infection of peripheral blood lymphocytes inhibits lymphoproliferative responses to 
polyclonal mitogen stimulation (Wahren et a1., 1986). For the prevention of an 
active CMV infection and disease, cellular immunity in general, and the action of 
cytotoxic T cells to CMV -infected target cells in particular, is the most important 
factor in the host defense mechanisms (Quinnan et a1., 1982; Reusser et a1., 1991; 
Riddel and Greenberg, 1994; Riddell et a1., 1992; Rook et a1., 1984). In kidney 
transplant recipients the outcome of CMV infection depends to a great extent on 
the activity ofT cells (Mosmann and Coffinan, 1989; Quinnan et a1., 1982 Reusser 
et al., 1991; Rook et'al., 1984). PBMC proliferation to PHA activation was 
measured in this study as an indicator of the T cell responses in kidney transplant 
recipients with and without active CMV infections. Transplant recipients were 
grouped on the basis of being positive or negative in the AA. Lymphocytes were 
obtained from all patients and stimulated with PHA (section 2.9.2). 
The results of PHA-induced proliferative responses of PBMC revealed that 
transplant recipients with an active CMV infection had lower levels of proliferation 
(S.1. <50) when compared to recipients without active CMV infections (S.L~50) 
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(section 3.3.2). Kidney transplant patients received an immunosuppressive drugs 
shortly after transplantation. Since patients became AA-positive between I and 3 
months after transplantation, it is unlikely that cyclosporin A had an influence on 
the proliferation of PBMC or the levels of Thl-type cytokines. If cyclosporin 
played a role it would have an effect on AA-negative kidney transplant recipients. 
The reduction in the PHA-induced response of PBMC shows an inverse 
correlation with the number of pp65 antigen positive cells (Fig. 9). PBMC of 
recipients with high numbers (500/50,000) of pp65 antigen-bearing cells showed 
very low PHA-induced responses (S.I.<5). This may reflect the fact that an 
ongoing, active CMV infection has a diminishing effect on T cell response. This 
illustrates the importance of helper T cell responses, and is consistent with the 
well-recognized role of CMV -specific cytotoxic T cells in recovery from 
opportunistic CMV infections (Quinnan et aZ., 1982; Reusser et aZ., 1991; Riddell 
and Greenberg, 1994; Riddell et aZ., 1992). Similar observations have been 
reported in relation to kidney transplant recipients; subjects with active CMV 
infection had diminished cytotoxic T cell responses (Rook et aZ., 1984). This 
current study provides evidence that the decline in T cell response may be due to 
the immunosuppressive effect of an active CMV infection in kidney transplant 
recipients. Similar results were seen when lymphocytes of kidney recipients were 
stimulated with PHA before, during and after CMV infection as tested by the AA 
(section 3.3.2). Stimulation indices were higher before CMV infection and declined 
With the detection of CMV infection (Fig. 10). Thus it appears likely that CMV 
infection leads to immunosuppression, measured here as a decline in the T cell 
response to mitogenic stimulation. 
CD4+ T cells regulate both cellular and humoral immune responses in vivo, 
Primarily by releasing numerous cytokines (Heinzel et aZ., 1991; Sad and 
Mosmann, 1994). CD4+ T cells exist as at least two distinct subsets, Thl and Th2. 
Thl cells are characterized by the production of high levels ofIFN-y, TNF-J3 and 
IL-2, whereas Th2 cells preferentially release IL-4, IL-5, IL-6, IL-I0 and IL-13 
(Mosmann and Coffinan, 1989; Romagnani, 1992). Thl-type cytokines are 
generally associated with effective defense mechanisms against intracellular 
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infectious agents by activating macrophages, promoting granuloma formation and 
inducing delayed type hypersensitivity (DTH) reactions (Mosmann and Coffinan, 
1989; Romagnani, 1992). Th2-associated cytokines such as IL-4 and IL-I0 
~metimes allow the progression of intracellular pathogens by down-regulating 
Thl responses (Heinzel et 01., 1991; Sad and Mosmann, 1994; Romagnani, 1994). 
It should be pointed out that while both Thl and Th2 cells produce TNF-a, it is 
secreted at considerably higher levels in Thl-type responses and that it mediates 
cytotoxic activity as a part of cell-mediated immunity (Romagnani, 1992). TNF-a 
also elicits the production of IFN-y, a Thl-type cytokine. Thus, while TNF-a is 
not a characteristic Thl-type cytokine, it is of great significance in Thl-type cell-
mediated responses. 
Immune responses show a broad spectrum of variations according to 
different infective diseases or autoimmune disorders. These are usually reflected in 
the patterns of Thl- and Th2-type pattern of cytokine production (Romagnani, 
1994). An increase in the level of Th2-type cytokines is usually associated with an 
enhanced antibody production, allergic disorders and immunopathological 
reactions to helminthic infestations. On the other hand an elevated level of Thl-
type cytokines is closely linked to acute allograft rejection, organ-specific 
autoimmunity, contact dermatitis and intracellular parasitic infection. Thus, Thl-
type cytokines are primarily involved in cell-mediated immunity, while Th2-type 
cytokines are related to antibody formation. Studies on intracellular pathogens 
such as HIV (Clerici and Shearer, 1993), murine AIDS (Gazzinelli et 01., 1992), 
vaccinia virus (Actor et 01., 1994), herpes simplex virus (Jayaraman et 01., 1993) 
and influenza virus (Graham et 01, 1994) have shown that Th2 responses generally 
exacerbate the infection, whereas Thl responses are clearly protective. Given the 
strong influence exerted by Thl- and Th2-type responses on the outcome of 
infections, It was of importance to elucidate Thl- and Th2-type profiles during 
CMV infection in renal transplantees. 
Cytokines play important roles in the outcome of a CMV infection and 
determining the level and ratio of major cytokines involved in ThllTh2 paradigm in 
cell-mediated immunity, may give an insight into components of the association 
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between CMV infection and cytokine production. The results of this analysis 
(section 3.4) showed that Thl-type cytokine levels elicited in response to 
stimulation with a mitogen are lower in kidney recipients with active CMV 
,infections than in those without active CMV infections. Since Thl-type cells 
provide help for mounting cell-mediated reactions against viral infection, a decline 
in Thl-type activity may well lead to poor defenses against viruses. At the same 
time it appears that Th2-type cytokine secretion is not influenced by the CMV 
status of patients. There was no significant difference in the production ofIL-4 and 
IL-IO between AA-positive and AA-negative kidney transplant recipients (section 
3.5). This is consistent with observations in relation to bone marrow 
transplantation; recipients with active CMV infections had a low level of Thl-type 
cytokine production while Th2-type cytokine production remained unaltered 
(Sparrelid et al., 1997). In the latter study the analysis focused on the local 
production of Thl and Th2-type cytokines within the lung. This may suggest a 
common feature in all immunosuppressed transplant patients. 
The observation that an ongoing CMV infection (diagnosed by the presence 
of antigenemia) was closely associated with the production of Thl-type cytokines 
raised questions about the effect of CMV containing antigen cells on PBMC 
cultured in vitro. Measurement of the proliferative responses and subsequent 
cytokine production of PBMC stimulated with CMV-infected and non-infected 
MRC-5 fibroblast cells showed that of 35 kidney recipients with an active CMV 
infection, diagnosed by the AA, 31(88%) showed poor proliferative responses 
(S.I.<3) when stimulated with CMV-infected fibroblasts (section 3.7). On the 
other hand, of 44 kidney recipients without an active CMV infection 40 (91%) 
responded with positive proliferation (S.I.>3). These results (the low S.I.) 
indicated that the presence of CMV antigen had a suppressive effect on the 
proliferation of PBMC. Reduced proliferation of PBMC may be explained in two 
ways; a) CMV has a direct suppressive effect on lymphocyte responses or b) there 
is a poor cellular response to CMV. 
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While the responder PBMC were stimulated with CMV -infected fibroblasts, 
it is unlikely that these cells served as antigen-presenting cells as fibroblasts are 
HLA class II-negative. Professional antigen-presenting cells in the responder 
,PBMC may have presented CMV antigens to the T cells. 
On the other hand, results obtained with CMV-stimulated PBMC (section 
3.7) agreed well with those obtained with PHA-stimulated PBMC when Thl-type 
cytokines (IFN-y, TNF-(l and IL-2) were produced at significantly higher levels in 
kidney recipients without an active than with an active infection CMV infection 
(Essa et al., 2000). Using CMV -infected fibroblasts to test the responses of 
PBMC, the response was very similar to that ofPHA stimulation; PBMC of kidney 
transplant recipients with active CMV infection produced a significantly lower 
level of IFN-y, TNF-(l and IL-2 than PBMC obtained from recipients without an 
ongoing CMV infection (section 3.8). Such a difference was not observed in the 
case ofTh2-type cytokines (IL-4 and IL-l 0) (section 3.9). 
While it is possible that the correlation between CMV-infection and down-
regulation of Thl cytokines is actually due to immunosuppressive therapy, this is 
unlikely, since both the CMV -infected and uninfected individuals received the same 
immunosuppressive regimen. It is more likely that CMV infection itself has a 
selective suppressive effect on Thl-type reactivity in some individuals (Boland et 
al., 1990). Since cell-mediated immunity in general, and Thl-type immunity in 
Particular is important for protection against CMV infection, the balance between 
Thl and Th2-related cytokines may determine the outcome of a CMV infection. 
Also, it seems that CMV has evolved diverse mechanisms for evading host cellular 
immune reactions through the inhibition of CD4+ T cell immunosurveillance by 
disrupting inducible and constitutive production of Thl-type cytokines. This is an 
advantage for the virus since escaping T lymphocyte immunosurveillance is of 
critical importance in immunoevasive strategies for intracellular pathogens. 
Levels of CD4+ and CD8+ T cell subsets can predict progression to acquired 
1IIUnune deficiency syndrome (AIDS) among human immunodeficiency virus-
Positive subjects. To investigate whether a similar situation exists in kidney 
transplant patients, the proportion of lymphocyte phenotype subsets and 
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granulocytes in the peripheral blood of kidney transplant recipients with and 
without active CMV infection were investigated. CMV infection is known to 
induce changes in the lymphocyte subset counts in peripheral blood (Beik et al., 
.1998, Belles-Isles et al., 1998). Beik et al., (1998) examined changes in the 
circulating T-cell subsets of renal transplant patients to see if consistent changes 
occur following CMV infections. Serial blood samples were taken from 28 patients 
Who were on standard triple immunosuppression therapy. Using flow cytometric 
analysis, the percentage of activated and naive CD4+ and CD8+ T cells were 
determined. During active CMV infections, percentage of activated CD4+ and 
CD8+ T cells were increased, while there was a decrease in the percentage of naive 
CD4+ and CD8+ T cells. Belles-Isles et al., (1998) also quantified the percentage of 
activated CD8+CD38+ T cell subsets in 77 kidney transplant patients with CMV 
disease by flow cytometry. They found that the number of activated CD8+CD38+ 
subsets was increased during active CMV infections. In my study, flow cytometric 
analysis of PMNL from the 35 AA-positive kidney transplant recipients (section 
3.10) showed a significant change in the percentage of CD3+ T cells (p<O.05) and 
CD4+ T cells (p<O.005) compared with the 44 AA-negative kidney transplant 
recipients. This may be related to immunologic abnormalities that predispose renal 
transplant recipients to CMV infection. On the other hand, the percentage of CD8+ 
T cells remains the same between the CMV -positive and CMV -negative kidney 
transplant recipients (Fig. 21). This data probably reflects that there are 
proportionally more CD8+ T cell within the CD3+ population in the CMV-infected 
than the uninfected population. It is difficult to compare our results with that of 
Beik et al., 1998 and Belles-Isles et al., 1998 which is due to the fact that we did 
not determine the percentage of activated and naive CD4+ and CD8+ T cells 
separately rather we quantified the percentage of total CD4+ and total CD8+ T 
cells. On the other hand, the significant reduction in the percentage ofCD4+ T cells 
in. the AA-positive group may play an important role in the reduced proliferative 
responses of the PBMC to PHA and CMV-antigen. 
As mentioned earlier, (section 1.5.2.2) CMV has evolved mechanisms to 
evade cytotoxic T cell recognition of infected cells by down-regulating Class I 
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molecules (Barnes and Grundy, 1992). Thus, as infection progresses, the infected 
cell loses its ability to present viral peptides to cytotoxic T cells via the class I 
pathway, and becomes refractory to lysis. This may explain the relatively small, 
and statistically insignificant change in the proportion of CD8+ T cells present in 
kidney transplant recipients with an ongoing CMV infection when compared to the 
recipients without an active CMV infection. Polymorphonuclear leukocytes 
(PMNL) and mononuclear cells are the principal subsets that express viral antigens 
during CMV infection. In general, more than 95% of all antigen-positive 
leukocytes belong to the PMNL fraction. Patient samples were analyzed for other 
cellular subsets of potential relevance in the development of CMV infection. No 
significant difference in the percentage of granulocytes, T cells, B cells and 
activated T cells subsets between AA-negative and AA-positive kidney transplant 
recipients could be seen. Similarly, analysis did not reveal any alteration in the 
percentage ofCD15+, CD2+, CD26+, CD19+ lymphocyte subsets. 
The proportion of NK cells did not differ significantly between the AA-
positive and AA-negative kidney transplant recipients (section 3.7) possibly 
suggesting that NK cells did not recognize CMV-infected cells. However, CMV 
infected cells in vitro have been shown to be killed by NK cells (Borysiewicz et al., 
. 1986; Starr and Garrabrant, 1984). As mentioned earlier, (section 1.5.2.3) in vivo, 
CMV may have evolved a mechanism for evading the killing activity of infected 
cells by NK cells by encoding a class I HLA homologue, the UL-18 gene product 
(Beck and Barrell, 1988; Chee et al., 1990), which, when transfected into cells, 
was able to bind to the CD94 complex on NK cells. This provided a strong 
inhibitory signal preventing the lysing activity of natural killer cells (Reyburn et al., 
1997). This may explain why no significant difference in the percentage of NK 
cells of the kidney transplant recipients according to their CMV antigenemia status 
could be seen. 
-The immunological mechanisms that predispose to CMV infection are 
poorly understood. The analysis of kidney transplant recipients indicates that an 
active CMV infection is characterized by decreased lymphocyte proliferative 
responses, decreased levels of Thl-type cytokines (IFN-y, TNF-a. and IL-2), low 
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number ofCD4+ and CD3+ lymphocytes. These alterations may contribute to or be 
part of the inadequate immunological responses that predispose the development 
of CMV disease in renal transplant recipients. Although larger studies are needed 
to investigate whether this observation may be exploited in a clinically useful 
manner, the data indicate that further studies on the immune defense mechanisms 
against CMV infections in humans are required. 
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ThI-Type Cytokines Production Is Decreased in 
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Sahar Essa,1* Raj Raghupathy,1 Alexander S. Pacsa,1 Amany EI-Shazly,l Tareq Said,2 and 
F'awaz Azizieh1 
IDepartment of Microbiology, Faculty of Medicine, Kuwait University, Kuwait 
20rgan Transplant Center, Ministry of Public Health, Kuwait 
Cytomegalovirus (CMV) infection is a major 
complication after kidney transplantation. De-
spite antiviral therapy ·the infection contributes 
significantly to high morbidity. The present 
study was aimed at determining: (a) the stimu-
lation index (S.I.) of phytohemagglutinin (PHA)-
stimulated peripheral blood mononuclear cells 
(PBMC) and (b) the levels of Th 1- and Th2- re-
lated cytokines in kidney transplant recipients 
with and without active CMV infection. Thirty-
five patients with, and 44 without active CMV 
infections, as diagnosed by a ~MV antigenemia 
assay, were inducted into this study. After PHA 
stimulation of PBMC from patients, stimulation 
index (S.I.) was determined by radioactive thy-
midine uptake while the production of Th1-type 
cytokines (interleukin-2 [IL-2l, interferon-'Y [IFN-
'Y], and tumor necrosis factor-a [TNF-a]) and 
Th2-type cytokines (lL-4, IL-10) were measured 
by enzyme-linked immunosorbent assay. PBMC 
of patients with active CMV infection showed 
significantly 10wer.S.1. values than patients with-
out an ongoing CMV infection (P< .0001). Levels 
of Th2-type cytokines in CMV-infected and unin-
fected kidney recipients were similar; however, 
the levels of the Th1-type cytokines were signifi-
cantly lower in CMV-infected patients. Low lev-
els of Th1-type cytokines seem to correlate well 
with active CMV infection in kidney recipients. 
J. Med. Virol. 60:223-229, 2000. 
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INTRODUCTION 
Although cytomegalovirus (CMV) infection in immu-
Il.ocompetent individuals usually causes only mild or 
sUbclinical disease, in immunocompromised patients it 
lll.ay cause severe clinical symptoms [Meyers et al., 
~ 2000 WILEY·LISS, INC. 
1986l. However, the mechanisms of tissue injury 
caused by CMV infection in renal transplant recipients 
are not well understood. Studies in immunosuppressed 
humans and animals have revealed that CD4+ and 
CD8+ T cells are of crucial importance in the mainte-
nance of immunity to CMV as well as for the eradica-
tion of an ongoing infection [Borysiewicz et al., 1988; 
Jonjic et al., 1994]. In human and animal experiments, 
the adoptive transfer of syngeneic, polyclonal CD8+ T 
cells to immunosuppressed individuals has been shown 
to provide protection from CMV disease [Quinnan et 
al., 1982; Reusser et al., 1991l. Adoptive immuno-
therapy with CMV-specific CD8+ T cell clones from al-
logeneic donors has been shown to prevent the devel-
opment of CMV disease [Reddehase et al., 1985, 1987l. 
In addition, allogeneic transfer of CMV-specific CD8+ 
cell clones has been found to reconstitute cellular im-
munity against CMV in vivo [Riddell et al., 1992l. It 
has also been shown that infusion of increasing doses of 
cells results in an increased CMV-specific cytotoxic T 
lymphocyte response in recipients [Walter et al., 1995l. 
It is clear that the Th1 and Th2 subsets are of major 
importance in determining the class of immunoprotec-
tive function in infectious diseases. Thus a bias either 
toward Th1-dominance or Th2-dominance can make a 
difference between effective elimination of the virus 
and exacerbation of the disease [Mosmann and Sad, 
1996l. Research on HIV infection [Clerici and Shearer, 
1993], murine AIDS [Gazzineli et al., 1992], vaccinia 
virus [Actor et al., 1993], herpes simplex virus [Jayara-
man et al., 1993] and influenza virus [Graham et al., 
1994l has shown that generally Th2 responses exacer-
bate the infection, whereas Th1 responses are protec-
tive. Given the strong influence exerted by Th1- and 
Th2-type immunity on the outcome of infections, we 
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considered it of importance to elucidate Th1- and Th2-
type profiles in CMV infection in renal transplantees. 
Because the proliferative response of T lymphocytes 
to mitogens generally reflects the status of cellular im-
munity, we have measured the stimulation index (S.l.) 
v.alues of phytohemagglutinin (PHA)-stimulated pe-
ripheral blood mononuclear cells (PBMC) from kidney 
recipients with and without active CMV infection. Cul-
ture supernatants ofPHA-stimulated PBMC were ana-
lyzed for Th1-type and Th2-type cytokines to deter-
mine the status of Th1-Th2 profiles. ' 
MATERIALS AND METHODS 
Study Population 
Seventy-nine kidney transplant patients (31 women, 
48 men) who received kidney transplants during 1996 
and 1997 were included in this study. Their ages 
ranged from 18 to 60 years; most subjects were 30-45 
years old (median age = 35 years). All patients re-
ceived an immunosuppressive regimen of cyclosporin 
~, azathioprine, and steroids. Of the 35 patients posi-
tIve for the CMV-pp65 antigen, 32 had one or more of 
the following symptoms associated with CMV infection/ 
d~sease: fever, arthralgia, leukopenia, thrombocytope-
ma, pneumonitis, hepatitis, retinitis, and gastrointes-
tinal ulceration. Diagnosis of CMV infection/disease 
conformed to the guidelines suggested in the Workshop 
on CMV Disease [Ljungman and Plotkin, 1995). Pa-
tients in this study had to have at least one of the 
CMV-associated symptoms in addition to being anti-
genemia-positive to be considered as having CMV dis-
ease. Serial samples were collected at different inter-
vals after transplantation and patients were monitored 
for 6 months. Blood samples were collected in two eth-
ylenediamine tetraacetic acid (EDTA)-containing tubes 
and transferred to the laboratory within 2-3 hr. Anti-
gen detection and mitogen-induced activation ofPBMC 
were carried out on the same day. 
CMV Antigenemia Assay (AA) 
A total of 5 ml blood was collected from each patient 
and processed immediately. Leukocytes were isolated 
by the dextran sedimentation method. Following incu-
bation and centrifugation, the cell pellet was sus-
pended in phosphate-buffered saline (PBS) and the 
erythrocytes were lysed with 0.8 mM ammonium chlo-
ride. The remaining cells were centrifuged, washed in 
PBS, counted and spotted onto glass slides (50,000 cells 
per spot). They were then dried and fixed in acetone-
methanol, stained with CMV-vue Kit (Incstar, Inc., 
Stillwater, MN) according to the manufacturer's rec-
ommended procedure for immunoperoxidase staining. 
Numbers of cells containing the CMV-specific pp65 an-
tigen were counted under a light microscope. Patients 
with 2:5 cells containing the CMV-specific pp65 anti-
gen out of 50,000 cells were considered to be positive for 
AA. Each patient was tested three or more times by the 
AA at different time points. Patients who tested posi-
tive at the time of mitogen-induced stimulation were· 
considered AA-positive in this study. 
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Mitogen-Induced Stimulation of PBMC 
PBMC from 35 antigenemia-positive and 44 antigen-
emia-negative transplant recipients were obtained by 
Ficoll-Hypaque (Pharmacia Biotech, Sweden) density 
gradient centrifugation of peripheral blood at 1500 x g 
for 20 min. PBMC were suspended in RPMI-1640 me-
dium (GIBCO BRL, Gaithersburg, MD) containing 10% 
fetal calf serum, aliquoted into 96-well tissue culture 
plates at a density of 105 cells per well, and then stimu-
lated with PHA at a concentration of 5 J-Lg/ml for a 
period of 96 hr. The concentration of 5 J-Lg/ml was cho-
sen on the basis of optimal proliferation in our labora-
tory. The supernatants from some of the wells were 
harvested 24 and 96 hr later, while some of the wells 
were pulsed with [3H] thymidine (1 J-LCi per well) at 72 
hr for assessment of mitogen-induced proliferation. 
Thymidine-pulsed wells were harvested 18 hr later and 
the radioactivity estimated. The S.1. was calculated as 
a ratio ofthymidine uptake by PHA-stimulated cells to 
that by nonstimulated cells. Background thymidine up-
take in the absence of PHA was in the range of 80-500 
cpm. Samples yielding S.1. ofless than 50 were consid-
ered as proliferation-negative. The cut-off of 50 waS 
based on experience in our Clinical Immunology Labo-
ratory that an S.1. less than 50 generally indicates loW 
proliferation due to poor immune status ofthe subjectS. 
Assay for Cytokines 
Levels of the Th1-type cytokines, interleukin-2 (IL-
2), tumor necrosis factor-a (TNF-a), and interferon-'Y 
(lFN--y), and the Th2-type cytokines, IL-4 and IL-IO, 
were estimated in the supernatants of PBMC of 44 
CMV antigenemia-negative kidney recipients and 35 
antigenemia-positive recipients stimulated with pIIA 
for 24 (for IL-2) and 96 hr (for TNF-a, IFN--y, IL-4, and 
IL-10). Th1-type cytokines and Th2-type cytokines 
were assayed by enzyme-linked immunosorbent assaY 
(ELISA) using kits obtained from Immunotech SA 
(France). These consisted of sandwich type ELISA; 
briefly, the first step led to the capture of the relev~nt 
cytokines by monoclonal anti-cytokine antibodIes 
bound to the wells of microtiter plates. In the second 
step, biotinylated monoclonal antibody was added to-
gether with streptavidin-enzyme (peroxidase or alka-
line phosphatase) conjugate. The biotinylated antibody 
binds to the antibody-antigen complex, and in turn, 
binds the conjugate. After incubation, the wells w~re 
washed and the binding of streptavidin-enzyme via bIO-
tin was followed by the addition of a chromogenic sub-
strate. The intensity of the coloration produced is pro-
portional to the concentration of the cytokine present 
in the sample. The sensitivity of each of the assays was 
as follows: 5 pg/ml for IL-2, 10 pg/ml for TNF-a, 3 pg/llll 
for IFN--y, 5 pg/ml for IL-4, and 5 pg/ml for IL-10. 
Statistical Analysis 
The standard Mann-Whitney test was used for non-
parametric comparisons of median cytokine levels. 
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Fig. 1. Stimulation indices (S.L) of 35 cyto-
megalovirus (CMV)-infected and 44 CMV-
uninfected kidney recipients. 
RESULTS 
PHA-Induced PBMC Proliferation 
Figure 1 shows the stimulation indices of PBMC 
from antigenemia-positive and antigenemia-negative 
kidney transplant recipients after stimulation with 
PHA. It was found that the indices in the antigenemia-
positive kidney recipients was inversely related to the 
degree of antigen positivity (r2 = 0.052, Fig. 2); in other 
words, patients who were highly antigenemia positive 
had lower stimulation indices than were patients who 
had low antigenemia. In the group of antigenemia-
positive recipients, the number of CMV-pp65-positive 
cells varied between 10 and 500 and the S.1. was as low 
as 2 when the number of CMV-pp65-positive cells was 
500; the S.1. was as high as 50 when the number of 
CMV-pp65-positive cells was around 10. As can be seen 
from Table I, ofthe 35 antigenemia-positive patients 33 
(94%) were proliferation negative. On the other hand, 
ofthe 44 antigenemia-negative patients only 1 was un-
responsive to PHA (2%). Figure 3 shows the stimula-
tion indices ofPBMC from antigenemia-positive kidney 
recipients before the detection of active CMV infection, 
during active CMV infection, and after the recovery 
from active CMV infection. It was found that the indi-
ces in the antigenemia-positive kidney recipients were 
decreased during active CMV infection (mean S.1. = 24, 
P < .0005) when compared with the indices in the same 
kidney recipients before active CMV infection (mean 
S.1. = 80, P < .0005). It was also found that the indices 
in these recipients are marginally increased, but still 
low after loss of antigenemia (mean S.1. = 28, P < .05). 
Thl Cytokines 
The levels of IL-2, TNF-<x, and IFN--y were consis-
tently higher. in kidney r~cipients without an active 
CMV infection than in the group of recipients with an 
active CMV infection (Fig. 4). These differences were 
statistically significant in the case of IL-2 (P < .05) at 
24 hr, and IFN--y (P < .0005) and TNF-<x (P < .005) at 96 
hr. P values were calculated by the Mann-Whitney test 
conducted on median cytokine levels. The median pg/ 
ml values (range) for IFN--y, TNF-<x, and IL-2 in the 
antigenemia-positive patients are 7 (0-321), 311 (0-
6893.9), and 447 (0-5136), respectively; on the other 
hand, in the antigenemia-negative patients, the me-
dian pg/ml values are 131 (0-815.6), 2213 (0-7074), 
and 1501 (0-7696), respectively. It is evident that kid-
ney recipients with an active CMV infection produce 
lower levels ofTh1 cytokines than do the kidney recipi-
ents without an active CMV infection. Therefore, these 
data suggest that CMV infection impairs the produc-
tion of Th1-related cytokines. 
Th2 Cytokines 
The levels of IL-4 and IL-10 were measured in anti-
gen-positive and antigen-negative patients. There were 
no statistically significant differences in the levels of 
IL-4 and IL-10 between antigenemia-positive and 
-negative groups (Fig. 5). . 
Thltrh2 Cytokines Ratios 
The ratio of Th1 to Th2 cytokines in a given sample 
is considered to be of greater significance than the lev-
els of cytokines alone. Therefore, we calculated the ra-
tios of different Th1 to Th2 cytokines produced by PHA-
stimulated PBMC. The mean values of Th1 cytokines 
were compared with that ofTh2 cytokines produced by 
PBMC of kidney recipients with and without active 
CMV infections. The difference between the two groups 
in some of the Th1:Th2 ratios was found to be striking. 
Table II depicts the ratios of Th1 to Th2 cytokines for 
the two time points tested. For example, the IL-2:IL-4 
ratio at 24 hr and TNF -<x:IL-4 ratio at 96 hr were lower 
in the antigenemia-positive group as compared with 
the antigenemia-negative group, indicating a lower 
Th1-bias in the antigenemia-positive group. In some 
other cases the differences in ratios were not as strik-
ing, even though the ratios were consistently lower in 
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Fig. 2. Correlation between lym-
phocyte proliferation (stimulation in-
dex) in response to mitogenic stimula-
tion and the number of antigenemia 
assay (AA)-positive cells in kidney 
transplant recipients. 
TABLE 1. Mitogen-Induced Proliferation* of PBMC in 
CMV-Infected and -Uninfected Transplant Recipients 
CMV infected 
CMV uninfected 
Total 
Proliferation 
positive 
2 
43 
45 
Proliferation 
negative 
33 
1 
34 
Total 
35 
44 
79 
PBMC, peripheral blood mononuclear cells; CMV, cytomegalovirus; 
S.L, stimulation index. 
*PBMC proliferation was considered positive when the S.L 2: 50. 
infected individuals. Thus, general trend supports a 
lower production ofTh1 cytokines by the antigenemia-
positive group than by the antigenemia-negative 
group. 
DISCUSSION 
For the prevention of an active CMV infection and 
CMV disease, cellular immunity in general, and the 
action of cytotoxic T cells to CMV-infected target cells 
in particular, is the most important factor in the host 
defense mechanisms [Rook et aI., 1984; De Waal Male-
fyte et aI., 1993]. In kidney recipients the outcome of 
CMV infection depends to a great extent on the activity 
ofT cells [Mosmann and Coffman, 1989l, and therefore 
PBMC proliferation to PHA was used as an indicator of 
the T-cell responses in kidney transplant recipients 
with and without CMV infections. 
Results of PHA-induced proliferative responses of 
PBMC revealed that recipients with an active CMV 
infection had lower levels of proliferation (S.I. < 50) as 
compared with recipients without active CMV infec-
tions (S.1. 2: 50). These results show that the reduction 
in the PHA-induced response of PBMC correlates well 
I 
with the development of an active CMV infection. This 
finding illustrates the importance of helper-T-cell re-
sponses, and fits in with the well-recognized role of 
CMV-specific cytotoxic T cells in recovery from oppor-
tunistic CMV infections [Quinn an et aI., 1982; Reusser 
et aI., 1991]. On the other hand, the diminished T-cell 
response may be due to the immunosuppressive effect 
of active CMV infection in kidney transplant recipients 
[Rook et aI., 1984l. The data (Fig. 3) indicate that 
stimulation indices are higher before CMV infection 
and declines with the detection of CMV infection. Thus 
it appears likely that CMV infection leads to immuno-
suppression, reflected here as a decline in the T-cell 
response to mitogenic stimulation. Interestingly, this 
immunosuppression is also reflected by a decline in the 
production of Th1-type cytokines. 
CD4+ T cells regulate both cellular and humoral im-
mune responses in vivo, primarily by releasing numer-
ous cytokines [Heinzel et aI., 1991; Sad and Mosmimn, 
1994l. CD4+ T cells exist as at least two distinct sub-
sets, the Th1 and Th2. Th1 cells are characterized by 
the production of high levels ofIFN-,)" TNF-[3, and IL-2, 
whereas Th2 cells preferentially release IL-4, IL-5, IL-
10, and IL-13 [Mosmann and Coffman, 1989; Romag-
nani, 1992]. Th1-type cytokines are generally associ-
ated with effective defense mechanisms against intra-
cellular infectious agents by activating macrophages; 
promoting granuloma formation and inducing delayed 
type hypersensitivity (DTH) reactions. Th2-associated 
cytokines such as IL-4 and IL-10 sometimes allow the 
progression of intracellular infectious diseases by 
'down-regulating Th1 responses [Heinzel et aI., 1991; 
Sad and Mosmann, 1994l. It should be pointed out that 
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Whereas both Th1 and Th2 cells produce TNF-a, it is 
secreted at higher levels in Th1 responses [Romagnani, 
1992] and that it mediates cytotoxic activity as a part of 
cell-mediated immunity. TNF-a also elicits the produc-
tion of IFN-,)" a Th1-type cytokine. Thus, although 
'I'NF-a is not a characteristic Th1-type cytokine, it is of 
great significance in Th1-type cell-mediated responses. 
This study shows that Th1 cytokine levels elicited.in 
response to stimulation with a mitogen are lower in 
kidney recipients with active CMV infections than in 
those without active CMV infections. Because Th1 cells 
provide help for cell-mediated reactions against viral 
• I 
r 
c 
IL-2 
Fig. 3. Stimulation indices in (A) 
kidney transplantees before cytomeg-
alovirus (CMV) infection as tested by 
the antigenemia assay, (B) during in-
fection, and (C) after infection as in-
dicated by a negative antigenemia as-
say. 
Fig. 4. Levels of Thl-type cytokines 
produced by mitogen-induced periph-
eral blood mononuclear cells (PBMC) af-
ter 24 hr of culture for interleukin-2 OL-
2) and 96 hr of culture for interferon-,! 
(lFN-,!) and tumor necrosis factor-a 
(TNF-a). Dark bars represent mean lev-
els (±SEM) of the cytokines in cytomeg-
alovirus (CMV)-negative individuals; 
white bars represent mean levels in 
CMV-positive subjects. 
infection, a decline in Th1 activity may well lead to 
poor defenses against viruses. Furthermore, a decline 
in Th1-type activity may adversely affect the outcome 
of adoptive immunotherapeutic transfer of virus-
specific T cells. Studies on the adoptive transfer of 
CMV-spec~fic clones, for example, are currently under-
way [Riddell and Greenberg, 1997]; the present data on 
depressed Th1-type activity may be relevant in this 
regard. There appears to be no significant difference in 
Th2 cytokine secretion between CMV-positive and 
CMV-negative patients. Similar observations have 
been published [Sparrelid et aI., 1997] in relation to 
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Fig. 5. Levels of Th2-type cytokines secreted by mitogen-induced 
peripheral blood mononuclear cells (PBMC) after 96 hr of culture. 
Dark bars represent mean levels (±SEM) of the cytokines in cytomeg-
alovirus (CMV)-negative individuals; white bars represent mean lev-
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TABLE II. Th1:Th2 Cytokine Ratios in CMV-Infected and 
-Uninfected Transplant Recipients* 
Th1:Th2 ratio 
After 24 hr of culture 
IL-2:IL-4 
IL-2:IL-1O 
After 96 hr of culture 
TNF:IL-4 
TNF:IL-10 
IFN:IL-4 
IFN:IL-lO 
CMV uninfected 
16.0 
2.2 
18.6 
2.6 
1.3 
0.1 
CMV infected 
7.0 
1.1 
8.4 
1.3 
0.2 
0.04 
*CMV, cytomegalovirus; IL, interleukin; TNF, tumor necrosis factor; 
IFN, interferon. 
bone marrow transplantation; recipients with active 
CMV infections had a low level of Thl cytokine produc-
tion whereas Th2 cytokine production remained unal-
tered. Though that study dealt with local production of 
Thl and Th2 cytokines within the lung, the results are 
similar to our findings. 
It is possible that the correlation between CMV in-
fection and down-regulation of Thl cytokines is actu-
ally due to immunosuppressive therapy. However, this 
explanation is unlikely, because both the CMV-infected 
and uninfected individuals received the same immuno-
suppressive regimen. It is more likely that CMV infec-
tion itself has a selective suppressive effect on Thl-type 
reactivity [Boland et aI., 1990]. Because cell-mediated 
immunity in general, and Thl-type immunity in par-
ticular, is important for protection against CMV infec-
tion, the balance between Thl-related and Th2-related 
cytokines may determine the outcome of a CMV infec-
tion. 
The data presented above indicate the importance of 
Essa et aL 
Thl-type cytokines in the pathogenesis of CMV infec-
tion. 
ACKNOWLEDGMENT 
We are grateful to Prof. J.C. Coleman for his help in 
revising the manuscript. This study was supported by 
Kuwait University Research Administration, Project 
No. MI096 and No. MI112. 
REFERENCES 
Actor JK, Shirai M, Kullberg MC, Buller RM, Sher A, Berzofsky JA. 
1993. Helminth infection results in decreased virus-specific CD8+ 
cytotoxic Thl cytokine responses as well as delayed virus clear-
ance. Proc Natl Acad Sci USA 90:948-952. 
Boland GJ, DEGast GC, Hene QJ, Jambroes G, Donckerwolcke R, :rhe 
TH, Mudde GC. 1990. Early detection of active cytomegalovl: uS 
(CMV) infection after heart and kidney transplantation by testmg 
for immediate early antigenemia and influence of cellular immU-
nity on the occurrence of CMV infection. J Clin Microbiol 28:2069-
2074. 
Borysiewicz LK, Hickling JK, Graham S, et al. 1988. Human cyto-
megalovirus-specific cytotoxic T cells. J Exp Med 168:919. 
Clerici M, Shearer GM. 1993. A Thl-Th2 switch is a critical step in 
the etiology of HIV infection. Immunol Today 14:190-191. 
De Waal Malefyte R, Figdor CG, Huijbers R, Mohan-Peterson S, Ben-
nett B, Culpepper J, Dang W, Zurawski G, De Vries JE. 199~. 
Effect of IL-13 on phenotype, cytokine production, and CytotOXIC 
function of human monocytes. Comparison with IL-4 and modU-
lation by IFN-gamma or IL-I0. J Immunol 151:6370-6381. 
Gazzinelli RT, Makino M, Chattopadhyay SK, Snapper CM, Sher /I., 
Hugin AW, Morse HC. 1992. CD+ subset regulation in viral infec-
tion. J Immunol 148:182-190. 
Graham MB, Braciale VL, Braciale TJ. 1994. Influenza virus-specific 
CD4+ T helper type 2 lymphocytes do not promote recovery from 
experimental virus infection. J Exp Med 180:1273-1282. 
Heinzel FP, Sadick MD, Mutha SS, Locksley RM. 1991. Production of 
interferon gamma, interleukin 2, interleukin 4, and interleukin 10 
by CD4+ lymphocytes in vivo during healing and progressive mU-
rine leishmaniasis. Proc Nat! Acad Sci USA 88:7011-7015. 
Jayaraman S, Heiligenhaus A, Rodriguez A, Sonkiasian S, Dorf.ME, 
Foster CS. 1993. Exacerbation of murine herpes simplex Vlrus-
mediated keratitis by Th2 type T cell. J Immunol 151:5777-5789. 
Jonjic S, Pavic I, Plic B, Crnkovic I, Lucin P, Koszinowski UR. 1994. 
Antibodies are not essential for the resolution of primary cytomeg-
alovirus infection but limit dissemination of recurrent virus. J ExP 
Med 179:1713. 
Ljungman P, Plotkin SA. 1995. Workshop on CMV disease: defin\ 
tions, clinical severity scores, and new syndromes. Scand J Infec 
Dis Suppl 99:87-89. 
Meyers JD, Flournoy N, Thomas ED. 1986. Risk factors for cytomef 
alovirus infection after bone marrow transplantation. J Infect DIS 
153:478-488. 
Mosmann TR, Coffman RL. 1989. THI and TH2 cells: different pat-
terns oflymphokines secretion lead to different functional proper-
ties. Annu Rev Immunol 7:145-173. 
Mosmann TR, Sad S. 1996. The expanding universe ofT-cell subsets: 
Thl, Th2 and more. Immunol Today 17:138-144. 
Quinnan GV Jr, Kirmani N, Rook AH, et al. 1982. Cytotoxic T cells ip 
cytomegalovirus infection: HLA-restricted T-Iymphocyte cytoto;(iC 
responses correlate with recovery from cytomegalovirus infectiOn 
in bone marrow-transplant recipients. N Engl J Med 307:7-13. 
Reddehase MJ, Mutter W, Munch K, Buhring HJ, Koszinowski UR 
1987. CD8-positive T lymphocytes specific for murine cytom~galoj 
virus immediate-early antigens mediate protective immunity. 
ViroI61:3102-3108. 
Reddehase MJ, Weiland F, Munch K, Jonic S, Luske A, Kosz!nowS~ 
UH. 1985. Interstitial murine cytomegalovirus pneumoma a~e 
irradiation: characterization of cells that limit viral replicatiOn 
during established infection of the lungs. J Virol 55:264-273. 
Reusser P, Riddell SR, Myers JD, Greenberg PD. 1991. Cytotox!~ 
T-Iymphocyte response to cytomegalovirus after human allogen.eln 
bone marrow transplantation: pattern of recovery and correlat8J<'o with cytomegalovirus infection and disease. Blood 78:1373-13 . 
Th-Type Cytokines in Kidney Recipients With CMV Infection 229 
Riddell SR, Greenberg PD. 1997. T cell therapy of human CMV and 
EBV infection in immunocompromised hosts. Rev Med Virol 7: 
181-192. 
Riddell SR, Watanabe KS, Goodrich JM, Agha ME, Greenberg PD. 
1992. Restoration of viral immunity in immunodeficient humans 
by the adoptive transfer ofT cell clones. Science 257:238-241. 
Romagnani S. 1992. Human Thl and Th2 subsets: regulation of dif-
ferentiation and role in protection and immunopathology. Int Arch 
Allergy Immunol-4:279-285. 
Rook AH, Quinnan GV Jr, Frederik W Jr, Manischewitz JF, Kirmani 
N, Dantzler T, Lee BB, Currier CB Jr. 1984. Importance of cyto-
toxic lymphocytes during cytomegalovirus infection of renal trans-
plant recipients. Am J Med 7:385-392. 
Sad S, Mosmann TR. 1994. Single IL-2-secreting precursor CD4 T cell 
can develop into either THI or TH2 cytokine secretion phenotype. 
J Immunol 153:3514-3522. 
Sparrelid E, Emanuel D, Fehniger T, Andersson U, Andersson J. 
1997. Interstitial pneumonitis in bone marrow transplant recipi-
ents is associated with local production ofTH2-type cytokines and 
lack of T cell-mediated cytotoxicity. Transplantation 63:1782-
1789. 
Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, 
Thomas ED, Riddell SR. 1995. Reconstitution of cellular immunity 
against cytomegalovirus in recipients of allogeneic bone marrow 
by transfer of T-cell clones from the donor. N Engl J Med 333: 
1038-1044. 
Ciin Transplantation 2000: 14: 147-151 
Printed in Ireland. All rights reserL'ed 
Copyright © Munksgaard 200() 
Clinical Transplantation 
ISSN 0902-0063 
The use of flow cytometry for the detection 
of CMV -specific antigen (pp65) in leukocytes 
of kidney recipients 
Essa S, Pacsa AS, AI-Attiyah R, EI-Shazly A, Raghupathy R, Said T. 
The use of flow cytometry for the detection of CMV -specific antigen 
(pp65) in leukocytes of kidney recipients. 
Sahar Essaa*, Alexander 
5 Pacsaa, Raja'a AI-Attiyaha, 
Amany EI-Shazlya, 
Clin Transplantation 2000: 14: 147-151. © Munksgaard, 2000 Raj Raghupathya and 
Tareq Saidb 
a Department of Microbiology, Faculty of 
Medicine, b Kuwait University & Organ 
Transplant Center, Ministry of Public Health, 
Kuwait 
Key words: CMV - flow cytometry - pp65 
assay - renal transplants 
Abstract: Flow cytometric assay (FCA) was used to detect a cy-
tomegalovirus (CMV) specific antigen (pp65) in CMV-infected fibrob-
last cells and in leukocytes of kidney recipients_ FCA distinguished 
clearly between the infected and non-infected fibroblast cells. Regarding 
transplant patients, the FCA was positive when the number of antigen-
emia assay (AA) positive cells was five or more per 5 x 104 • Moreover, 
the percentage of antigenemia-positive cells by FCA correlated well 
with symptomatic CMV infections_ 
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Cytomegalovirus (CMV) infection has been recog-
nized as a significant cause of morbidity and mor-
tality in bone marrow, cardiac, and renal 
transplant patients as well as in patients infected 
With human immunodeficiency virus (HIV) (1-5). 
Traditionally, CMV infection is detected either by 
virus isolation or by the demonstration of charac-
teristic inclusion bodies in biopsy specimens (6). 
Serological testing is also used to confirm exposure 
to CMV, but it is not reliable since immunosup-
pressed patients may not have a change in anti-
body titer or produce CMV-IgM in case of an 
active CMV infection (2, 7)_ Among the different 
techniques used to confirm an active CMV infec-
tion is the detection of the CMV-specific early 
antigen (pp65)_ This antigenemia assay (AA) has 
~he advantage of quantifying the viral load accord-
Ing to the number of antigen-containing cells, 
which correlates well with manifestations of CMV 
disease (8, 9). However, the quantification of anti-
gen-positive cells by the AA is subjective and de-
mands very careful and time-consuming micro-
scopic examination (8). With the advent of effec-
tive antiviral chemotherapy for human CMV infec-
tion, more rapid and sensitive techniques are 
required to identify CMV infection during the 
acute stage of the illness and also to monitor 
antiviral therapy (l0, 11). The use of flow cytome-
try in the detection of viral infections has grown to 
significant proportions (12-16). Flow cytometry is 
an advanced technology, which can be used to 
analyze a large number of specifically labeled cells 
in a quantitative manner. In this study, we looked 
at the possibility of using flow cytometry for rapid 
and accurate detection of CMV-specific antigens in 
clinical samples for the early detection of CMV-in-
fected cells in transplant patients. 
Here we present the results of the flow cytomet-
ric assay (FCA) for direct quantification of CMV-
infected cells in human embryonic fibroblast 
cultures (MRC-5) and in polymorphonuclear 
leukocytes (PMNLs) of transplant patients. 
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Materials and methods 
Cell line 
M.R.C-5 fibroblast cell cultures were propagated in 
mIl1l1nal essential medium (MEM; GIBCO, Grand 
Island, NY) supplemented with 10'/,(, fetal calf 
serum (FCS; GIBCO), 100 U/mL penicillin, and 
100 ~lg/mL streptomycin. Cells were grown in 50 
cm2 size flasks at 37°C in the presence of 5'/,(, CO2 , 
Virus 
The ADI69 strain of human CMV obtained from 
the An~erican Type Culture Collection was propa-
gated Il1 our laboratory. The MRC-5 cells were 
infected with a multiplicity rate of 0.1 virus/cell 
and,. after a 30 min absorption period, fresh 
medIUm was added and the incubation started. 
This was considered 0 time. 
Trypsinization and fixation of CMV-infected cell culture 
Cells were removed with a 0.25% trypsin solution. 
After detachment (5-10 min at 3rC), cells were 
suspended in 2 mL of 10% MEM, washed by 
centrifugation (2 x in PBS), then resuspended in I 
mL PBS and counted. The number of cells was 
adjusted to 1.0 1.5 X 106 cells/mL and stored in 
90% methanol at ~ 20°C and stained within < 24 
h for FCA. 
Study population 
Seventy-nine kidney transplant patients (31 female, 
48 male) who received kidney transplants during 
1996 and 1998 were inducted into this study. Their 
ages ranged from 18 to 60 yr, the majority being 
30-45 yr old with a median age of 35. All patients 
(35 AA-positive and 44 AA-negative) received an 
immunosuppressive regimen of cyclosporin A, aza-
thioprine, and steroids. Of the 35 patients positive 
for the CMV -pp65 antigen, 32 had one or more of 
the following symptoms associated with CMV in-
fection/disease: fever, arthralgia, leukopenia, 
thrombocytopenia, pneumonitis, hepatitis, retini-
tis, and gastrointestinal ulceration. Diagnosis of 
CMV infection/disease conformed to the guidelines 
suggested in the Workshop on CMV disease (17). 
Patients in this study had to have at least one of 
the CMV-associated symptoms in addition to be-
ing antigenemia-positive in order to consider them 
as having CMV disease. Serial samples were col-
lected at different intervals after transplantation 
and patients were monitored for 2-12 wk. Blood 
samples were collected in EDT A containing tubes 
and transferred to the laboratory within 2-3 h. All 
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samples were processed on the same day. For both 
AA and FCA only one sample for each patient was 
included in this study. If the patient was AA-posi-
tive during the period of monitoring only the sam-
ples with the highest number of AA-positive cells 
were tested also for FCA. 
Isolation of PMNLs 
Blood samples taken from the patients were pro-
cessed immediately to isolate PMNLs by using the 
dextran sedimentation method as previously de-
scribed (16). Briefly, following the incubation of 
blood with 5% dextran at 37°C for 10-15 min, the 
leukocyte-rich layer was transferred to a test-tube 
and centrifuged for 10-11 min at 300 g. The pellet 
was then suspended in a RBC Lysing Medium and 
incubated for 4-6 min at room temperature. 
PMNLs were then washed twice with PBS, 
counted and adjusted to 2 x 106 cells/mL with cold 
PBS and the cells were divided into two parts. One 
part of the cells was fixed with 1 % paraformalde-
hyde for 15 min at 4°C, washed once with PBS, 
resuspended in cold 80% methanol (2 parts PBS + 
8 parts MEOH) and kept at ~ 20°e. FCA was 
performed within < 24 h, while the other part was 
used immediately for the AA. 
Antegenemia assay 
AA was performed as described by the manufac-
tU~'er (CMV -vue Kit; INCST AR Corporation, 
StIllwater, MN). Briefly, 5 x 104 cells/25 ilL were 
added to two test wells on the CMV-vue micro-
scope slide. Cells were then fixed with acetone for 
10 min and allowed to air dry. Then, 25 ilL of a 
monoclonal antibody to CMV lower matrix, early 
structural protein (pp65) was added to control and 
test wells and incubated for 45·-50 min at 3rC in 
a moist chamber. The slides were then incubated 
with 25 ilL of the conjugate (anti-mouse IgO la-
beled with peroxidase) at 37°C for 45-50 min. At 
the end of the incubation period, slides were im-
mersed into substrate solution for 10-11 min at 
room temperature and washed with PBS. After 
mounting the slides, control and sample wells were 
examined with brightfield microscopy at 200 >< -
400 x magnification. Prominent red-brown nu-
clear staining indicated the presence of the antigen. 
FCA 
Fixed and permeabilized cells (MRC-5 or PMNLs) 
were stained as previously described (14, 16) using 
mouse monoclonal antibodies (CIO/Cll; Clonab 
Detection of cytomegalovirus infection in kidney recipients 
CMV, Biotest, Landsteinerstrasse 5, Dreieich, 
Germany), specific to the CMV lower matrix, 
early structural (pp65) antigen. Briefly, after re-
moving the fixative by centrifugation (1000 g for 5 
min), cells were washed in PBS containing 20% 
AB serum (PBS/ AB). Cells were then resuspended 
in 200 ilL of the monoclonal antibody to pp65 
diluted 1:5 in PBS/AB. For each test sample, a 
control sample was included using an isotypically 
matched monoclonal antibody (Caltag/Tebu, 
Marnes la Coquette, France). Both tubes were 
then incubated at 37°C for 60 min. After washing 
and centrifugation (2 x in PBS), the second anti-
body which is FITC-conjugated goat-anti-mouse 
immunoglobulin (Biotest, Breieich, Germany) di-
luted at 1 :20 was added and incubated at 37°C for 
60 min. This was followed by two rinses in PBS/ 
AB and the cells were resuspended in 200 ilL of 
PBS/AB and analyzed by an EPICS-Profile II 
(Coulter Electronics,. Luton, United Kingdom) 
flow cytometer. 
Controls used: mock-infected MRC-5 fibroblast 
cells, PMNLs from patients without active CMV 
infections served as negative controls. MRC-5 
cells infected with the AD 169 reference strain (at 
a multiplicity of infection between 0.01 and 0.1) 
served as positive control. 
Fluorescence intensity of the cells was analyzed 
with a 488-nm air-cooled argon laser. The instru-
ment was calibrated daily by using various quality 
control reagents. Data acquisition was triggered 
by cell size (forward versus 90° scatter). The green 
fluorescence was filtered through a 530/30 band 
pass absorption filter. At least 50000 PMNLs or 
10000 MRC-5 fibroblasts were gated by light 
Scatter (PMNLs gates were assessed for accuracy 
When appropriate by using CD 15 staining (lm-
munotech, Marseille, France), debris and dead 
cells were excluded from the analysis by the con-
Ventional scatter gating method. All data were 
expressed in log fluorescence histogram form us-
ing a region defined according to isotype control 
analysis. 
Table 1. Number of antigen-positive PMNLs as determined by AA and FCA 
Statistical analysis 
For calculating the posItIve predictive value 
(posPV) and the negative predictive value (NegPV) 
the following formulas were used: PosPV = (num-
ber of patients with positive test results and CMV-
related disease/total patients with positive test 
results) x 100. NegPV = (number of patients with 
negative test result and without CMV -related 
symptoms/total patients with negative test re-
sults) x 100. Calculation of the mean, standard 
deviation ( ± SD) values and correlation were car-
ried out using an SPSS software package. 
Results 
Establishment of a model cell culture system for 
standardizing flow cytometry for the detection of 
CMV-specific antigen 
It was shown that the percentage of cells express-
ing the pp65 antigen increases proportionally with 
time after infection. On day 1 post-infection, 51 % 
of the cells expressed the antigen. That was fol-
lowed by gradual increase until it reached 90% on 
day 7. Mean fluorescence intensity (FI) values also 
correlated with the percentage of infected cells. 
Furthermore, FCA gave a complete separation be-
tween uninfected and infected MRC-5 cells. 
Detection of CMV-specific pp65 antigen in PMNLs by 
antigenemia and flow cytometry assays 
For the sake of comparison, 79 samples were 
tested by both assays (AA and FCA). The follow-
ing results were obtained by the AA: 12 patients 
had 5-20, 9 patients had 21-50, 8 patients had 
51-200 and 3 more than 200 AA-positive cells/5 x 
104 (Table 1). FCA resulted in the following: all of 
the AA-negative patients (n = 47) were also nega-
tive, samples with 5-20 AA-positive cells per 5 x 
104 proved to be positive in FCA with 0.16% mean 
fluorescence. As Table I shows, the mean % of 
fluorescence increases proportionally with the 
Patients tested AA-positive cellsa FCA fluorescenceb FCA mean FI CMV-related clinical symptoms 
valuec 
47 0-4 0.01 (± 0.01) 0.4 No symptoms, AA-negative 
12 5-20 0.6 (± 0.02) 0.8 No symptoms 
9 21-50 1.8 (± 0.02) 3.6 Fever, leukopenia 
8 51-200 3.5 (± 0.04) 5.8 Fever, leukopenia 
3 >200 7.8 (± 0.05) 11.8 Fever, leukopenia, hepatitis and elevated liver enzymes 
a M is considered as positive when five or more pp65 positive cells per 50000 are detected. 
b Results are expressed as mean of % ± SD. 
C Mean FI values were obtained by gating on the population of interest and calculating the mean FI. 
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Fig. 1. Correlation bctween FCA fluorescence and the number 
of AA-positive cells in 35 kidncy transplant recipients. 
number of AA-positive cells to reach 3.5'1<, when 
the number of AA-positive cells was > 200. Fig-
ure I shows a strong correlation between AA and 
FCA. Regarding CMV -related clinical manifesta-
tions FCA had a negative predictive value of 
97.5% while its positive predictive value was 
82.4%. Since the determination of the number of 
CMV-infected cells by the AA is a rather cumber-
some and subjective methodology, FCA may offer 
an alternative, being a much faster and objective 
method for detecting CMV antigen-positive cells 
by screening a larger number of cells with a con-
siderable accuracy. Therefore, the FCA has the 
potential to diagnose an on-going CMV disease 
and to monitor the effect of antiviral therapy 111 
kidney recipient. 
Discussion 
Since flow cytometer analysis offers a rapid and 
reliable quantification of cells stained with 
fluorochrome-labeled antibodies, it has the poten-
tial for the diagnosis of CMV infection in trans-
plant patients. However, prior to its use for 
diagnostic purposes, it should be standardized and 
compared to an established method. Indeed, 
parameters of FCA can be tested with human 
diploid fibroblast cells infected with CMV. In this 
system FCA performed well by detecting fibrob-
last cells stained with FITC-Iabeled monoclonal 
antibodies specific to CMV-related early matrix 
protein (pp65). A comparison with the so-called 
CMV AA showed that the FCA has approxi-
mately the same sensitivity as that of the AA. This 
result was encouraging to use the FCA for the 
detection of pp65-antigen in leukocytes of kidney 
recipients. In samples of kidney recipients, FCA 
150 
detected the pp65 antigen even when the number 
of AA-positive cells was between 5 and 20. This 
indicates that FCA is as sensitive as the AA. 
These results show that FCA detects the CMV 
pp65 antigen in PMNLs of kidney recipients with 
active CMV infection. The definite advantage of 
the FCA is that a large number of cells can be 
screened in a short time with accuracy. This may 
enhance the validity of the results. These data 
show that the FCA has the potential to be used 
for the diagnosis of on-going CMV infections. It 
seems to be a valuable approach for monitoring 
the effect of antiviral therapy in transplant pa-
tients. 
Further studies should be carried out to study 
the effect of fixation and storage on the perfor-
mance of FCA. This method may also be useful 
for the detection of other pathogens, where spe-
cific monoclonal antibodies are available. 
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Abstract 
Objective: Cytomegalovirus (CMV) infection 
is a frequent complication of kidney trans-
plantation contributing substantially to mor-
bidity and mortality. Early diagnosis of the 
infection is essential to implement an effec-
tive antiviral therapy. This study is aimed at 
establishing the CMV antigenemia assay for 
the diagnosis of CMV infection, and for moni-
toring the effectiveness of ganciclovir thera-
py in kidney recipients in Kuwait. Methods: 
Leukocyte-enriched fractions of 215 blood 
specimens from 92 kidney recipients were 
processed for the detection of CMV-specific 
protein (pp65) by using a commercial kit (Inc-
star Corp., USA). Plasma fractions were also 
tested for the presence of CMV IgM anti-
bOdies, and selected samples (n = 15) were 
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processed for virus isolation in MRC-5 dip-
loid cell culture. Results: Regarding symp-
tomatic (n = 35) and' asymptomatic patients 
(n = 57) the assay showed an 86% positive 
and a 79% negative predictive value, com-
pared to the 55% and 70% values, respective-
ly, for CMV IgM antibodies. The number of 
positive cells was parallel with the severity of 
symptoms. Using a cutoff level of >5 anti-
gen-positive leukocytes/50,000 cells, the as-
say reached 93% positive and 96% negative 
predictive values. There was a very good 
agreement between the assay and virus iso-
lation. Ganciclovir therapy could be moni-
tored effectively with the assay, and in 11 
symptomatic patients treated with ganciclo-
vir, a prompt decrease in the number of anti-
gen-positive cells was noted. Conclusion: 
The CMV antigenemia assay is a valuable 
tool for the early diagnosis of symptomatic 
. CMV infection and monitoring antiviral ther-
apy in kidney transplant patients. 
Dr. A.S. Pacsa 
Department of Microbiology, Faculty of Medicine 
University of Kuwait, PO Box 24923 
13110 Safat (Kuwait) 
Fax +965 5332719, E-Mail pacsa@hsc.kuniv.edu.kw 
Introduction 
In transplant patients active cytomegalovi-
rus (CMV) infection frequently occur and 
cause serious disease [1]. The incidence of 
clinical manifestation varies between 40 and 
90o/b [2]. Antiviral therapy, when imple-
mented early in a CMV infection, reduces the 
mortality of CMV disease substantially [3, 4]. 
In kidney and other transplant patients, it is 
essential to diagnose active CMV infection as 
early as possible. Rapid diagnostic tests are of 
practical value to differentiate CMV infection 
from other infections and to guide the use of 
antiviral therapy [5]. 
Isolation of infectious virus in cell culture 
is still considered the gold standard in the 
diagnosis of CMV infection [6]. However, the 
potential of virus isolation for the early diag-
nosis of CMV infection is limited by the long 
time requirement and the relatively low sensi-
tivity of the method [7]. Polymerase chain 
reaction may have a strong impact on the 
diagnosis of CMV infection, but there is a 
need for further standardization and simplifi-
cation [8]. 
Primary CMV infection may be diagnosed 
by serological methods. Although IgM detec-
tion is reliable to identify a recent CMV infec-
tion in healthy individuals, in immunocom-
promised patients, such as transplant recipi-
ents, CMV infection is produced in approxi-
mately 50-75% of the cases [6]. 
For the diagnosis of an active CMV infec-
tion, the detection of the CMV structural anti-
gen (pp65) in polymorphonuclear leukocytes 
seems to be the best approach [9, 10]. The 
method now known as CMV antigenemia as-
say (AA) has been extremely useful for diag-
nosing active CMV infection in transplant 
patients [11-13]. 
In Kuwait, where several hundreds of 
transplant patients are under clinical surveil-
lance, rapid and reliable laboratory diagnosis 
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of CMV disease is essential. Therefore, we 
studied the usefulness of the AA for early 
diagnosis of CMV infection in kidney trans-
plant patients. 
Materials and Methods 
Study Population. We enrolled 92 kidney trans-
plant patients (35 females and 57 males), who received 
their transplants during 1996 and 1997. Their age 
spanned from 18 to 60 years, and 78% were between 
30 and 45 years of age. All patients received an immu-
nosuppressive regimen of cyclosporin A, azathioprine 
and steroids. One blood sample was collected from 38 
patients, and two or more from 54 patients. From IS of 
those 32 patients who developed any of the symptoms 
associated with CMV disease (unexplained fever, ar-
thralgia, leukopenia, thrombocytopenia, elevated ami-
notransferase level, pneumonitis, hepatitis, retinitis, 
gastrointestinal ulceration), serial samples at different 
intervals were collected after transplantation and pa-
tients were monitored for 6-20 weeks. Eleven of these 
patients were treated with ganciclovir. Blood samples 
were collected in EDT A-containing tubes and trans-
ferred to the laboratory within 2-3 h. All the samples 
were processed for antigen detection on the same day. 
Plasma fractions of the samples were tested for the 
presence ofCMV-lgM. Part of the separated cells were 
stored at _70 0 C for virus isolation. 
CMV AA. From each patient 5 ml of blood was col-
lected and processed immediately to isolate leukocytes 
by the use of dextran sedimentation method. Follow-
ing incubation and centrifugation, the cell pellet was 
suspended in phosphate-butTered saline (PBS), eryth-
rocytes were lysed with 0.8 mM ammonium-chloride, 
centrifuged, washed in PBS, counted and spotted onto 
glass slides (50,000 cells per spot). They were then 
dried and fixed in acetone bath, stained with Incstar 
CMV-vu Kit according to recommended procedures. 
The number of cells containing the CMV -specific pp65 
antigen were counted with a light microscope ( x 400). 
Virus Isolation. Diploid fibroblast cell mono layers 
grown in LabTek 4-chamber slides were inoculated 
with polymorphonuclear blood leukocytes stored at 
-70°C. Before inoculation, cells were treated with 3 
cycles of freezing and thawing. Two chambers were 
used for each sample. After inoculation cultures were 
incubated for 2 h at 37°C, fed with a medium and 
incubated further for 3-4 days in the presence of 5% 
CO2. Then the cells were fixed in cold methanol, 
washed with PBS, incubated immediately with a 
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Table 1. Presence of CMV pp65 
AA 
antigen in leukocytes of kidney 
recipients 
Positive 
Negative 
monoclonal antibody to CMV early antigen (Biosoft, 
Paris, France) for 2 h. Finally, fluorescein-conjugated 
antimouse IgG was added to the cells and incubated 
for 1 h. Cells showing greenish fluorescence were de-
tected by UV microscopy. 
Serology. CMV-specific IgM antibodies (CMV-
IgM) were detected with the use of conventional 
ELISA (Sorin , Biomedica), and/or immunofluores-
cence tests and confirmed with CMV-lgM blot assay 
(Genlabs Diagnostics, Singapore). 
Statistics. For calcu lating the positive predictive 
value (posPV) and the negative predictive value 
(NegPV) the following formulae were used: PosPV = 
(number of patients with positive test result and CMV-
related disease/total patients with positive test result) 
X LOO. NegPV = (number of patients with negative 
test result and without CMV-relat!!d symptoms/total 
patients with negative test result) x 100. 
Results 
Presence of CMV Antigen in Leukocytes. 
Among the 92 patients, 35 had symptomatic 
infection and 32 of them were positive for the 
pp65 antigen. Among the 57 asymptomatic 
patients, 12 patients had CMV antigen in 
their leukocytes (table 1). Accordingly the 
PosPV and NegPV of the assay are 86 and 
79%, respectively. However, in 15 patients 
monitored for a longer period of time (6-20 
Weeks) by testing 3 or more consecutive sam-
ples from each patient, the presence of antigen 
Correlated even more closely with the clinical 
condition. All of the 11 patients who had 
Cytomegalovirus Infection in Kidney 
l'ransplantation Patients 
Patients Samples Patients 
with without 
symptoms symptoms 
43 (47%) 79 (37%) 31 (89%) 12 (21 %) 
49 (53%) 136 (63%) 4 (i 1%) 45 (79 %) 
92 2 15 35/92 (38%) 57/92 (62 %) 
Table 2. Correlation between AA and CMV-lgM test 
AA 
Positive 
Negative 
Total 
IgM test 
positive 
33 (42%) 
20(15%) 
53 
negative 
46 (58%) 
116 (85%) 
162 
Total 
79 
136 
215 
symptomatic infection during the follow-up 
period were positive by the AA. 
Comparison of AA and JgM Detection. 
From the 92 patients 215 samples were col-
lected and tested both with the AA and the 
IgM test. CMV-IgM could be detected only in 
42% of the 79 antigen-positive samples. On 
the other hand, there was a relatively good 
agreement between the two tests regarding the 
136 antigen-negative samples; 85% of them 
were negative for the presence of CMV-IgM 
(table 2). 
When symptomatic and asymptomatic pa-
tients were compared (table 3), the result 
showed that IgM antibody could be detected 
in only 17 of the 35 symptomatic patients. 
The PosPV was 55% and the NegPV of the 
test (70%) approximated that of the AA 
(79%). 
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Table 3. Presence ofpp65 antigen 
and CMV IgM antibodies in 
patients with and without clinical 
symptoms 
Patients 
symptomatic asymptomatic 
positive negative positive negative 
AA 31 /35 (89%) 4/35 (i 1%) 
CMV-IgM 17/35 (49%) 14/35 (40 %) 
12/57 (21 %) 45/57 (79%) 
14/57 (25 %) 43/57 (75%) 
Table 4. Number of pp65 antigen-positive leukocytes 
in symptomatic and asymptomatic patients 
Patients Positivity scale 
very low high very total 
low high 
Symptomatic (n = 35) 
n 6 9 10 6 31 
% 17.1 25.7 28.6 17.1 88.5 
Asymptomatic (n = 57) 
n 10 2 0 0 12 
% 17.5 3.5 21.0 
Positivity scale: very low = 1-5 positive cells; low = 
6- 10 positive cells; high = II-50 positive cells; very 
high = >50 positive cells. 
Comparison of AA and Virus Isolation. In 
selected samples AA was compared to virus 
isolation. A strong agreement between the two 
methods was noted. Only one antigen-posi-
tive sample was negative in virus isolation. 
Number of Antigen-Positive Leukocytes 
and Clinical Symptoms. The number of anti-
gen-bearing cells varied extensively, from 0 to 
several hundred. For rating the positivity the 
following arbitrary scale has been formulated: 
1-5 cells = very low positive; 6-10 cells = low 
positive; 11-50 cells = positive, and >50 = 
high positive. Grouping antigen-positive leu-
kocytes detected in symptomatic and asymp-
88 Med Principles Pract 1999;8:85-90 
tomatic patients by this scale shows that 
detecting just a few cells (1-5) among the 
50,000s screened did not give a definite indi-
cation of an ongoing CMV infection. On the 
other hand, the presence of more than 5 posi-
tive cells was strongly associated with clinical 
symptoms. With a cutoff of more than 5 cells 
as a positive test, the AA has a 93% PosPV 
and a 96% NegPV (table 4). 
Positive AA and Ganciclovir Treatment. 
Eleven patients have received ganciclovir 
treatment for various periods of time (from 
2 to 8 weeks). One patient became antigen-
positive 8 weeks after transplantation and 
was symptomatic. Ganciclovir therapy waS 
started and continued for 2 weeks. When the 
patient was tested 4 and 8 weeks later he was 
asymptomatic and negative in the AA. Four 
patients followed the same pattern becoming 
antigen-negative and asymptomatic after the 
antiviral treatment. Four other patients had a 
somewhat different course. At the time when 
clinical symptoms were present, a high num-
ber of antigen-positive leukocytes could be 
detected. Their number reduced gradually but 
positive cells were still present when patients 
became asymptomatic. One patient who had 
a multiple, concomitant disease process in-
cluding pneumococcal meningitis responded 
to ganciclovir treatment, and the initially high 
number of positive cells (175) was reduced to. 
4. Another patient who responded to gancicIO-
vir treatment (antigen-positive cells could not 
-----------------------Pacsa/El-Shazly/Guptal J oh nyl 
Nampoory/TarekJGadalla/Essa 
be detected at week 12 after transplantation) 
presented with central nervous system lym-
phoma and became critically ill. There were 4 
patients with symptoms who did not receive 
antiviral treatment. Two of them were very 
low positive (1-2 cells) in the AA and they 
became asymptomatic spontaneously. The 
other 2 patients had an increase in the num-
ber of antigen-positive cells and presented 
with CMV-compatible symptoms. Unfortu-
nately, their follow-up could not be continued 
further because they left the country. 
Discussion 
Detection of the CMV-related pp65 anti-
gen in peripheralleu~ocytes of transplant pa-
tients has become an increasingly important 
assay for the diagnosis of CMV infection [14, 
15]. The CMV AA has substantial advan-
tages: it gives rapid results (available within 
5-6 h), correlates exceptionally well with 
symptomatic CMV infections, and can be 
used for monitoring the effectiveness of anti-
viral therapy [16]. The assay is relatively easy 
to perform and inexpensive when compared 
to either cell culture or PCR methodologies 
[17]. 
In this study, the diagnostic significance of 
the AA was determined on 92 kidney trans-
plant patients with and without symptomatic 
infections. Among the 35 symptomatic pa-
tients there were 4 AA-negative patients. All 
of them presented only with one clinical 
symptom (unexplained fever) which may not 
have been related to CMV infection. The 31 
patients who had more than one CMV-related 
symptom were positive by the AA. Among the 
57 asymptomatic patients, 12 had the antigen 
in their leukocytes, however, the number of 
antigen-positive cells never exceeded 10. Ifwe 
used a cutoff value> 10 positive cells none of . 
the asymptomatic patients would fall into the 
Cytomegalovirus Infection in Kidney 
Transplantation Patients 
positive range. Indeed quantification seems 
possible [18, 19] and it is important in rela-
tion to patient management [10]. The higher 
the number of antigen-positive cells the closer 
is the association with more severe symptom-
atic CMV infections. 
Although in this study only 15 selected 
samples were tested for both the AA and virus 
isolation, the result showed a good agreement 
between the two tests. There was only 1 AA-
positive case with negative virus isolation but 
the number of antigen-positive cells was very 
low (2 cells only). 
The scale upon which the positivity of the 
AA is determined may differ from one labora-
tory to the other, however, it does not jeopar-
dize the value of the assay. Since several mod-
ifications of the assay are available [20], it 
would not be reasonable to set a unified rating 
scale. 
A comparison between AA and CMV-IgM 
showed that only 49% of symptomatic cases 
had CMV IgM antibodies, which means that 
the PosPV of the IgM test is much lower 
(55%) than that of the AA (86%). It may be 
due to several factors like antibody status 
before transplantation, source of grafts, im-
munological compatibility, immunosuppres-
sive therapy etc., which influence the produc-
tion oflgM in organ transplant patients [18]. 
It is of interest that the 4 patients with the 
highest number of antigen-positive cells did 
not produce detectable CMV IgM antibodies. 
The assay has an obvious impact on moni-
toring ganciclovir therapy. In all the 11 pa-
tients treated with the drug, the num-
ber of CMV antigen-positive cells decreased 
promptly as the clinical conditions of the 
patients improved. The 4 patients without 
treatment had a relatively low number of AA-
positive cells. Nevertheless, 2 patients were 
symptomatic when they had more than 5 pos-
itive cells. Unfortunately their follow-up 
could not be continued. 
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In summary we conclude that the CMV 
AA is a valuable laboratory method for diag-
nosing CMV infections and monitoring anti-
CMV therapy in kidney transplant patients. 
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